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Chapter 1 
 
Aminoglycoside antibiotics and  
modifications of neamine 
 
 
 
Abstract: 
 
Aminoglycoside antibiotics form an extensive class of compounds offering protection against 
infectious diseases since many years. However, only recently the aminoglycoside mechanism of 
action has been understood, especially that of the neomycin class of antibiotics. Based on the 
finding that the main recognition motif is the pseudodisaccharide neamine, in recent years 
several research groups have investigated the synthesis and activity of neamine analogues in an 
attempt to enhance its antibiotic potency. A part from that, an important driving force of such 
investigations is to avoid  growing bacterial resistance as well as undesired side reactions such 
as oto- and nephrotoxicity. The challenging synthesis of such compounds and subsequent 
biological assessment are the central theme of this thesis.  
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1.1 Introduction 
 
 Aminoglycoside antibiotics are highly potent antibacterial agents with a broad 
spectrum of activity against life-threatening infections. The aminoglycoside history 
begins in 1944, when Selman Waksman and co-workers discovered streptomycin, the 
first antituberculosis agent, by systematic screening of bacterial cultures for the 
presence of M. tuberculosis inhibitory activity1. The following years featured the 
successive introduction of a series of milestone compounds (neomycin, kanamycin, 
gentamicin and tobramycin), which established the usefulness of aminoglycosides for 
the treatment of gram-negative bacillary infections. In the 1970s, some semisynthetic 
aminoglycosides such as dibekacin and amikacin showed the possibility of obtaining 
compounds that retained activity against strains that had developed resistance against 
earlier aminoglycosides. Since then the emergence of new antibiotics has markedly 
slowed down. Only in recent years several research groups have started to search for 
new variants of aminoglycoside antibiotics. The interest to overcome the problem of 
bacterial resistance2 and distinct toxicological profiles (such as nephro- and 
ototoxicity3) was prompted by the recent understanding of the aminoglycoside 
mechanism of action. Although it was known that the ribosome is the antibiotic target 
in the cell only recently important insights into the mechanisms of antibiotic action 
have been obtained. RNA crystallography provided a detailed view of the interactions 
between antibiotics and rRNA, thus paving the way for the development of new  
RNA-targeting antibiotics. 
 Additionally, aminoglycosides as potential antiviral agents were also reported. 
The replication of human immunodeficiency virus type 1 (HIV-1) can be activated by 
two RNA-protein interactions4. One of them is the transactivator protein (Tat) and its 
responsive RNA element (TAR), and the other is the regulator of virion expression 
(Rev) and its responsive RNA (RRE). Recent studies suggest that neomycin is able to 
bind either TAR or RRE RNA specifically and disturb corresponding RNA-protein 
interactions. 
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1.2 Mode of action 
 
 In the 16S ribosomal subunit, the best-studied site of drug action is the A-site 
(tRNA acceptor site) or decoding centre which is targeted by aminoglycosides  
(Figure 1.1). The A-site comprises a segment of an extended rRNA helix  
(named helix 44) that resides on the interface surface of the small subunit5. The general 
organization of this rRNA element is not significantly influenced by contacts with 
other ribosome elements and structure is preserved even when isolated from the 
ribosome. As a consequence, it has been possible to study fairly small artificial 
molecular complexes to understand how aminoglycosides interact with their rRNA 
target6. 
 
 
Figure 1.1                               16S ribosomal subunit and its A-site. 
 
 
 Common aminoglycoside antibiotics share the universal two-ring structure of 
neamine that includes the 2-deoxystreptamine moiety (ring II). Depending on the type 
of ring II substitution (4,5 or 4,6), the aminoglycoside drugs fall either in the 
neomycin/paromomycin or in the kanamycin/tobramycin family, respectively  
(Figure 1.2). 
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Figure 1.2                   4,5- and 4,6-substituted 2-DOS aminoglycosides 
 
NMR and crystallographic studies showed that the universal neamine two-ring 
structure forms a solid lock-and-key type of interaction with the target site5,7  
(Figure 1.3). The ring I is inserted into helix 44 by stacking against G1491 and by 
forming a pseudo-base pair by establishing two hydrogen bonds with the universally 
conserved A1408. The conserved ring II establishes hydrogen bonds with G1494 and 
U1495 of 16S rRNA. The universal interactions of rings I and II of the neamine moiety 
of aminoglycosides with the decoding centre are supplemented by opportunistic 
interactions that drug-specific rings III and IV of aminoglycosides establish with helix 
44 of 16S rRNA. These fuzzy contacts fine-tune placement of the drug within its RNA 
target and define the drug specificity of aminoglycoside resistance mutations. 
 
Figure 1.3  Neomycin bound to the A-site of the 16S ribosomal subunit. Adenines 1492 and 
1493 flip out from the helix by the specific interactions (based on the crystal structure)7e. 
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 X-ray crystallographic studies of the ribosome have provided a clear view of 
the mechanism of action of aminoglycoside drugs that act at the decoding centre5. The 
neamine core-based aminoglycoside drugs affect the ribosome accuracy at the initial 
step of aminoacyl-tRNA selection. Binding of the universal aminoglycoside rings I and 
II to the decoding centre changes the orientation of the two universally conserved 
adenine residues at positions 1492 and 1493 of 16S rRNA. A similar conformational 
switch occurs during mRNA decoding when these two adenines monitor the accuracy 
of codon–anticodon base pairing at the first and second anticodon positions. Flipping 
out of the adenines 1492/1493 during decoding normally signals the establishment of 
an accurate codon–anticodon pairing. Reorientation of A1492/A1493 induced by 
aminoglycosides (Figure 1.3) explains the miscoding effect of these drugs. In the 
presence of a bound aminoglycoside the decoding centre issues an approval signal, 
even on the binding of a non-cognate tRNA, thereby increasing the frequency of amino 
acid misincorporation5,8. An aminoacyl-tRNA enters the ribosome in complex with  
EF-Tu (an elongation factor) and GTP. GTP hydrolysis is required for EF-Tu 
dissociation and aminoacyl-tRNA accommodation in the A site. In case of the cognate 
codon–anticodon interaction the induction of GTP hydrolysis is faster than in case of 
non-cognate or near-cognate codons8. This difference in the rate of activation of GTP 
hydrolysis contributes significantly to the accuracy of translation. Paromomycin, an 
aminoglycoside of the neamine type, increases the rate of GTP hydrolysis in case of the 
near-cognate tRNA to be closer to the cognate value9.  
 
 
1.3 Overview on modifications of neamine and synthetic analogues 
 
 Neamine (1a, Figure 1.4) plays a central role in the binding of aminoglycosides 
to rRNA and their mechanism of action. Not surprisingly therefore, it is a central 
moiety for modification by resistance enzymes. In recent years, several modifications 
and reconstructions on neamine have been reported in an attempt to circumvent 
undesired side-effects and the problem of bacterial resistance to antibiotics. Relevant 
work in this field is described in this section. 
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1.3.1 Modifications on the neamine periphery 
 
 Wong and co-workers synthesised a series of compounds with amino groups at 
variable positions on ring I in order to find an optimal substitution pattern10 while 
keeping the same stereochemistry (Figure 1.4).  Compounds 1a–1f were analysed for 
binding to models of the E. coli 16S A-site ribosomal RNA and for antibacterial activity. 
They were also screened on streptavidin-modified SPR (surface plasmon resonance) 
chips for RNA-binding activity. Data from SPR screenings11 revealed that the  
2',6'-diamino compound neamine was the most effective and specific A-site binder, 
while the monoamino compounds only showed little activity. 
 
 
 
 
 
 
Figure 1.4 
 
 Following the previous study, Wong et al. constructed a series of analogues 
where ring II was functionalised at O5 with various polyamino, amino alcohol, or 
aromatic substituents10. The compounds 2a-2i were designed to improve RNA binding 
affinity and potentially antibacterial activity. The compounds were screened on a 
streptavidin-modified SPR chip for RNA binding against three related 5'-biotinylated 
RNA oligonucleotides (Figure 1.5). AS-wt contains the wild type sequence from E. coli, 
U1406A contains a single-base mutation which improves binding of aminoglycosides, 
and U1495A contains a single-base mutation which is detrimental to binding. 
Compounds 2f and 2g showed better activity than neamine. For the other compounds, 
the discrepancy between a better binding affinity to the naked RNA fragment and a 
loss in antibiotic activity was explained by two major factors which are cell 
permeability and high ribosome concentration in the cell. 
 
 R1 R2 R3 R4 
1a NH2 OH OH NH2 
1b OH
 
OH OH OH 
1c NH2 OH OH OH 
1d OH NH2 OH OH 
1e OH OH NH2 OH 
1f OH OH OH NH2 
O OH
H2N NH2
OH
O
R1R3
R4
R2
I
II
1
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 AS-wt U1406A U1495A MIC, E. coli  AS-wt U1406A U1495A MIC, E. coli 
2a 0.7 0.4 1.5 100 2f 0.8 0.7 1.6 25 
2b 0.5 0.4 1.0 50 2g 1.0 0.7 1.8 25 
2c 0.8 0.5 1.0 100 2h 4.0 4.0 6.0 100 
2d 0.4 0.25 0.7 100 2i 4.9 3.1 3.7 >100 
2e 7.0 8.0 10 >100 1a 7.8 5.5 31 50 
 
Figure 1.5   Neamine derivatives with polyamino, amino alcohol and aromatic substituents and 
their RNA binding to variants of the decoding region A-site and MIC on E. coli (ATCC 25922). 
 
 The recent achievement in understanding the structure of paromomycin-RNA 
complex prompted interest in performing modifications on paromomycin and 
paromamine, the pseudodisaccharide consisting of ring I and ring II of paromomycin. 
Based on structural data from X-ray crystallography and molecular modeling studies, 
it was suggested that modification at the 6' and 4'-positions of paromamine ring I 
might allow for additional hydrogen-bond interactions with the decoding-site RNA. 
Hermann et al. synthesised paromamine derivatives with diverse functional groups at 
the 6'-position and aromatic residues at the 4'-position, and tested binding affinities of 
the analogues to the decoding-site RNA, as well as the efficacy as bacterial inhibitors in 
vitro translation12 (Fig. 1.6). However, none of the synthetic derivatives showed 
superior activity to paromamine in the translation assay. The observed structure-
activity relationships for the paromamine 6'-derivatives revealed an exquisite 
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sensitivity of the 6'-position towards substitution, indicating the pivotal role of the 
group in this position in RNA target recognition.  
 
 R1 R2 IC50(mM) 
3a OH CH2OH 3.9 
3b OH CO2H 620 
3c OH CONH2 >1000 
3d OH CH2CONH2 380 
3e OH CH2CH2OH 170 
3f OH CH2CH(OH)CH3 97 
3g OH CH(OH)CH3 23 
3h OH CH(OH)CH2OH 24 
3i COPh CH2OH >1000 
3j CO−4−biphenyl CH2OH 380 
3k CO−6−benzotriazole CH2OH 450 
Figure 1.6 
 
 Mobashery et al.13 considered steric and electronic contributions to interactions 
between RNA and aminoglycosides to make a random search of 273,000 compounds 
from the Cambridge Structural Database and the National Cancer Institute 3-D 
database of ribosomal aminoglycoside-binding pocket. A total of seven compounds 
were designed and synthesised, with the expectation that they would bind to the A-site 
of bacterial ribosomal RNA (Figure 1.7). All synthetic compounds were found to bind 
to the target RNA comparable to the parent antibiotic neamine, with dissociation 
constants in the low micromolar range. The synthetic compounds were evaluated for 
antibacterial activity against a set of important pathogenic bacteria. These designed 
antibiotics showed considerably enhanced antibacterial activities against pathogens, 
including organisms that expressed resistance enzymes to aminoglycosides. Further 
analysis of 4b, 4c, 4f and 4g with two important purified resistance enzymes for 
aminoglycosides indicated that the compounds were poor substrates, thus the activity 
of these synthetic antibiotics does not appear to be compromised by the existing 
resistance mechanisms. Later, the X-ray structure of compound 4c in complex with the 
A-site was reported14, and provided a detailed view of the molecular interaction 
underlying its mechanism of action and avoidance of modification by resistance 
enzymes. The disclosed results hold the promise of the generation of a large series of 
designer antibiotics uncompromised by the existing mechanisms of resistance.  
 
O OH
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OH
O
NH2R1
R2
OH 3
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Figure 1.7 
  
 Hung and co-workers developed an efficient strategy for the assembly of 
kanamycin B-like aminoglycosides by regioselective glycosylation of neamine 
derivatives at O6-position in ring II with high yields15. Similar work was executed by 
Chang et al. which resulted in the synthesis and antibacterial evaluation of a library of 
kanamycin B analogues16 (Figure 1.8). The strategy holds great promise to rapidly 
build previously inaccessible but biologically significant analogues of kanamycin. 
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 R1 R2 R3 R4 R5 α : β MIC E. coli [µM]  MIC S. aureus [µM] 
kanamycin B NH2 OH H OH OH - 1.4 0.5 
6a OH OH H OH OH 10:1 50 8 
6b OH OH H NH2 OH 11:1 inactive 30 
6c OH NH2 H NH2 OH only α 22 29 
6d OH H OH NH2 OH only α 22 8 
6e OH NH2 H H OH only α 12 2 
6f OH H NH2 H OH only α inactive 16 
6g NH2 OH H OH OH 20:1 6 1 
6h OH NH2 H OH OH only α 23 4 
6i OH OH H OH NH2 2.5:1 23 4 
6j OH H NH2 NH2 OH only α inactive 57 
6k NH2 OH H NH2 OH 10:1 22 2 
6l OH H NH2 OH OH only α inactive 16 
6m NH2 H NH2 OH OH only α - 4 
Figure 1.8 
 
 It is well known that the most prevalent mode of resistance to aminoglycosides 
is enzyme-catalysed modification. Over 50 different types of aminoglycoside-
modifying enzymes, found in resistant bacteria, are known to be responsible for the 
inactivation of aminoglycosides. The aminoglycoside-modifying enzymes can be 
grouped into three classes including aminoglycoside phosphotransferases (APHs), 
aminoglycoside acetyltransferases (AACs), and aminoglycoside 
nucleotidyltransferases (ANTs). With a few exceptions, all of the known 
aminoglycoside-modifying enzymes introduce chemical groups on the neamine core 
(rings I and II) of the aminoglycosides including neomycin and kanamycin. 
 Under the consideration that many aminoglycoside antibiotics such as 
neomycin and kanamycin carry a glucosamine substituent at the 4-position of 
2-deoxystreptamine, and removal of the 2-DOS 5-hydroxy group leads to enhanced 
activity against aminoglycoside-resistant bacteria17, Hermann and co-workers 
described18 the design and synthesis of neamine derivatives with the 2-DOS core 
adapted by the 2,5-dideoxystreptamine (2,5-dDOS) core (Figure 1.9). Specifically, the 
synthesis of O6-alkyl, O6-alkylamine, O6-acetamide, as well as N1-alkyl and N1-amide 
O O
H2N NH2
OH
O
NH2HO
NH2
OH
O OH
N3 N3
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N3AcO
N3
OAc
O
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R5 R
2
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5 6
steps
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derivatives was achieved. These substituents were chosen to project into the 
aminoglycoside antibiotic hygromycin B binding site, which is located immediately 
adjacent to that of neomycin and paromomycin. The synthetic compounds were 
evaluated in a coupled in vitro transcription-translation assay using firefly luciferase as 
a reporter. Several compounds were active as inhibitors of bacterial translation, 
although none of the tested compounds exhibited potency superior to the natural 
aminoglycosides. Some relevant structures are depicted in Figure 1.9. 
 
 
 
 
 
 
 
 R1 = H, R2 = BIVTIC50 [µM] MIC [µg mL-1] 
7a H
 
0.25 16/4 
7b 
H
N OH
 
0.39 32/16 
7c 
H
N
 
0.32 64/16 
7d HN NH2
O
 
0.89 32/8 
7e 
H
N NH2
O
HN
N
 
0.55 4/16 
1a neamine 0.37 16/8 
 
Figure 1.9   BIVTIC50: concentration required for 50% inhibition in a bacterial in vitro 
transcription assay. MIC: minimum inhibitory concentration against E. coli (first value) and 
Staphylococcus aureus (second value). 
 
 Mobashery et al. designed a self-regenerating aminoglycoside 8a to circumvent 
resistance caused by the aminoglycoside phosphotransferases (APHs)19. Generally, 
APHs act on aminoglycosides via transferring the phosphoryl group of ATP to the  
3'-OH of aminoglycosides (Figure 1.10). The designed compound 8a, mainly existing in 
the stable hydrated form 8b, undergoes enzymatic phosphorylation at the 3'-OH of 
ring I to produce 8c. However, the structure of the phosphorylated molecule is 
chemically unstable, thus leading to the elimination of phosphate and regeneration of 
O OR2
H2N NHR1
O
NH2HO
NH2
OH
7
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the original antibiotic. The effectiveness of the modified aminoglycoside in killing both 
susceptible and resistant E. coli was evaluated. When resistant E. coli was treated with 
kanamycin A, the MIC increased 500 to 1,000-fold, whereas with the regenerating 
aminoglycoside 8a, MIC increased only fourfold. However, MIC for the non-resistant  
E. coli was higher for the regenerating aminoglycoside 8a than for kanamycin A. The 
results demonstrated that this strategy is perfectly viable in lowering MIC for resistant 
organisms. 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 
 
 
1.3.2 Neamine analogues by modification of ring II 
 
 Boons et al. employed a convergent approach for facile synthesis of a library of 
24 disaccharides that were α(1–3)-, β(1–3)-, α(1–4)-, or β(1–4)-linked and contained 2 to 4 
amino groups20. These disaccharides were designed to mimic the unique spatial 
arrangements of neamine that are required for the recognition of the RNA target. 
Fourier-transformation ion cyclotron resonance mass spectrometry (FT-ICR MS) was 
used to determine dissociation constants (Kd) for the binding of the disaccharides to a 
prototypical fragment of 16S ribosomal RNA21. Only compounds with three or four 
amino groups showed affinities greater then 50 µM (Figure 1.11). The best compound 
tested was the α(1–4)-linked derivative 10f-α with four amino groups at C2, C2', C6, 
and C6' positions, which displayed an affinity similar to that of neamine.  
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R1 R2 R3 (1–3)−linked Kd [µM] (1–4)−linked Kd [µM] 
NH2 OH OH 9a-α 69 10a-α 166 
NH2 OH OH 9a-β 121 10a-β 71 
OH NH2 OH 9b-α 107 10b-α n.d. 
OH NH2 OH 9b-β 97 10b-β n.d. 
NH2 NH2 OH 9c-α 68 10c-α 40 
NH2 NH2 OH 9c-β 119 10c-β 81 
OH NH2 NH2 9d-α 211 10d-α 187 
OH NH2 NH2 9d-β 108 10d-β 136 
NH2 OH NH2 9e-α 49 10e-α 26 
NH2 OH NH2 9e-β 81 10e-β 87 
NH2 NH2 NH2 9f-α 37 10f-α 11 
NH2 NH2 NH2 9f-β 85 10f-β 39 
   neamine 7   
Figure 1.11 
 
Compounds 9f-α and 10f-α were superimposed on the neamine moiety of 
paromomycin (Figure 1.12). The conformation of paromomycin was the same as that 
observed in the crystal structure complexed with the ribosomal decoding site7a. The Φ 
and Ψ dihedral angles in 9f-α and 10f-α were adjusted to the same values as that 
observed in the bound conformation of paromomycin. The superimposition indicated 
that three of the four amino groups have similar spatial orientations. 
 
 
Figure 1.12      Superimposition of compound A) 9f-α and B) 10f-α with paromomycin. 
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 Hermann et al. published studies on linking the sugar ring of either neamine or 
paromamine to 3-(aminomethyl)piperidine scaffolds22. Eight piperidine derivatives 
were prepared and their antibacterial activities were evaluated (Figure 1.13). It was 
shown that the 3-(aminomethyl)piperidine scaffold does not confer a high potency 
comparable to that of the natural aminoglycosides. 
Figure 1.13 
 
 Based on insights evolving from structural data from X-ray crystallography5,23, 
molecular modelling studies and previous investigations24, Hermann et al. synthesised 
a series of azepane glycosides in which a substituted heterocycle was introduced to 
mimic the unique spatial arrangement of key functional groups in 2-DOS (Figure 1.14). 
The designed ligands 12a and 12b showed moderate antibacterial activity against  
S. aureus and retained this activity against aminoglycoside-resistant strains. 
 To minimize the main recognition motif, Wong and co-workers designed an 
approach that would attach the core pyranoside I to readily available building blocks25. 
Based on a conserved structure of ring I bearing the 1,3-hydroxyamine motif, a 
combinatorial library was constructed via a parallel solution phase method to discover 
small molecules that bind to RNA. In the library, the structures were varied at two 
points, that is, at the anomeric position and at position 2 of the glucose ring through 
reductive amination and acylation respectively (Figure 1.15). The compounds were 
screened in an automated assay based upon SPR, and some were found effective at 
binding a 27-nucleotide model of A-site 16S rRNA as well as a drug-resistant mutant 
RNA in the micromolar range. These small molecules simplify the complexity of 
naturally occurring aminoglycoside antibiotics. 
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 IVT IC50 [µM] RNA IC50 [µM] MIC E. coli [µg mL-1] MIC S. aureus [µg mL-1] 
12a 5.7 11 >64 64 
12b 6.4 12 >64 32 
Figure 1.14   Only azepane glycosides 12a and 12b showed some biological activity. 
 
 Vourloumis et al.26 synthesised a series of acyclic deoxystreptamine mimetics 
targeting the ribosomal decoding site. New strategies were developed for linking ring I 
to alternative scaffolds that may mimic the spatial arrangement of the functional 
groups in 2-DOS, required for the recognition of the bacterial decoding-site RNA 
target. The biological activities of the novel aminoglycoside mimetics as inhibitors of 
bacterial and eukaryotic protein synthesis were evaluated with in vitro translation 
assays that measure the inhibitory effect of compounds on production of luciferase 
reporter protein in a cell-free system. The summarised structure-activity relationship 
for these synthetic compounds showed that none of the acyclic scaffolds confer 
potency comparable to that of the natural aminoglycosides. Some relevant examples 
are depicted in Figure 1.16. 
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 glycosidic substituent BIVTIC50 [µM] EIVTIC50 [µM] RNA IC50 [µM] MIC [µg mL-1] 
15a O NH2
OH
 
860 31 >1000 >64/>64 
15b O NH2
O
 
>1000 88 n.d. n.d. 
15c 
O NH2
O
 
170 >250 >1000 >64/>64 
15d 
O NH2
O
 
180 22 2.3 >64/>64 
15e 
O NH2
O
 
210 49 2.8 >64/>64 
15f 
O NH2
O N
O
H2N
 
130 1.0 41 >64/>64 
15g 
O NH2
O
N
 
190 36 4.9 >64/>64 
 
Figure 1.16   IC50: concentration required for 50% inhibition. BIVT:  inhibition in a bacterial in 
vitro transcription assay. EIVT: inhibition in an eucariotic in vitro transcription assay. RNA: 
RNA-binding affinity assay. MIC: minimum inhibitory concentration against E. coli (first 
value) and S. aureus (second value). 
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1.3.3 Neamine analogues by modification of ring I 
 
 The application of aminoglycosides in a medicinal chemistry program, where a 
rapid preparation of compounds is necessary, is generally thwarted by the required 
synthetic challenge that relies on these structures. Ding et al.24 synthesised mimetics of 
aminoglycosides that have a simpler structure. Computer modelling studies indicated 
that if ring I of neomycin B was replaced by an aromatic group the resulting compound 
would keep the conformation of neomycin B, and the 4-heterocyclic 2-DOS derivatives  
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Figure 1.17   Dissociation constants of 16S ligand complexes based on gas-phase measurements 
of the ratio of free and bound RNA targets (ligands: 75 µM, target RNA: 2.5 µM). a Kd 
measured for the non-separable mixture of two or three isomers. 
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16a–16o (Figure 1.17) were synthesised. Electrospray ionisation mass spectrometry was 
employed to determine solution-phase dissociation constants of the RNA–ligand 
complex on the basis of gas-phase measurements of the ratio of free and bound RNA 
target27. The non-separable mixture of 4-purine-2-deoxystreptamine derivatives 16n,o 
with the dissociation constant 100 µM showed better binding affinities than other 
4-heterocyclic 2-DOS derivatives. On the basis of these results, the synthesis of more 
complex mimetics of aminoglycosides was realised, obtaining a paromomycin 
derivative with ring I replaced by an heterocycle which showed a potency comparable 
to the natural compound28.   
 2,5-dDOS-4-carboxyl amide derivatives in which the ring I was replaced with 
planar non-sugar motifs were prepared by Vourloumis et al.29 (Figure 1.18). The 
biological activity of the compounds was evaluated with the decoding site of bacterial 
16S RNA in a coupled in vitro transcription-translation assay using firefly luciferase as 
a reporter. However, no significant antibiotic activity increase was achieved by 
comparing with the parental aminoglycosides and only compound 17g proved to have 
a moderate activity. 
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Figure 1.18  IC50 values were measured by a coupled in vitro transcription-translation assay 
using firefly luciferase. a A counter screen suggested that compounds 17h and 17i are inhibitors 
of the luciferase reporter enzyme and these values might not be accurate.  
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1.4 Aim of the project 
 
 Based on the NMR and crystallographic studies which proved the presence of 
internal hydrogen bonds involving the 2'-position of neomycin and paromomycin in 
their bioactive conformation7a,b (Figure 1.3), we envisaged the synthesis of 2'-modified 
neamine analogues which may serve as scaffolds for simpler synthetic 
aminoglycosides. Such analogues could be further functionalised in a selective manner, 
or serve as intermediates towards constrained neamine analogues mimicking the 
bioactive conformation of neomycin (Chapter 6). 
The structures of aminoglycosides are synthetically challenging. Due to their structural 
complexity, selective protection followed by chemical modification is complex, thus 
thwarting the rapid preparation usually necessary in a medicinal chemistry project. We 
intended to simplify our synthetic challenge by commencing with the individual 
building blocks of the pseudodisaccharide neamine. In this thesis we report highly 
convergent syntheses by coupling asymmetric 2-deoxystreptamine (Chapter 2) with 
different sugar moieties. In such task we succeeded by performing Michael additions 
to nitroglycals (Chapter 3) or α-glycosidations (Chapter 4). In either case the 2'-position 
is free for further manipulation, and in this context, a procedure to convert  
α-mannosides to α-glucosides was investigated (Chapter 5). 
After deprotection, final compounds were tested in several bioassays as well as NMR 
binding experiments to rRNA (Chapter 7). 
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Chapter 2 
 
Synthesis of asymmetrically protected  
2-deoxystreptamine precursors 
 
 
 
Abstract: 
 
2-Deoxystreptamine (2-DOS) is the central scaffold of aminoglycoside antibiotics and as such a 
key element in the development of new aminoglycoside analogues. Several groups have reported 
total syntheses of 2-DOS, but in the majority of cases many synthetic steps were required. 
A more straightforward route to 2-DOS involves acidic degradation of naturally occurring 
aminoglycoside antibiotics. The unprotected 2-deoxystreptamine obtained by full hydrolysis of 
glycosidic bonds is, however, a meso compound and therefore reagents or enzymes are 
inevitable to perform selective differentiation on the functional groups of this molecule. 
Alternatively, aminoglycoside antibiotics such as neomycin can be selectively O-protected, thus 
paving the way for a selective cleavage of glycosidic bonds to obtain 2-DOS as a versatile chiral 
derivative. 
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2.1 Introduction 
 
In the first chapter the central role of 2-deoxystreptamine (2-DOS) in the 
bioactivity of most aminoglycoside antibiotics was discussed. The essential presence of 
2-DOS in an aminoglycoside has been broadly recognised and several synthetic routes 
towards 2-DOS or protected variants thereof have been reported through the years1. 
Despite the synthetic efforts, however, the simplest way to obtain 2-DOS still involves 
full acid hydrolysis of all glycosidic bonds of a naturally occurring aminoglycoside.  
In particular, neomycin trisulfate (1) stands out, because neomycin is readily obtained 
from Streptomyces and is commercially available for approximately  
0.7 €/g. Upon reflux with concentrated hydrobromic acid, all glycosidic bonds in 
neomycin are hydrolysed, yielding 2-DOS as a dihydrobromide salt after a simple 
filtration procedure (Scheme 2.1). 
Scheme 2.1 
 
The resulting diaminohexanetriol, however, has lost stereochemical integrity due 
to the internal plane of symmetry. Consequently, structure 2 is a meso compound and 
requires regioselective protection for application as an enantiomerically pure building 
block. Only few approaches to convert 2 into an enantiopure derivative have been 
reported involving either enzymatic or chemical enantiodifferentiation. Enzymatic 
routes include enantioselective N-allyloxycarbonylation under the action of subtilisin2, 
selective monohydrolysis of bis-N-phenylacetyl protected 2-DOS3  or resolution by 
enantioselective acetate hydrolysis of the tri-O-acetylated diazido derivative of 2-DOS4. 
In the same paper, chemical desymmetrization was also achieved by application of the 
chiral dispiroketal protective group. Alternatively, the functional groups of neomycin 
(1) can be sequentially protected before hydrolysis of the glycosidic bonds, leading to 
1
HO
H2N NH2
OH
OH
conc. HBr
2
O
H2N NH2
OHO
O
OHHO
OH
NH2
O
NH2
OH
NH2
OH
O
H2N
O
·3 H2SO4
HO
·2 HBr
Synthesis of asymmetrically protected 2-deoxystreptamine precursors 
 
25 
asymmetrically and suitably functionalised 2-DOS in a few straightforward steps and 
100% enantiomeric excess. For the purpose of this project the last method was chosen. 
 
 
2.2 Degradation of neomycin 
 
 Treatment of neomycin trisulfate (1) with 2 M hydrochloric acid in refluxing 
methanol leads to selective hydrolysis of the furanosyl glycosidic bond (Scheme 2.2), 
giving a mixture of two dimeric structures, i.e. neamine 3 and neobiosamine B 
methylglycoside (not depicted). Gratifyingly, the desired neamine tetrahydrochloride 
selectively crystallises out of the reaction mixture upon cooling. Although several 
authors5 reported on the preferential use of neomycin free base as starting material for 
the acid hydrolysis, we have experienced that the time-consuming ion exchange 
chromatography is not rewarded by a significantly higher yield6.  
Following chemistry reported by Mobashery et al.7 the amino groups of neamine 
3 were Cbz-protected upon treatment with benzyl chloroformate, followed by 
differentiation of the two vicinal diols by subjection of 4 to 1,1-dimethoxycyclohexane 
in the presence of p-toluenesulfonic acid and DMF.  Under these conditions an acetal 
was selectively introduced between O5 and O6 to give compound 5, although the 
formation of minor amounts of biscyclohexylidene-protected derivative (6) could not 
be avoided. Fortunately, the yield of the desired acetal 5 could be further raised by 
treatment of the bisprotected structure 6 with a catalytic amount of p-toluenesulfonic 
acid in a solution of MeOH and dry DMF. 
 
Scheme 2.2 
 
With minor modification, conditions reported by Cañas-Rodriguez et al.8 were 
applied to selectively remove the diaminoglycopyranoside of 5 without affecting 
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protective groups. Thus, diol 5 was subjected to oxidative glycol cleavage with sodium 
periodate in a mixture of tetrahydrofuran, water and dioxane, to form dialdehyde 7 as 
a crude intermediate. Without further purification, 7 was treated with triethylamine in 
ethanol to induce β-elimination and yield the conveniently protected 2-DOS derivative 
8. For purification reasons, the concomitantly formed α,β-unsaturated dialdehyde was 
reduced with sodium borohydride prior to silica gel chromatography to obtain 
compound 8 in 42% yield from 5 (Scheme 2.3). Thus, an enantiopure 2-DOS derivative 
was obtained in only five synthetic steps and 18% overall yield from neomycin, with 
the O-4 position selectively unprotected. Compound 8 will serve as a useful building 
block for the generation of neamine analogues, as will be delineated in later chapters. 
 
Scheme 2.3 
 
 
2.3 Azide protection 
 
Despite the apparent usefulness of compound 8 generated above, there are some 
specific disadvantages associated with the use of benzyloxycarbonyl groups for amine 
protection, in particular with regards to solubility and analysis. Firstly, carbamate-
protected aminosugars are usually poorly soluble and require tedious silica gel 
chromatography, as in the separation of monocyclohexylidene-protected 5 from the 
bisprotected by-product 6. In addition, carbamates are typically present as a mixture of 
slowly rotating rotamers, thus rendering 1H NMR interpretation complex, particularly 
in case of multiple carbamates in a single molecule.  In order to circumvent the 
disadvantages associated with carbamates, an alternative mode of amine masking by 
means of azide was investigated. Free amines can be converted into azides in a single 
transformation involving a so-called azido transfer reaction, induced by treatment of 
an amine with trifluoromethanesulfonyl (triflyl) azide (9) as shown in Scheme 2.4. 
Triflyl azide is unstable and must be freshly generated from triflic anhydride and 
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sodium azide. It can be explosive when dried9 and must be handled in solution before 
addition of the amine. 
Scheme 2.4 
 
 Thus, in order to liberate the free amines, the benzyloxycarbonyl groups of 
compound 8 were removed by hydrogenation to generate 10. Without further 
purification, the azido transfer reaction was performed with 10 applying Wong's 
protocol10, involving the addition of catalytic copper sulfate, to afford the protected  
2-DOS derivative 11 (Scheme 2.5).  
 
 
 
 
 
 
Scheme 2.5 
 
 Figure 3.1 shows the 1H NMR of 8, where the signals are broad due to the 
presence of carbamates. Figure 3.2 shows the simpler spectrum of compound 11, in 
which the signals appear sharp. It is interesting to note the singularity of the 
diastereotopic methylidene group at C2. The equatorial proton is quite deshielded and 
appears at lower field than expected (2.3 ppm). The coupling constants with the two 
vicinal protons are identical while the geminal proton couples with a larger constant 
showing a doublet of triplets. The axial proton appears as a quartet overlapped by the 
cyclohexylidene signals. In addition, compound 11 proved to be slightly more soluble 
than 8 in organic solvents, especially in toluene and ethyl acetate.  
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Figure 3.1   1H NMR spectrum of 8 (400 MHz, CDCl3). 
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Figure 3.2   1H NMR spectrum of 11 (400 MHz, CDCl3). 
  
The advantages of diazido compound 11 with respect to the biscarbamate 8 , both 
in terms of solubility and NMR analysis, stimulated us to investigate whether 11 could 
be obtained in a more efficient and straightforward manner.  In particular, we reasoned 
that the elaborate protective group interconversions could be circumvented by direct 
transformation of neamine into a tetraazido derivative before elimination of the 
diaminoglucopyranoside ring. Thus, azido transfer reaction on neamine (3) led to 
tetraazido compound 12 in good yield. It was found that the use of zinc chloride 
catalyst instead of copper sulfate led to an improved yield with respect to the original 
conditions as reported by Wong11. Following chemistry reported by Chang et al.12, 
differentiation of the two vicinal diols was performed, as before, by selective 
introduction of a cyclohexylidene group at O-5 and O-6. In contrast to cyclohexylidene-
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protection of tetracarbamate 4, it was found that in this case the reaction did not go to 
completion. On the other hand, the undesired double protection of both diols was not 
encountered to give exclusively the desired monoprotected compound 13, which was 
readily separated from remaining starting material. Finally, the residual sugar diol was 
oxidatively cleaved to a dialdehyde, followed by β-elimination and reductive work-up 
to afford diazido 2-DOS precursor 11 (Scheme 2.6) in only three steps from neamine 
tetrahydrochloride and an overall yield of 26%. 
 
Scheme 2.6 
 
As anticipated, tetrazidoneamine 12 as well as the monocyclohexylidene 
derivative 13 were more soluble than the corresponding carbamates. Cyclohexylidene 
protection was performed in acetonitrile instead of DMF and chromatographic 
purification was facilitated by good solubility in ethyl acetate. In fact, 12 forms a 
strongly coordinating complex with ethyl acetate, necessitating azeotropic distillation 
with methanol for complete removal. What also came as a surprise was the finding that 
compound 12 was completely insoluble in chlorinated solvents (CHCl3, CH2Cl2).  
 
 
2.4 Conclusions 
 
Enantiopure and asymmetrically protected 2-DOS derivatives were obtained in a 
few straightforward steps from readily available neomycin trisulfate (1).  A comparison 
was made between the application of carbamate groups to protect the amines and 
temporary masking as azides. Significantly different behaviour in terms of solubility 
and spectroscopic analysis was encountered, favouring the azido precursors in both 
respects.  Two alternative routes towards an enantiopure cyclohexylidene-protected 
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diazido derivative of 2-DOS were explored, favouring the azido transfer reaction at the 
stage of the neamine precursor. The resulting 2-DOS precursors may serve as versatile 
scaffolds for novel O-4 linked neamine-type aminoglycosides for application as  
RNA-binding ligands.   
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2.6 Experimental Section 
 
General methods and materials 
Solvents were distilled from appropriate drying agents prior to use and stored under 
nitrogen. Reactions were carried out under an inert atmosphere of dry nitrogen or 
argon. Standard syringe techniques were applied for the transfer of dry solvents and 
air- or moisture-sensitive reagents. RF values were obtained using thin layer 
chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the indicated 
solvent mixture. Compounds were detected with UV-light, ammonium molybdate 
solution, potassium permanganate, ninhydrin, or with anisaldehyde/H2SO4. Melting 
points were analysed with a Büchi melting point B-545. IR spectra were recorded on an 
ATI Mattson Genesis Series FTIR spectrometer, or a Bruker Tensor 27 FTIR 
spectrometer. NMR spectra were recorded on a Bruker DMX 300 (300 MHz) and a 
Varian 400 (400 MHz) spectrometer in CDCl3 or D2O solutions (unless otherwise 
reported). Chemical shifts are given in ppm with respect to tetramethylsilane (TMS) or 
HDO (4.79 ppm)13 as internal standard. Coupling constants are reported as J-values in 
Hz. Peak assignment in 13C spectra are based on 2D-GHSQC and GHMBC spectra. 
Column or flash chromatography was carried out using ACROS silica gel (0.035–0.070 
mm, and ca 6 nm pore diameter). Ion-exchange column chromatography was carried 
out using Amberlite CG-50 resin in NH4+ form. Optical rotations were determined with 
a Perkin Elmer 241 polarimeter. High resolution mass spectra were recorded on a JEOL 
AccuTOF (ESI), or a MAT900 (EI, CI, and ESI). MALDI-TOF-MS spectra were 
measured on a Bruker Biflex III machine, with dihydroxybenzoic acid (DHB) as matrix. 
Elemental analyses were carried out using a Carlo Erba Instruments CHNS-O EA 1108 
element analyser. 
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Neamine tetrahydrochloride (3) 
Neomycin trisulfate (52 g, 57.2 mmol) was mixed with MeOH 
(1500 mL) and brought to reflux. The starting material slowly 
dissolved while concentrated HCl (12.1 N) was added 
dropwise until an approx. 2 N solution was obtained (280 mL). 
Refluxing conditions were maintained for 12 h before cooling 
the reaction to room temperature. The light yellow solution was evaporated to half of 
its volume and cooled to 0 °C. A solid precipitated and was filtered on a Büchner 
funnel, then placed under high vacuum for 3 days to give the desired product 3 as a 
white powder (15.7 g, 33.7 mmol, 59% yield). Analytical data were identical to those 
reported by Wong et al.5  
 
1,3,2',6'-Tetra-N-benzyloxycarbonylneamine (4)  
 Compound 4 was synthesised as reported by Wong et al.5 
 
 
 
 
 
1,3,2',6'-tetra-N-benzyloxycarbonyl-5,6-O-cyclohexylideneneamine (5) 
Compound 5 was synthesised as reported by Mobashery  
et al.7 
 
 
 
 
1,3-Di-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine (8) 
 Solutions of 6 (9.36 g, 10.0 mmol) in THF (100 mL) and sodium 
periodate (4.5 equiv., 9.6 g, 44.9 mmol) in water (100 mL) were 
mixed and 1,4-dioxane (25 mL) was added. The reaction was 
stirred for 20 h. THF and dioxane were evaporated and the water 
extracted with CH2Cl2 (3 x 75 mL). The combined extracts were 
washed with brine, dried over MgSO4 and concentrated. The crude dialdehyde was 
dissolved in EtOH (160 mL) and Et3N was added (16 mL). The solution was stirred for 
3 days and then concentrated. The syrupy residue was dissolved in EtOH (160 mL), 
treated with a solution of NaBH4 (2.1 equiv., 792 mg, 20.9 mmol) in H2O (20 mL) and 
stirred for 12 h. The solvent was evaporated, H2O was added (60 mL) and extracted 
with CH2Cl2 (3 x 60 mL). The combined extracts were dried over MgSO4 and 
concentrated. The crude product was purified by flash column chromatography on 
silica gel by eluting with EtOAc/heptane (1/1) containing 1% of Et3N, affording 
compound 8 as a white powder (2.14 g, 4.19 mmol, 42%). RF = 0.24 (EtOAc/heptane, 
1/1); [α]20D = –16.4 (c = 0.01 g mL-1, CH2Cl2); mp = 160-162 ºC; 1H NMR (400 MHz, 
CDCl3): δ = 7.34-7.32 (m, 10H), 5.13-5.06 (m, 4H), 4.95 (d, J = 7.6 Hz, 2H), 3.82-3.55 (m, 
3H), 3.46 (t, J = 9.2 Hz, 1H), 3.38-3.34 (br m, 1H), 3.17 (br s, 1H), 2.52-2.50 (br m, 1H), 
1.66-1.59 (m, 8H), 1.38 (br s, 3H);  13C NMR (75 MHz, CDCl3): δ = 156.41, 155.42, 135.95, 
135.81, 128.34, 128.31, 128.29, 128.02, 127.96, 112.58, 80.40, 77.95, 73.54, 67.16, 66.94, 
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65.29, 53.79, 49.52, 36.45, 36.29, 25.05, 23.78, 23.72; IR (neat): ν = 3304, 1687, 1539, 1276, 
1065;  HRMS (ESI): calcd for C28H34N2O7Na (M + Na+) 533.2264, found 533.2259. 
 
1,3-Diazido-1,3-dideamino-5,6-O-cyclohexylidene-2-deoxystreptamine (11) 
From 8: Compound 8 (100 mg, 0.196 mmol) was dissolved in MeOH and 
a catalytic amount of 10% palladium on carbon was added. The reaction 
mixture was stirred under 1 atm of H2 for two days, then filtered 
through Celite and the solvent evaporated to obtain the crude 
intermediate 11. Tf2O (10 equiv., 330 µl, 1.96 mmol) in CH2Cl2 (1 mL) 
was added to a solution of NaN3 (70 equiv., 892 mg, 13.72 mmol), K2CO3 (14 equiv., 379 
mg, 2.74 mmol) and crude 10 in H2O (2 mL). The reaction mixture was stirred at rt for  
2 h. Then MeOH (1 mL) and CuSO4·5H2O (0.1 equiv., 5 mg, 0.020 mmol) were added 
and the mixture stirred for another 22 h. The reaction was treated with 1 N NaOH to 
homogeneity and repeatedly extracted with EtOAc, dried over MgSO4 and 
concentrated under reduce pressure. The crude product was purified by flash column 
chromatography on silica gel by eluting with EtOAc/heptane (1/4) containing 1% of 
Et3N. Compound 11 was obtained as white needles (38 mg, 0.129 mmol, 66% over two 
steps). 
From 13: Solutions of 13 (7.7 g, 15.20 mmol) in dioxane (125 mL) and NaIO4  
(4.5 equiv., 14.63 g, 68.41 mmol) in H2O (250 mL) were mixed and MeOH (125 mL) was 
added. The reaction was stirred for 20 h. Dioxane and MeOH were evaporated and the 
H2O extracted with CH2Cl2 (3 x 200 mL). The combined extracts were washed with 
brine, dried over MgSO4 and concentrated. The crude dialdehyde was dissolved in 
EtOH (160 mL) and Et3N was added (15 mL). The solution was stirred for 2 days and 
then concentrated to eliminate the Et3N. The syrupy residue was dissolved in EtOH 
(160 mL) treated with NaBH4 (2.1 equiv., 1.21 g, 31.93 mmol) and stirred for 12 h. The 
solvent was evaporated, H2O was added (60 mL) and extracted with CH2Cl2  
(3 x 60 mL). The combined extracts were dried over MgSO4 and concentrated. The 
crude product was purified by flash column chromatography on silica gel by eluting 
with EtOAc/heptane (1/4) containing 1% of Et3N. Compound 11 was obtained as 
white needles (1.92 g, 6.54 mmol, 43% over two steps). RF = 0.25 (EtOAc/heptane, 1/4), 
[α]20D = –2.3 (c = 0.01 g mL-1, CH2Cl2); mp = 88-90 ºC; 1H NMR (400 MHz, CDCl3):  
δ = 3.74-3.61 (m, 2H), 3.46-3.37 (m, 3H) 3.03 (s, 1H), 2.29 (dt, J = 13.7 Hz, J = 5.0 Hz, 1H, 
H-2eq), 1.73-1.58 (m, 8H), 1.49-1.35 (m, 3H);  13C NMR (75 MHz, CDCl3): δ = 113.73, 
79.56, 79.43, 74.44, 62.70, 57.78, 36.69, 36.62, 34.15, 25.36, 24.18, 24.10; IR (neat): ν = 3434, 
2099;  HRMS (ESI): calcd for C12H19N6O3 (M + H+) 295.1519, found 295.1494. 
 
1,3,2',6'-Tetraazido-1,3,2',6'-tetradeaminoneamine (12) 
Synthesis of compound 12 was reported in literature10,12, but no 
analytical data had been provided, therefore we include it in this 
chapter. White powder; RF = 0.39 (EtOAc/heptane, 2/1); 
[α]20D = +124.1 (c = 0.01 g mL-1, CH2Cl2); mp = 54-55 ºC; 1H NMR 
(400 MHz, CD3OD): δ = 5.64 (d, J = 3.7 Hz, 1H), 4.17 (m, 1H), 
3.86 (dd, J = 10.5 Hz, J = 8.9 Hz, 1H), 3.54-3.24 (m, 8H), 3.12 (dd, J = 10.5 Hz, J = 3.7 Hz, 
1H), 2.25 (dt, J = 12.3 Hz, J = 4.2 Hz, 1H, H-2eq), 1.41 (q, J = 12.3 Hz, 1H, H-2ax);   
13C NMR (75 MHz, CD3OD): δ = 99.65, 81.07, 77.93, 77.87, 73.20, 72.67, 72.22, 64.67, 
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61.77, 60.87, 52.60, 33.18; IR (neat): ν = 3369, 2100, 1030;  HRMS (ESI): calcd for 
C12H18N12O6Na (M + Na+) 449.1370, found 449.1408. 
 
1,3,2',6'-tetraazido-5,6-O-cyclohexylideneneamine (13) 
Compound 13 was synthesised as reported by Chang et al.12 
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Chapter 3 
 
 Glycals as building blocks for the synthesis of  
2'-modified neamine analogues 
 
 
 
Abstract: 
 
Glycals, carbohydrates with a 1,2-double bond, offer a wide possibility of reactions by virtue of 
the enol ether functionality. The versatility of glycals was studied in a variety of model 
couplings followed by application to 2-deoxystreptamine in the preparation of new analogues of 
neamine. Two alternative strategies were followed involving either iodoglycosylation or 
nucleophilic addition to nitroglycal. Iodoglycosidation of glucal with suitably protected  
2-deoxystreptamine led to an α-configured coupling product with an iodide at the 2’-position 
for further transformation. The alternative strategy involved prior conversion of glycal to a 
2-nitroglycal thereby providing a suitable electrophile for carbohydrate coupling via Michael 
addition. 
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3.1 Introduction 
 
In Chapter 2 several strategies were described to obtain suitably protected 
2-deoxystreptamine (2-DOS), a key scaffold en route to analogues of aminoglycoside 
antibiotics. Typically, 2-DOS is substituted with carbohydrates at position O4, in 
combination with further glycosylation patterns at either O5 or O6. As a consequence, 
aminoglycoside antibiotics can be roughly divided in the so-called 4,5- and  
4,6-substituted subclasses (Figure 3.1). Within the subclass of 2-DOS 4,5-substituted 
derivatives, the carbohydrate at the O4 position is in the vast majority of cases a 
(partially deoxygenated) 2,6-diaminoglycoside. As such the pseudo-disaccharide 
neamine, i.e. 4-O-(α-2,6-diaminoglucopyranosyl)-2-deoxystreptamine, may be 
considered a privileged scaffold for the generation of libraries of aminoglycoside 
analogues. However, the regioselective functionalisation of neamine itself, although 
readily obtained by acid hydrolysis of neomycin, is thwarted by the cumbersome 
differentiation of the plethora of functional groups. Thus, it was envisioned that a  
step-wise construction of neamine analogues from 2-deoxystreptamine would entail a 
more versatile and flexible strategy, and we anticipated that glycals could act as 
convenient building blocks for the synthesis of such analogues. In this chapter, studies 
are presented to obtain novel neamine analogues based on a variety of coupling 
reactions of enantiomerically protected 2-DOS derivatives with glycals.  
 
Figure 3.1                   4,5- and 4,6-substituted 2-DOS aminoglycosides 
 
 A typical glycosylation, i.e. condensation of two carbohydrate fragments by 
formation of a new glycosidic bond, proceeds through oxycarbenium ion generation by 
leaving group activation at one carbohydrate (the 'donor') in the presence of a second 
carbohydrate coupling partner (the 'acceptor'). For the two methods described in this 
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chapter, however, activation of a leaving group at the anomeric centre is unnecessary 
(Scheme 3.1). In the first method an electrophile, typically a positively charged 
halogen, reacts with the electron-rich double bond of the donor glycal 1, thereby 
generating an activated halonium ion species. Subsequently, the free hydroxyl function 
of a carbohydrate acceptor or other alcohol (ROH) will attack, leading 
stereospecifically to the 1,2-trans product. The halogen E that ends up in product 2 at 
position C2 may serve as a versatile synthetic handle for further transformations. 
 
 
 
 
 
 
Scheme 3.1 
 
 The second approach involves the introduction of a nitro group in the 2-position 
of a glycal. The resulting 2-nitroglycal 3 is an electron-deficient alkene and may 
therefore be subjected to Michael addition with an alcohol at the anomeric position. 
The remaining nitro function in product 4 can act as a masked amino group. 
 
 
3.2 Iodoglycosylation of glycals  
 
 Iodoglycosylation of a glycal involves an oxidative coupling first developed by 
Lemieux1 and Thiem2 and later improved by Danishefsky3 (Scheme 3.2). Typically, a 
glycal double bond is attacked by a iodonium source such as N-iodosuccinimide (NIS) 
or iodonium di-sym-collidine perchlorate (IDCP). The resulting 1,2-iodonium ion 
intermediate 5 is a highly electrophilic species that triggers the addition of an alcohol at 
the anomeric position. The stereochemistry of the second step of the iodoetherification 
involves a stereospecific trans-addition of the alcohol, leading in the majority of cases 
to a manno-configured α-linked 2-deoxy-2-iodoglycoside4 (6).  
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Scheme 3.2 
 
Products like 6 have been mainly used to synthesise 2-deoxy-α-glycosides by 
reductive dehalogenation5. However, we were interested in the possibility of the direct 
conversion of iodide 6, by SN2 reaction with azide as a masked amino function, into a 
2-amino glycoside precursor.  
Our initial studies on the iodoglycosylation of glycals focused on the oxidative 
coupling of tri-O-acetyl-D-glucal (8) with diisopropylidene-D-glucose6 (10) as a model 
carbohydrate (Scheme 3.3). However, under the action of NIS or IDCP no reaction 
occurred. Obviously, the electron-withdrawing character of the acetyl substituents of 8 
rendered the 1,2-double bond insufficiently electron-rich for activation. Indeed, similar 
treatment of tribenzyl-protected D-glucal (9) with IDCP in the presence of 10 
successfully produced dimer 12 in good yield.  
 
Scheme 3.3 
 
 Encouraged by this result, coupling of glucal 9 with the suitably protected 2-DOS 
derivative 13 was attempted under identical conditions (Scheme 3.4). Much to our 
satisfaction, the dimeric structure 14 was formed in good yield. Moreover, compound 
14 possesses the proper α-manno-configuration, suitable for direct introduction of an 
azido function at C2 by nucleophilic substitution. 
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Scheme 3.4 
 
Different attempts to displace the iodide of 14 with azide were undertaken. 
However, no reaction was observed by prolonged treatment of 14 with sodium azide 
in DMF, even in the presence of 15-crown-5. Similarly, addition of a source of Ag+ such 
as silver triflate or silver tetrafluoroborate produced only tiny amounts of a product, 
the structure of which could not be elucidated since it could not be effectively 
separated from the substrate. Due to the reluctance of 2-DOS derivative 14 to undergo 
nucleophilic substitution and the inability to determine the nature of the formed  
side-product, the more readily available compound 12 was investigated as a model 
iodoglycoside to elucidate the degradation mechanism (Scheme 3.5). Thus, after 
stirring in DMF at 55 ºC for three days, in the presence of sodium azide and  
15-crown-5, a new product was isolated in good yield. Analysis by NMR, IR 
spectroscopy and mass spectrometry revealed that the formed material was 
elimination product 15. Apparently, the secondary iodide is rather unreactive for direct 
nucleophilic substitution by equatorial nucleophilic attack. Instead, the good leaving 
group ability of the iodide leads to effective E2 elimination via deprotonation of the 
antiperiplanar axial proton at C3. As a consequence of the reluctance of the 2-iodide to 
nucleophilic displacement the strategy of oxidative coupling of glycals was abandoned. 
 
 
 
 
 
 
Scheme 3.5 
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3.3 Michael addition to nitroglycals 
 
An interesting alternative to the oxidative coupling of glycals is found in  
Michael-type addition reactions of (deprotonated) carbohydrate alcohols to  
2-nitro-D-galactal7 or 2-nitro-D-glucal8. We were particularly interested in applying 
nitrogalactal chemistry in the synthesis of neamine analogues for two reasons. First of 
all, it has been reported that Michael addition to nitrogalactals proceeds with high 
stereoselectivity, leading to the desired α-configured 1,2-cis product. Secondly, the 
axially oriented 4'-OH of the resulting adducts differs from the all-equatorial neamine 
stereochemistry, and as such may lead to interesting new candidates for bioactivity 
studies. 
 The first preparation of 2-nitroglycals was reported by Lemieux et al. and 
involved the treatment of glycals with nitrogen dioxide9. Later, Holzapfel et al. 
improved the procedure by subjecting glycals to nitronium tretrafluoroborate at low 
temperature8a. More recently Schmidt et al.7,10 further improved the nitroglycal 
synthesis by applying in situ generated acetyl nitrate at low temperature. Thus, galactal 
16 (Scheme 3.6) was converted into nitroacetate derivative 17 and subsequently into 
nitrogalactal 18 via elimination with triethylamine.  
 
 
Scheme 3.6 
 
The latter nitrogalactal 18 has been shown to be particularly suitable for the 
synthesis of disaccharides, as well as glycopeptides, by virtue of the highly 
stereoselective Michael addition of alcohols, affording the 1,2-cis configured α-2-deoxy-
2-nitropyranoside adduct. On the other hand, Michael-type addition reaction of an 
alcohol to the corresponding gluco-configured tri-O-benzyl-2-nitro-D-glycal showed 
contradictory results. Holzapfel et al. reported the selective formation of β-gluco 
configuration8a, however only relatively small nucleophiles without sterically 
demanding groups were used. Vankar et al. reported an α/β-gluco mixture for the 
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addition of the carbanion derived from dimethyl malonate8b. A similar result was most 
recently reported by Schmidt et al., and involved the formation of α/β-mixtures with 
variable ratios in the addition of a range of lactate ester anions8c. Since these findings 
provided no clear indication whether nucleophilic addition of a suitably protected 
2-DOS to 2-nitroglucal could afford the desired diastereoisomer, model studies were 
performed to determine the optimal conditions for stereoselective addition.  
Initial test additions involved the nucleophilic addition of alcohol 10 to 
nitrogalactal 18. Based on literature precedent7a,c, the use of THF or toluene as solvent, 
in combination with two different bases, KOtBu and potassium hexamethyldisilazanide 
(KHMDS) appeared most logical. The outcome of a set of ten reactions with different 
conditions is depicted in Table 3.1. 
 
 
 
 
 
 
 
entry 10 (equiv.) solvent base (equiv.) yield of 19 (%) 
1 1.1 THF KOtBu (0.15) 31 
2 2 THF KOtBu (0.15) 19 
3 1.1 THF KHMDS (1.1) 0 
4 2 THF KHMDS (1.1) 0 
5 1.1 THF KHMDS (1.1) 43 
6 1.1 toluene KOtBu (0.15) 59 
7 2 toluene KOtBu (0.15) 38 
8 1.1 toluene KHMDS (1.1) 0 
9 2 toluene KHMDS (1.1) 0 
10 1.1 toluene KHMDS (1.1) 65 
 
Table 3.1          All reactions were performed at rt and quenched with acetic acid.  
                          Typical reaction time was 2 h. 
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In a typical experiment, nitrogalactal 18 and alcohol 10 were dissolved in THF or 
toluene and treated at room temperature with a specific amount of base. The latter 
stoichiometry was found to be of essential influence on the outcome of the reaction, 
since addition of a small excess of base (1.1. equiv.) resulted, unexpectedly, in 
decomposition of the nitrogalactal 18 (entries 3, 4, 8 and 9). In contrast, the use of only 
a catalytic amount of base (0.15 equiv.) significantly improved the yield. It was also 
found that toluene generally afforded the desired adducts with higher yield. Best 
results were obtained in entries 6 and 10, where galactal 18 and a small excess of 
glucoside alcohol 10 were dissolved in toluene, and a substoichiometric amount of base 
was applied. Surprisingly, a higher ratio of alcohol to nitrogalactal led to a decrease in 
yield (entries 2 and 7). Product yield was optimal when KHMDS was applied instead 
of KOtBu (entry 10). Proof of the stereochemical identity of product 19 was mostly 
based on the spin-coupling constant of the anomeric proton11 (δ1’H = 5.62, J1’,2’ = 4.3 Hz). 
However, apart from the desired major product, TLC analysis showed the formation of 
traces of side-products in all cases. To our dismay, none could be isolated in sufficient 
amounts to determine the stereochemical identity of the other diastereoisomers. 
Formation of 19 as the major product can be rationalised by steric factors, where the 
nucleophile approaches preferentially to the α-side of the nitrogalactal, both in the 4H5 
and 5H4 conformers.  
 After these model studies, attention was focussed on the addition of 2-DOS 13 to 
nitrogalactal 18. Application of the optimal conditions of Table 3.1 (toluene, catalytic 
KHMDS) successfully led to the desired product 20 with good stereochemical control 
(Scheme 3.7). The somewhat lower yield with respect to addition of diisopropylidene 
glucoside 10 may be due to the more sterically demanding hindrance of 13. The galacto-
configured compound 20 would afford a new neamine analogue after deprotection, as 
described in Chapter 7. 
 
 
 
 
 
Scheme 3.7 
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The successful application of nitroglycal chemistry for the formation of the  
α-galacto configured adducts, stimulated us to investigate the application of the 
methodology to nitroglucals. Therefore, again a model study was performed by 
addition of glucofuranoside 10 to tri-O-benzyl-2-nitro-D-glucal 218a,12. Under the 
previous developed conditions (entry 10 of Table 3.1), an incomplete reaction was 
observed between the separate reaction partners and the Michael adduct 22  
(Scheme 3.8). Upon quenching, the obtained α/β mixture (2:1) of Michael addition 
products appeared difficult to separate. Nevertheless, besides a mixture of two 
stereoisomers (20%), a small amount (6%) of the major product could be obtained in 
pure form, which after careful NMR analysis was found to be the desired α-configured 
addition product 22. Thus, the anomeric proton H1' appeared at δ1'H = 5.66 with a 
typical 1,2-cis coupling constant J1',2' = 3.9 Hz. The β-configured adduct 22-β could not 
be obtained in pure form but elucidation from the spectrum of the α/β mixture 
revealed a δ1'H = 4.90 and a typical 1,2-trans coupling constant of J1',2' = 8.2 Hz. 
Interestingly, subjecting the α/β mixture to identical reaction conditions led to 
formation of the substrates, thus providing a clue that the Michael addition reaction is 
in equilibrium with an E1cB-mechanism leading back to the starting components. 
 
 
 
 
 
 
Scheme 3.8 
 
 Despite the poor yield of α-22, reactions were nevertheless performed to 
investigate the base-induced Michael addition of 2-DOS derivative 13 to nitroglucal 21 
(Table 3.2). Also in this case, under identical conditions as above an equilibrium 
reaction was observed with α-glucoside (δ1'H = 5.75, J1',2' = 3.9 Hz) predominating in an 
inseparable mixture that was isolated in 38% yield (entry 2, ratio 20:3). More 
surprisingly, the minor component was not the β-configured glucoside, but the  
α-mannoside instead (δ1'H = 5.70, J1',2' = 1.8 Hz). 
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entry 13 (equiv.) base (equiv.) yield of 23 (%) α-glc : α-man 
1 1.1 KHMDS (1.1) - - 
2 1.1 KHMDS (0.15) 38a 20 : 3 
3 0.5 KHMDS (0.15) 50b 20 : 3 
 
Table 3.2          aBORSM: 60%. bYield related to 13  
 
Again, an equimolar amount of KHMDS with respect to the alcohol resulted in 
decomposition of the nitroglycal (entry 1). Interestingly, lowering the amount of  
2-deoxystreptamine alcohol 13 to 0.5 equiv. rendered 23 in an enhanced 50% yield 
(entry 3).  
 Finally, it was investigated whether the stereoselectivity of the Michael reaction 
could be influenced by introduction of a bulky TBDPS-group on the 6-O-position of the 
glucal, similar to results reported for 3,4-di-O-benzyl-6-O-TBDPS-2-nitro-D-galactal7c. 
To this end, compound 25 was synthesised from known glucal 2413 in the same manner 
as before. Michael addition of 13 to 25 was catalysed by potassium tert-butoxide but 
unfortunately led to the formation of only 17% of the desired product 26 (δ1'H = 5.70,  
J1',2' = 3.6 Hz), along with 22% of a non-separable mixture of diastereoisomers of 
undefined stereochemistry (Scheme 3.9). The use of catalytic KHMDS gave even a 
lower yield of 10%. 
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3.4 Conclusions 
 
 Iodoetherification of tri-O-benzyl-D-glucal with a cyclohexylidene-protected  
2-DOS derivative under the action of IDCP proved to be an efficient and stereoselective 
method for the formation of a new glycosidic bond with the desired stereochemistry. 
Unfortunately, attempts to exchange the axial 2'-iodo substituent by nucleophilic 
substitution failed to afford the requisite 2'-azido derivative. 
 Michael additions to tri-O-benzyl-2-nitro-D-galactal worked well with the use of 
KHMDS in catalytic amounts and showed good diastereoselectivity, leading to a 
precursor for a novel stereoisomer of paromomine. However, in the case of 
nitroglucals, the stereochemical outcome was more unpredictable. Reactions turned 
out to be an equilibrium between starting compounds and products, thereby 
precluding the formation of good yields of desired product. Moreover, the α-gluco 
configured Michael adduct was always accompanied by undesired stereoisomers that 
were difficult to separate. Nevertheless, addition of 2-DOS 13 to tri-O-benzyl-2-nitro-D-
glucal under basic conditions gave mainly the desired α-gluco configured product.  
 
 
3.5 Experimental Section 
 
General methods and materials (see: Section 2.5). 
 
3-O-(2-Deoxy-2-iodo-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-1,2:5,6-di-O-
isopropylidene-D-glucofuranose (12) 
To a solution of tri-O-benzyl-D-glucal (9) (250 mg, 0.60 mmol) 
and diisopropylidene-D-glucose6 (10) (1.1 equiv., 172 mg,  
0.66 mmol) in dry CH2Cl2 (15 mL) was added activated 
powdered 4Å MS (120 mg). The resulting mixture was stirred 
at room temperature for 1 h and then I(sym-collidine)2ClO4  
(1.5 equiv., 42.5 mg, 0.25 mmol) was added as a solid. After 1 h 
the reaction mixture was filtered washing with CH2Cl2. The 
resulting filtrate was washed with 10% aqueous Na2S2O3, dried over MgSO4 and 
concentrated. Flash chromatography of the residual oil on silica gel (RF = 0.32, 
EtOAc/heptane, 2/7) provided the coupled product 12 as a colourless gum (385 mg, 
0.48 mmol, 80% yield). [α]20D = +9.2 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, 
CDCl3): δ = 7.42-7.16 (m, 15H), 5.80 (d, J = 3.5 Hz, 1H), 5.50 (s, 1H), 4.85 (d, J = 10.5 Hz, 
1H), 4.70-4.65 (m, 3H), 4.55-4.43 (m, 4H), 4.23 (br s, 1H), 4.12-4.08 (m, 1H), 4.05-4.03 (m, 
2H), 3.95-3.92 (m, 1H), 3.90-3.88 (m, 2H), 3.80-3.72 (m, 2H), 3.26-3.23 (m, 1H), 1.47 (s, 
3H), 1.40 (s, 3H), 1.36 (s, 3H), 1.21 (s, 3H); 13C NMR (75 MHz, CDCl3):  
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δ = 137.92, 137.67, 137.22, 128.21, 128.16, 128.07, 127.93, 127.85, 127.70, 127.60, 127.45, 
127.29, 111.77, 109.15, 105.10, 102.43, 83.32, 81.36, 81.28, 76.52, 75.86, 75.32, 73.45, 72.96, 
72.39, 71.12, 68.95, 67.86, 32.51, 26.92, 26.89, 26.20, 25.65; IR (neat): ν = 1070, 1022, 732, 
698;  HRMS (ESI): calcd for C39H47IO10Na (M + Na+) 825.2112, found 825.2118.  
 
4-O-(2-Deoxy-2-iodo-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-1,3-di-N-
benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine (14) 
The same procedure described for 12 was followed.  
Tri-O-benzyl-D-glucal (9) (70 mg, 0.168 mmol) and 2-DOS 
derivative 1314 (1.1 equiv., 94 mg, 0.185 mmol) gave the 
couple product 14 (122 mg, 0.116 mmol, 69% yield) as a 
white gum. RF = 0.61 (EtOAc/heptane, 1/1); [α]20D = +2.95  
(c = 0.002 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.43-7.15 (m, 25H), 5.66 (s, 
1H), 5.07-5.05 (m, 4H), 4.89-4.81 (m, 3H), 4.71-4.37 (m, 5H), 4.07-4.03 (m, 1H), 3.76-3.56 
(m, 6H), 3.43-3.28 (m, 4H), 2.43 (br s, 1H), 1.62-1.26 (m, 11H); 13C NMR (75 MHz, 
CDCl3): δ = 155.44, 155.25, 137.98, 137.88, 137.50, 136.11, 136.00, 128.29, 128.16, 128.15, 
128.05, 128.02, 127.93, 127.82, 127.78, 127.74, 127.69, 127.54, 127.40, 127.34, 112.72, 
100.81, 80.43, 78.16, 77.34, 77.19, 75.94, 74.86, 73.40, 72.09, 71.10, 69.39, 66.88, 51.16, 
49.34, 36.57, 36.14, 33.16, 25.13, 24.40, 24.09, 23.84, 8.46; IR (neat): ν = 3321, 1697, 1040; 
HRMS (ESI): calcd for C55H61IN2O11Na (M + Na+) 1075.3218, found 1075.3200. 
 
3-O-(2,3-Didehydro-2-deoxy-3,4,6-tri-O-benzyl-α-D-glucopyranosyl)-1,2:5,6-di-O-
isopropylidene-D-glucofuranose (15) 
Compound 12 (100 mg, 0.125 mmol), NaN3 (3 equiv., 24.4 mg, 
0.375 mmol) and 15-crown-5 (3 equiv., 82.6 mg, 0.375 mmol) 
were dissolved in DMF (2 mL) and stirred at 55 ºC for 3 d.  
The solvent was evaporated and the crude dissolved in CH2Cl2, 
filtrated and evaporated again. Flash chromatography on silica 
gel gave the undesired elimination product 15 (60 mg, 0.089 
mmol, 71% yield) as thick oil. RF = 0.27  (EtOAc/heptane, 1/3); 
[α]20D = +90.5 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.37-7.13 (m, 
15H), 5.83 (d, J = 3.5 Hz, 1H), 5.42 (d, J = 3.7 Hz, 1H), 4.88-4.84 (m, 3H), 4.76 (d, J = 11.5 
Hz, 1H), 4.71 (d, J = 3.5 Hz, 1H), 4.62 (d, J = 12.3 Hz, 1H), 4.50  (d, J = 12.3 Hz, 1H), 4.42 
(d, J = 10.9 Hz, 1H), 4.30 (d, J = 2.9 Hz, 1H), 4.25-4.07 (m, 5H), 3.98 (dd, J = 8.7 Hz,  
J = 5.6 Hz, 1H), 3.72-3.65 (m, 2H), 1.48 (s, 3H), 1.41 (s, 3H), 1.33 (s, 3H), 1.20 (s, 3H);  
13C NMR (75 MHz, CDCl3): δ = 157.61, 137.78, 137.76, 136.02, 128.28, 128.15, 128.02, 
128.01, 127.83, 127.65, 127.49, 127.44, 127.37, 111.59, 108.82, 105.23, 97.23, 95.38, 83.98, 
81.19, 80.74, 74.48, 73.46, 72.72, 71.11, 70.29, 69.54, 69.06, 67.65, 27.07, 27.01, 26.29, 25.68; 
IR (neat): ν = 1662, 1070, 1022;  HRMS (ESI): calcd for C39H46O10Na (M + Na+) 697.2988, 
found 697.3019.  
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3-O-(2-Deoxy-2-nitro-3,4,6-tri-O-benzyl-α-D-galactopyranosyl)-1,2:5,6-di-O-
isopropylidene-D-glucofuranose (19) 
Tri-O-benzyl-2-nitro-D-galactal (18) (35 mg, 0.076 mmol) and 
diisopropylidene-D-glucose6 (10) (1.1 equiv., 21.8 mg, 0.084 
mmol) were co-evaporated twice with dry toluene and then 
dissolved in dry toluene (5 mL) under argon. KHMDS solution 
(0.15 equiv., 22.8 µl of a 0.5 M solution in toluene) was added 
and the reaction stirred for 2 h. The reaction was quenched 
with AcOH (50 µl) and solvents removed under reduced 
pressure. The residue was purified by flash column chromatography (RF = 0.35, 
EtOAc/heptane, 1/3) to obtain 19 as a colourless gum (36 mg, 0.049 mmol, 65%). 
[α]20D = +70.2 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.36-7.25 (m, 
15H), 5.86 (d, J = 3.7 Hz, 1H), 5.62 (d, J = 4.3 Hz, 1H), 5.01 (dd, J = 10.8 Hz, J = 4.2 Hz, 
1H), 4.85 (d, J = 11.3 Hz, 1H), 4.74-4.69 (m, 3H), 4.48-4.39 (m, 4H), 4.19 (s, 1H), 4.11-4.08 
(m, 1H), 4.01-3.96 (m, 4H), 3.90-3.87 (m, 1H), 3.60 (dd, J = 9.5 Hz, J = 6.5 Hz, 1H), 3.47 
(dd, J = 9.6 Hz, J = 5.9 Hz, 1H), 1.46 (s, 3H), 1.39 (s, 3H), 1.37 (s, 3H), 1.18 (s, 3H);  
13C NMR (75 MHz, CDCl3): δ = 137.86, 137.70, 137.30, 128.70, 128.63, 128.53, 128.33, 
128.30, 128.11, 128.06, 127.94, 112.08, 109.53, 105.32, 97.27, 84.01, 83.24, 81.87, 81.82, 
75.22, 75.14, 73.82, 73.36, 73.35, 71.86, 70.86, 69.16, 67.77, 26.87, 26.83, 26.21, 24.89;  
IR (neat): ν = 1557, 1063;  HRMS (ESI): calcd for C39H47NO12Na (M + Na+) 744.2996, 
found 744.2996. 
 
4-O-(2-Deoxy-2-nitro-3,4,6-tri-O-benzyl-α-D-galactopyranosyl)-1,3-di-N-
benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine (20) 
Tri-O-benzyl-2-nitro-D-galactal (18) (40 mg, 0.087 mmol) and 
2-DOS derivative 1314 (1.1 equiv., 49 mg, 0.095 mmol) were 
co-evaporated twice with dry toluene and then dissolved in 
dry toluene (6 mL) under argon. KHMDS solution (0.15 
equiv., 26 µl of a 0.5 M solution in toluene) was added and 
the reaction stirred for 2 h. The reaction was quenched with 
AcOH (50 µl) and solvents removed under reduced pressure. The residue was purified 
by flash column chromatography (RF = 0.41, EtOAc/heptane, 2/3) to provide 20 as a 
white gum (37 mg, 0.038 mmol, 44%). [α]20D = +54.6 (c = 0.01 g mL-1, CH2Cl2); 1H NMR  
(400 MHz, CDCl3): δ = 7.37-7.25 (m, 25H), 5.77 (br s, 1H), 5.20-5.04 (m, 5H), 5.00-4.93 
(m, 2H), 4.84-4.79 (m, 2H), 472-462 (m, 3H), 4.49-4.33 (m, 4H), 4.02 (br s, 1H), 3.74-3.65 
(m, 3H), 3.62-3.54 (m, 2H), 3.35-3.30 (m, 1H), 2.45 (br s, 1H), 1.66-1.49 (m, 11H);  
13C NMR (75 MHz, CDCl3): δ = 155.73, 155.68, 137.95, 137.74, 137.46, 136.83, 136.35, 
128.68, 128.66, 128.58, 128.52, 128.29, 128.22, 128.19, 128.08, 113.22, 95.02, 84.07, 80.10, 
77.36, 76.66, 75.48, 74.68, 73.93, 73.37, 73.27, 70.21, 69.87, 67.08, 67.04, 66.62, 51.17, 49.28, 
36.74, 35.87, 25.09, 23.73, 23.60; IR (neat): ν = 3321, 1702, 1550, 1044; HRMS (ESI): calcd 
for C55H61N3O13Na (M + Na+) 994.4102, found 994.4089. 
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3-O-(2-Deoxy-2-nitro-3,4,6-tri-O-benzyl-α-D-glucopyranosyl)-1,2:5,6-di-O-
isopropylidene-D-glucofuranose and β-isomer (22) 
 Tri-O-benzyl-2-nitro-D-glucal (21) (318 
mg, 0.689 mmol) and diisopropylidene-D-
glucose6 (10) (1.45 equiv., 260 mg, 0.999 
mmol) were co-evaporated twice with 
dry toluene and then dissolved in dry 
toluene (6 mL) under argon. KHMDS 
solution (0.5 equiv., 229 µl of a 0.5 M 
solution in toluene) was added and the reaction stirred for 2 h. The reaction was 
quenched with AcOH (0.5 mL) and solvents removed under reduced pressure. The 
residue was purified by flash column chromatography to provide the pure α-isomer of 
22 (31 mg, 0.043 mmol, 6%) and an α/β mixture in a ratio 1:0.86 (98 mg, 0.136 mmol, 
20%), both as a white gum. RF (α) = 0.25, RF (β) = 0.20 (AcOEt/heptane, 1/3). Analytical 
data is given for 22-α: [α]20D = +45.7 (c = 0.01 g mL-1, CH2Cl2); 1H NMR  
(400 MHz, CDCl3): δ = 7.34-7.27 (m, 15H), 5.87 (d, J = 3.5 Hz, 1H), 5.66 (d, J = 3.9 Hz, 
1H), 4.91-4.85 (m, 2H), 4.81 (d, J = 10.7 Hz, 1H), 4.67-4.60 (m, 3H), 4.57-4.50 (m, 3H), 
4.24 (m, 1H), 4.11 (dd, J = 8.4 Hz, J = 5.5 Hz, 1H), 4.02-3.96 (m, 2H), 3.91-3.87 (m, 2H), 
3.74-3.69 (m, 3H), 1.47 (s, 3H), 1.39 (s, 3H), 1.37 (s, 3H), 1.23 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ = 137.74, 137.61, 137.45, 128.74, 128.64, 128.60, 128.29, 128.11, 128.07, 128.03, 
112.15, 109.60, 105.32, 96.79, 86.50, 83.52, 81.86, 81.23, 78.40, 77.28, 76.08, 75.55, 73.83, 
71.78, 68.10, 67.91, 26.87, 26.26, 24.88; IR (neat): ν = 1558, 1069; HRMS (ESI): calcd for 
C39H47NO12Na (M + Na+) 744.2996, found 744.2995. 
 
4-O-(2-Deoxy-2-nitro-3,4,6-tri-O-benzyl-α-D-glucopyranosyl)-1,3-di-N-
benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine and 4-O-(2-Deoxy-2-
nitro-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-1,3-di-N-benzyloxycarbonyl-5,6-O-
cyclohexylidene-2-deoxystreptamine (23) 
Tri-O-benzyl-2-nitro-D-glucal (21) 
(200 mg, 0.433 mmol) and 2-DOS 
derivative 1314 (1.1 equiv., 243 mg, 
0.476 mmol) were co-evaporated 
twice in dry toluene and then 
dissolved in dry toluene (10 mL) 
under argon. KHMDS solution (0.15 equiv., 130 µl of a 0.5 M solution in toluene) was 
added and the reaction stirred for 2 h. The reaction was quenched with AcOH (200 µl) 
and solvents removed under reduced pressure. The residue was purified by flash 
column chromatography (RF = 0.36, EtOAc/heptane, 2/3, 1% Et3N). Tri-O-benzyl-2-
nitro-D-glucal (21) (72 mg, 0.156 mmol, 36%) and 2-DOS derivative 13 (120 mg, 0.235 
mmol, 49%) were recovered, and a non-separable mixture of α-gluco and α-manno 
isomers of 23 (20:3, 161 mg, 0.166 mmol, 38% or BORSM: 60%) was obtained as a 
yellowish solid. Analytical data are given for the α-gluco isomer, except the optical 
rotation and the melting point which are given for the 20:3 mixture of isomers.  
[α]20D = +38.8 (c = 0.01 g mL-1, CH2Cl2); mp = 134-137 ºC; 1H NMR (400 MHz, CDCl3):  
δ = 7.34-7.23 (m, 25H), 5.75 (d, J = 3.9 Hz, 1H), 5.12-4.99 (m, 6H), 4.88-4.79 (m, 4H), 4.56-
4.44 (m, 5H), 4.04-3.56 (m, 6H), 3.36-3.32 (m, 2H), 2.46 (br s, 1H), 1.63-1.50 (m, 11H);  
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13C NMR (75 MHz, CDCl3): δ = 155.71, 155.59, 137.89, 137.78, 137.68, 136.34, 136.25, 
128.66, 128.62, 128.61, 128.56, 128.32, 128.27, 128.12, 128.06, 128.00, 127.88, 113.31, 95.12, 
86.81, 80.15, 78.45, 77.50, 77.27, 76.05, 75.24, 73.78, 71.08, 68.28, 67.05, 51.44, 49.36, 49.35, 
36.75, 35.89, 25.10, 25.06, 23.74, 23.73, 23.54; IR (neat): ν = 3325, 1704, 1551, 1047; HRMS 
(ESI): calcd for C55H61N3O13Na (M + Na+) 994.4102, found 994.4104. 
 
3,4-Di-O-benzyl-6-O-(tert-butyldiphenylsilyl)-2-nitro-D-glucal (25) 
 Concentrated HNO3 (0.8 mL) was added dropwise to Ac2O (7 mL) at 
10 ºC under constant stirring. The external temperature was further 
lowered to -10 ºC to compensate the overheat during the addition. 
When the addition was complete, the solution was cooled to -50 ºC 
upon which a precipitate formed. Then a solution of 6-O-(tert-
butyldiphenylsilyl)-4,5-di-O-benzyl-D-glucal (24) (600 mg, 1.06 mmol) in Ac2O (5 mL) 
was added over a period of 15 min, and the mixture stirred at this temperature for 30 
min. The reaction mixture was allowed to warm to -10 ºC and poured into ice-H2O  
(20 mL). Brine was added and the aqueous layer extracted with CH2Cl2. The combined 
organic extracts were dried over MgSO4 and the solvents removed by co-evaporation 
with toluene. The crude intermediate was dissolved in CH2Cl2 (5 mL) and slowly 
added to an ice-cold stirred solution of Et3N (1 mL) in CH2Cl2 (5 mL). After complete 
addition the cooling bath was removed and stirring continued for 20 min. The organic 
phase was washed with 2N HCl solution and dried over MgSO4. Solvents were 
removed under reduce pressure and the residue was purified by flash silica column 
chromatography (toluene/ethyl acetate, 98/2) to obtain 25 (270 mg, 0.44 mmol, 42%) as 
a colourless oil. 1H NMR (300 MHz, CDCl3): δ = 8.02 (s, 1H), 7.59-7.17 (m, 20H),  
4.65-4.45 (m, 6H), 3.92-3.83 (m, 3H), 1.03 (s, 9H). This compound was fully used before 
other analytical data were gathered. 
 
4-O-[2-Deoxy-2-nitro-3,4-di-O-benzyl-6-O-(tert-butyldiphenylsilyl)-α-D-
glucopyranosyl]-1,3-di-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-
deoxystreptamine (26) 
Compound 25 (55 mg, 0.090 mmol) and 2-DOS derivative 
1314 (1.1 equiv., 50.5 mg, 0.099 mmol) were co-evaporated 
twice with toluene and then dissolved in dry toluene (5 mL) 
under argon. KOtBu solution (0.15 equiv., 27 µl of a 0.5 M 
solution in THF) was added and the reaction stirred for 2 h. 
The reaction was quenched with AcOH (50 µl) and solvents 
removed under reduced pressure. The residue was purified by flash column 
chromatography (EtOAc/heptane, 2/5) to obtain a non-separable mixture of 
undetermined diastereomers (22 mg, 0.020 mmol, 22%) and 26 (17 mg, 0.015 mmol, 
17%) as a white amorphous solid. 1H NMR (300 MHz, CDCl3): δ = 7.67-7.15 (m, 30H), 
5.70 (d, J= 3.6 Hz, 1H), 5.07 (br s, 2H), 4.89-4.58 (m, 10H), 3.87-3.32 (m, 8H), 2.47-2.42 
(m, 1H), 1.65-1.48 (m, 11H), 1.03 (s, 9H); MS (MALDI): calcd for C64H73N3O13SiAg  
(M + Ag+) 1226.40, found 1226.87. 
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Chapter 4 
 
Stereoselective α-glycosidation of thioglycosides in 
the synthesis of 2'-modified neamine analogues 
 
 
 
Abstract: 
 
The glycosidation of conveniently functionalised thioglycosides with 2-deoxystreptamine as 
acceptor offers a versatile route towards new neamine analogues. Conditions were investigated 
for stereoselective α-glycosidations, employing two different types of thioglycosides: 
oxazolidinone-protected 2-amino-2-deoxy-D-thioglucosides and 3,4-O-dimethoxybutanediyl- 
protected mannothioglycosides. The latter procedure was applied to a range of model acceptors 
and proved effective, by subsequent and selective 2’-O-deprotection, in the preparation of 
α-mannoglycosides with a free 2’-OH group. 
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4.1 Introduction 
 
Aminoglycosides form a class of compounds with strong bactericidal activity, 
due to the ability to interfere with the fidelity of mRNA translation to the appropriate 
protein. Unfortunately, the clinical usefulness of the aminoglycosides is thwarted by 
emerging resistance of bacteria, in particular due to aminoglycoside-modifying 
enzymes. We hypothesised that capturing a particular aminoglycoside in its bioactive 
ribosome-bound conformation might not only improve the RNA binding 
characteristics, but may also result in reduced aminoglycoside recognition by the 
bacterial modifying enzymes. The recently elucidated NMR and crystal structure of 
neomycin bound to the bacterial ribosome clearly shows intramolecular hydrogen 
bonds between 4 and 5-OH of 2-deoxystreptamine and 2'-NH2 of the diaminoglycoside 
ring I. A main objective became the synthesis of selectively 2'-modified neamine 
analogues that may subsequently lead to conformationally restricted analogues of 
neomycin (see also: Chapter 6). Obviously, for neomycin such a target requires access 
to selectively 2'-NH2 liberated aminoglycoside analogues. We reasoned that in order to 
avoid lengthy protective group schemes to selectively liberate the relevant 2'-NH2 
group, a condensation approach from two components would be most promising. 
Additionally, such approach would offer access to new neamine-type stereoisomers. In 
the present chapter we discuss the use of thioglycoside couplings for this purpose. 
 Thioglycosides have been studied in great extent as useful glycosyl donors due 
to high stability combined with highly selective activation under particular reaction 
conditions with thiophilic agents. However, as with any glycosylation protocol, a 
general approach to fully control the stereochemical formation of α-glycosidic bonds 
remains unrealised for thioglycosides, and usually depends on the right choice of 
reaction conditions and protecting groups. Since the glycosidic bond between 
2-deoxystreptamine and the 2,6-diaminoglucose ring is α-configured, two different 
strategies were followed to perform the glycosidation reaction. 
We first turned our attention to the application of 2-amino-2-deoxy-α-glucose 
derivatives with the obvious advantage of already having the 2'-NH2 installed in the 
carbohydrate donor. The stereoselective formation of 1,2-cis products of 2-aminosugars 
is of special difficulty, and usually involves the activation of 2-azidoglucosyl donors 
leading to α/β-mixtures with ratios depending heavily on coupling conditions and 
carbohydrate acceptor.  We were encouraged by the results of Kerns et al.1, who 
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showed that great α-stereocontrol can be achieved by activation of oxazolidinone-
protected 2-amino-2-deoxy-D-thioglucoside 1 with phenylsulfenyl triflate (PST), as 
exemplified in Scheme 4.1. Subsequent oxazolidinone deprotection offers the 
possibility of selective functionalisation at the 2'-amino group.  
Scheme 4.1 
 
An alternative approach that was followed involves the application of 
α-mannose derived donors, since the stereoselective formation of 1,2-trans glycosides is 
much easier to control. Crich et al.2 reported the use of a Ley's bisacetal type protecting 
group3 on mannothioglycoside donors such as 4. The 3,4-O-dimethoxybutanediyl 
(DMB) protection was found to have excellent features for the promotion of  
α-stereoselective couplings2 (Scheme 4.2).  
Scheme 4.2 
 
We envisaged that the use of DMB-protected mannothioglycosides not only 
allowed straightforward differentiation between positions 2-OH and 6-OH, but 
subsequent coupling with 2-DOS would also directly result in new neamine analogues. 
Thus, based on a series of differentially protected donors and different acceptors, 
several conditions were screened that would allow both stereoselective α-glycosidation 
and selective deprotection on the 2'-position of the coupled products. Since the 
resulting dimeric structures still possess the manno-configuration on the non-reducing 
sugar, procedures were investigated to obtain α-glucosides via inversion of 
configuration at the 2'-position (Chapter 5).  
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4.2 Oxazolidinone protected 2-amino-2-deoxy-D-glucose 
 
Thioglycoside 1 with 2,3-N,O-oxazolidinone protection was synthesised and 
tested as reported by Kerns et al.1 Several attempts to couple 1 to diisopropylidene-D- 
glucose 2, however, gave a maximum yield of the desired dimer 3 of only 36%, in sharp 
contrast with the 97% yield reported by Kerns and co-workers (Scheme 4.1). An 
attempted coupling of 1 with asymmetrically protected 2-DOS 64 also proceeded 
unsuccessfully (Scheme 4.3). TLC analysis showed thioglycoside activation as well as 
supposed glycosidation, but the product rapidly hydrolysed in the reaction mixture.  
  
Scheme 4.3 
 
We tried to activate 1 with other thioglycoside activating reagent systems, such as  
1-(phenylsulfinyl)piperidine/triflic anhydride5 (PSP/Tf2O)6 and diphenyl 
sulfoxide/triflic anhydride7, but these reagents were either insufficient at promoting 
glycosidation or formed detrimental adducts resulting in degradation of the donor. 
Similar results have been later reported Kerns et al.8 
 A successful coupling with 1 requires at least two equivalents of PST because 
one equivalent is used in the inevitable N-sulfenylation of the oxazolidinone nitrogen. 
It was anticipated therefore that protection of the 2'-NH would not only reduce the 
requisite amount of activator to a slight excess but also have a beneficial effect on 
activation of the donor. Thirdly, the introduction of an allyl group at the 2'-nitrogen 
would at the same time offer the possibility, after coupling, of further manipulation 
towards conformationally restricted compounds. Unfortunately, allylation proceeded 
in low yield due to the lability of the acetate groups under such basic conditions, 
resulting in a mixture of allylated compounds 8 and 9. After separation but without 
further optimisation, a coupling reaction was attempted with desired allylated donor 8, 
but again none of the desired dimeric product 10 was obtained (Scheme 4.4). 
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Scheme 4.4 
 
It is clear that the 2,3-oxazolidinone protection dramatically disarms the 
thioglycoside for glycosyl activation. While this research was in progress, Kerns and 
co-workers reported similar problems when trying to broaden the scope of the 
oxazolidinone-protected thioglycoside donors9. In a similar structure, Boons et al. also 
reported significant disarming of 2,3-carbonate protected thioglycoside derivatives10, 
although in this case PST activation seemed to proceed more desirably. Additionally, 
the acetate groups on thioglycosides 1 and 8 in positions O4 and O6 have a further 
deactivating effect. A logical option involved the introduction of electron-donating 
substituents instead of the acetyl functions in order to increase the reactivity. Thus, 
compound 11 (precursor of 1)1 was treated with 2.2 equivalents of benzyl bromide in 
an attempt to selectively benzylate the hydroxyl groups, but much to our dismay only 
tribenzylated compound 12 could be isolated from a non-separable mixture of other 
benzylated products (Scheme 4.5). 
 
 
 
 
Scheme 4.5 
 
 After all these findings it was clear that the problems that arose from the 
oxazolidinone protection were difficult to circumvent and Kerns' reported 
glycosidations were difficult to reproduce. At this stage we decided to look further into 
other glycosidation methods. 
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4.3 Synthesis of mannothioglycoside donors 
 
 As discussed above, an interesting alternative for α-stereoselective 
thioglycoside coupling and subsequent 2'-modification towards neamine analogues 
involves the use of dimethoxybutanediyl-protected mannothioglycosides. 
Mannothioglycoside 14, readily obtained from 13 following a reported procedure2, can 
be preferentially protected with the DMB on the trans-vicinal alcohols, which in the 
mannopyranoside case corresponds to the 3-OH and 4-OH groups. The resulting 
compound 14 is suitable for differentiation and selective protection and/or 
functionalisation of the 2-OH and 6-OH groups, thereby enabling manipulation at O2 
at a later stage. Such an assumption was corroborated by selective benzylation of the  
6-hydroxyl to form 15, giving the monobenzylated product in good yield. However, to 
obtain a useful aminoglycoside, the synthesis of a precursor with a latent amino 
functionality at C6 was undertaken. For this purpose, the 6-OH was converted into a 
good leaving group upon treatment with tosyl chloride to obtain 16, followed by 
treatment with sodium azide in DMF to form azide 18 in 82% yield. A slightly better 
alternative was found in the conversion of 16 into iodide 17, prior to displacement of 
the iodide with azide, giving 18 in 88% yield over the two steps (Scheme 4.6). 
Scheme 4.6 
 
 
4.4 Couplings of mannothioglycoside donors and 2'-deprotection 
 
 Having compound 18 at hand, the stage was set for glycosidation reactions 
with a range of carbohydrate acceptors, but not before protection of the 2-OH. 
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Mannothioglycoside 18 was treated with acetic anhydride to provide the  
2-O-acetylated compound 19. Unfortunately, several attempts to glycosidate 19 with 
alcohol 2 proved to be futile (Scheme 4.7). Activation occurred, but presumably an 
unstable ortho ester was formed which hydrolyses in a matter of minutes. A validation 
for such an assumption was found in literature, where under identical activating 
conditions Crich et al. reported the formation of an ortho ester from a perbenzoylated 
galactosyl donor5. 
Scheme 4.7 
 
 Since an ester function appeared too electron-withdrawing, a strategy involving 
benzyl ether protection at the 2-position of 18 was followed next. Glycosidation of the 
resulting product 21 was performed with diisopropylidene-D-glucose 2 as acceptor and 
PSP and Tf2O as the activating system 11, a more practical and cheaper combination of 
reagents than the earlier applied PST (Scheme 4.7). Much to our satisfaction, the 
desired α-mannoside 22 was isolated as the sole stereoisomer in acceptable yield. 
Scheme 4.8 
 
In order to liberate the 2'-OH, compound 22 was subjected to hydrogen and palladium 
hydroxide to form 23 in excellent yield. The concomitant reduction of the 6'-azide to a 
6'-NH2 was not considered disadvantageous, since the two resulting functionalities can 
be easily differentiated. 
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 After the selective coupling and hydrogenation of mannothioglycoside 21 to 
model acceptor 2, glycosidation was next executed with benzyloxycarbonyl protected 
2-DOS derivative 64. As above, glycosidation proceeded in good yield and with 
excellent stereoselectivity with the PSP/Tf2O system (Scheme 4.9), leading to the 
desired dimer 24 in 72% isolated yield. The slightly better yield may be explained by 
the fact that the reaction was quenched with triethyl phosphite, which traps the 
remaining active sulfur species7. The coupled product 24 was next subjected to 
hydrogenolysis to remove the 2'-O-benzyl and the Cbz-groups, both at atmospheric 
and high pressure (40 atm),  but IR and 1H NMR experiments of the crude product 
indicated the formation of the triamino-compound 25, with the 2'-O-benzyl ether still 
intact. 
 
Scheme 4.9 
 
Possibly, compound 24 adopts a conformation with the benzylic position too hindered 
to be reached by the catalyst. Under these circumstances, lithium in liquid ammonia 
proved to work, followed by treatment with Boc2O, to afford compound 26. However, 
the low yield and the necessity to reprotect the amino groups prompted us to search 
for a more reliable 2'-protection. 
 We turned our attention to the use of silyl ethers, with the advantage that silyl 
groups can be readily and selectively removed with a fluoride source.  Thus, treatment 
of 18 with tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) and 2,6-lutidine 
in dichloromethane afforded compound 27 in 93% yield (Scheme 4.10). Gratifyingly, 
glycosidation with diisopropylidene-D-glucose 2 as a model acceptor under PSP/Tf2O 
conditions gave the coupled compound 29a in an excellent 93% yield (Table 4.1,  
entry 1). Glycosidation proceeded with complete α-stereoselectivity, no trace of  
β-coupled product was observed. Finally, the TBS protecting group was cleanly 
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removed upon treatment with 1.1 equiv. of TBAF, leading to 30a with a free 2'-OH and 
the 6'-azide group unaffected. 
Since glycosidation reactions with silyl groups in the 2-position of the donor are 
relatively rare, the previous encouraging results were a stimulus to investigate the 
scope and application of the methodology involving the use of silyl ether protection. 
To this end, several other acceptors were glycosylated with TBS-protected donor 27, as 
summarised in Table 4.1 (entries 1-3 and 5). Firstly, primary alcohol diisopropylidene-
D-galactose was used as acceptor (entry 2). Glycosylation with TBS-protected 
mannothioglycoside 27 under PSP/Tf2O conditions afforded 85% of coupled product 
as an α/β mixture in 41:1 ratio. The two isomers have a slightly different retention value 
on silica chromatography, which allowed the isolation of compound 29b in 69% yield, 
and a non-separable fraction (16% yield) of  and α/β mixture (8:1 ratio). Treatment of 
29b with TBAF in THF liberated the 2'-OH to afford 30b in good yield. 
 
Scheme 4.10 
 
 N-Cbz-L-serine benzyl ester was used as another model acceptor (entries 3 and 
4), in order to establish the validity of the coupling-deprotection sequence in the 
presence of an N-Cbz functionality. Glycosidation of 27 under the PSP/Tf2O system in 
this case gave solely the α-coupled product 29c in good yield (entry 3). However, much 
to our surprise, treatment of 29c with TBAF produced a slow basic hydrolysis of the 
benzyl ester instead of the anticipated removal of the silyl ether. Addition of acetic acid 
to reduce the basicity of TBAF avoided the undesired ester hydrolysis, but again the 
silyl ether of 29c remained unaffected. The unexpected stability of the silyl ether 
challenged us to attempt the same sequence with a more labile silyl ether. Thus, 
mannothioglycoside 18 was treated with hexamethyldisilazane and a catalytic amount 
of trimethylsilyl chloride in acetonitrile to give, after filtration and evaporation, 
trimethylsilyl (TMS) protected 28 in excellent yield and purity (Scheme 4.10). Under 
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the influence of PSP/Tf2O activation, 28 and N-Cbz-L-serine benzyl ester were coupled, 
to our delight, without affecting the TMS group (entry 4). Glycosidation proceeded 
with an α/β ratio of 28:1, as determined by 1H NMR of the crude reaction mixture. The 
isomers were separated to afford 29d in 75% yield, along with almost 3% of the  
β-isomer. As anticipated, removal of the TMS group from 29d now occurred smoothly 
with TBAF in THF to afford 30d in near quantitative yield. 
 
entry donor R'OH dimer  α:βa yield (%)b alcohol yield (%)b 
1 27  2 29a  1:0  93 30a 86 
2 27  
OH
O
O
O
O
O
 
29b 41:1 69 30b 95 
3 
4 
27  
28 CbzHN CO2Bn
HO
  
29c 
29d 
 1:0 
28:1 
83 
78 
30c 
30d 
0 
96 
5 
6 
27 
28 6 
29e 
29f 
1:0 
1:0 
80 
75 
30e 
30f 
0 
91 
7 28 HO
N3 N3
O
O
 
29g 56:1 71 30g 99 
 
Table 4.1     a Based on crude 1H NMR. b Isolated yields.   
 
 With the experience of the model acceptors, the coupling and deprotection 
sequence was attempted with TBS-protected mannothioglycoside 27 and 
dibenzyloxycarbonyl protected 2-DOS acceptor 6. To our delight, the glycosidation 
procedure afforded solely the glycosylated 2-deoxystreptamine 29e in good yield. 
However, as was the case with dimer 29c, the TBS group from 29e resisted removal 
under several conditions. Use of TBAF in THF again led to hydrolysis of the 
benzyloxycarbonyl protecting groups, but left the TBS group untouched. Addition of 
acetic acid failed to lead to any conversion, whereas treatment with HF-pyridine did 
not liberate the 2'-OH, but only degradation of 29e was observed after a few days. 
 Fortunately, when the sequence was repeated with the TMS-protected 
mannothioglycoside 28 (entry 6), the reaction afforded only the α-isomer 29f. 
Moreover, TMS deprotection proceeded rapidly and smoothly (TBAF, 10 min) in THF 
to obtain pseudodisaccharide 30f with a free 2'-OH in near quantitative yield.   
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Finally, when TMS-protected mannothioglycoside 28 was also glycosidated 
with a diazido 2-DOS derivative4 (entry 7), 29g was obtained in 71% yield after 
purification, along with a small non-separable fraction (2% yield) of α/β mixture (ratio 
4:5). As expected, treatment of 29g with TBAF in THF removed the TMS group 
uneventfully to afford 30g in quantitative yield. 
  The results concerning the use of silyl ethers as protecting groups that are 
summarised in Table 4.1, show that in all cases the glycosidation was performed in 
excellent yield and stereoselectivity. There were two factors that influenced the 
stereochemical outcome of the coupling reaction. One is the bulkiness of the silyl ether 
on the mannothioglycoside, and the other the steric interaction with the different 
glycosyl acceptors. In general, primary or less sterically hindered alcohols appear to 
lead to small amount of β-coupled dimers. The slightly lower stereoselectivity may be 
explained by the enhanced reactivity of the more sterically accessible alcohol. 
 All the mannothioglycosides used so far have a 6-azido functionality as a 
masked amino function. In order to expand the variability of aminoglycoside 
structures it was also interesting to have a 6-OH precursor. Thus, 6-O-benzylated 
mannothioglycoside 15 was treated with hexamethyldisilazane and a catalytic amount 
of trimethylsilyl chloride to protect the 2-OH with a TMS group. Standard coupling 
conditions were applied with 2-DOS derivative 6 as acceptor, although triethyl 
phosphite was not added as a quenching reagent. Unfortunately, under such 
conditions the silyl ether was removed and a non-separable mixture of compound 32 
and 2-DOS acceptor 6 was obtained. Exposure of the mixture to AcOH/THF/H2O 
(v/v/ν, 3/2/1) at 55 ºC led to hydrolysis of the cyclohexylidene and facilitated 
separation, to afford compound 33 in 35% yield over two steps (Scheme 4.11). 
 
 
 
 
 
 
Scheme 4.11  
 
The stability of the 2-O-TMS group might be affected either by the presence of reactive 
species or an influence of the benzyl ether at C6 with respect to the azide. 
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4.5 Conclusions 
 
 En route to 2'-modified neamine analogues, two alternative strategies were 
explored to prepare α-configured 2-aminoglycosides by glycosidation of 
thioglycosides. A first approach towards the synthesis of 2-amino-2-deoxy-α-D-
glucosides from oxazolidinone protected 2-amino-2-deoxy-D-thioglucoside 1 was 
unsuccessful. The reported procedure was difficult to reproduce and application of the 
described reaction conditions to condensation with a 2-deoxystreptamine acceptor 
afforded no detectable glycosidation product. 
 Alternatively, acetal-protected mannothioglycoside donors proved to be very 
efficient in promoting α-glycosidations with several acceptors and with excellent 
stereoselectivity. The 2-O-protective group of the carbohydrate donor turned out to 
have an essential influence on the outcome of the glycosidation reaction. A regular 
participating 2-O-acyl function rendered the donor completely inactive, whereas a 
benzylated donor coupled nicely but gave significant problems during deprotection.  
Interestingly, installation of a proper silyl protective group at the 2-O-position (TBS or 
TMS) gave access to the desired pseudodisaccharide in good yield by a glycosidation-
deprotection protocol. Deprotection afforded several free 2'-OH disaccharides and 
pseudodisaccharides with potential as synthetic intermediates for 2'-modified neamine 
analogues.  
 2-DOS containing pseudodisaccharides afforded two new manno-configured 
neamine analogues. Further manipulation of the C2' position to give α-configured 
glucosides will be further discussed in Chapter 5. Deprotection, purification and 
measurement of biological activity and interaction with rRNA will be discussed in 
Chapter 7. 
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4.7 Experimental section 
 
General methods and materials (see: Section 2.5). 
 
Phenyl 2-N-allyl-2-N,3-O-carbonyl-4,6-di-O-acetyl-1-thio-β-D-glucopyranoside (8) 
and phenyl 2-N-allyl-2-N,3-O-carbonyl-6-O-acetyl-1-thio-β-D-glucopyranoside (9) 
Thioglycoside 1 (150 mg, 0.393 mmol) was 
coevaporated twice with toluene and dissolved 
in dry DMF (3 mL). The solution was cooled to  
0 ºC, NaH (1.3 equiv., 20.4 mg, 60% in mineral 
oil, 0.511 mmol) was added and the reaction 
mixture was stirred for 2 h at rt. TBAI (0.1 equiv., 14.5 mg, 0.039 mmol) and ally 
bromide (1.3 equiv., 44.2 µL, 0.511 mmol) were added. The reaction was further stirred 
until the starting material disappeared, then quenched by addition of H2O. The solvent 
was evaporated and the crude product was redissolved in CH2Cl2, washed with H2O 
and extracted with CH2Cl2. The combine organic extracts were dried with MgSO4, 
filtered and evaporated. The crude was purified by flash silica gel chromatography and 
compounds 8 (48 mg, 0.114 mmol, 29%) and 9 (30 mg, 0.079 mmol, 20%) were isolated. 
Compound 8: white solid; RF = 0.26 (EtOAc/heptane, 2/3); [α]20D = –168.1  
(c = 0.01 g mL-1, CH2Cl2); mp = 128-129 ºC; 1H NMR (400 MHz, CDCl3): δ = 7.55-753 (m, 
2H), 7.35-7.33 (m, 3H), 5.86-5.76 (m, 1H), 5.39-5.25 (m, 3H), 4.82 (d, J = 9.4 Hz, 1H), 
4.28-4.20 (m, 2H), 4.17-4.08 (m, 3H), 3.77-3-73 (m, 1H), 3.56 (dd, J = 11.1 Hz, J = 9.4 Hz, 
1H), 2.10 (s, 3H), 2.08 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 170.11, 168.82, 157.72, 
132.39, 131.62, 130.96, 128.98, 128.44, 119.61, 86.48, 79.59, 77.19, 67.46, 62.28, 60.00, 46.43, 
20.92, 20.81, ; IR (neat): ν =1766, 1746, 1231;  HRMS (ESI): calcd for C20H23NO7SNa  
(M + Na+) 444.1093, found 444.1079.  
Compound 912: 1H NMR (400 MHz, CDCl3): δ = 7.54-7.52 (m, 2H), 7.35-7.32 (m, 3H), 
5.85-5.75 (m, 1H), 5.38-5.27 (m, 2H), 4.82 (d, J = 9.6 Hz, 1H), 4.45-4.37 (m, 2H), 4.16-4.14 
(m, 2H), 4.04 (t, J = 10 Hz, 1H), 3.91 (t, J = 10 Hz, 1H), 3.61-3.57 (m, 1H), 3.45 (dd, J = 10 
Hz, J = 9.6 Hz, 1H), 2.10 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 170.95, 158.57, 132.12, 
131.95, 131.12, 128.92, 128.22, 119.37, 86.26, 82.23, 79.26, 67.66, 63.02, 59.97, 46.36, 21.04; 
IR (neat): ν = 3438, 1735, 1242, 1035.  
 
Phenyl 2-N-benzyl-4,6-di-O-benzyl-2-N,3-O-carbonyl-1-thio-β-D-glucopyranoside 
(12) 
Thioglucoside 11 (200 mg, 0.673 mmol) was dissolved in dry THF  
(6 mL) and NaH (2.2 equiv., 59 mg, 60% in mineral oil, 1.481 mmol) 
was added at 0 ºC and stirred for 1 h under argon. Benzyl bromide  
(2.2 equiv., 176 µL, 1.481 mmol) was added and the reaction mixture 
was stirred at rt for 12 h. The solvent was evaporated. The obtained 
white solid was mixed with H2O and acidified with some drops of AcOH. The H2O 
was extracted three times with CH2Cl2 and the combined organic extracts dried with 
MgSO4, filtered and evaporated. TLC showed a main spot in a mixture of products 
difficult to separate. Chromatography on silica gel afforded compound 12 (47 mg, 
0.083 mmol, 12%) as colourless oil. RF = 0.32 (EtOAc/heptane, 1/3); [α]20D = -69.3  
O
NAcO
O
OAc
SPh
O
O
NBnBnO
O
OBn
SPh
O
O
NHO
O
OAc
SPh
O
Chapter 4 
 
 
64 
(c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.33-7.18 (m, 20H), 4.88 (d, 
J = 11.1 Hz, 1H), 4.76-4.73 (m, 3H), 4.57-4.47 (m, 3H), 4.17 (dd, J = 11.1 Hz, J = 10.0 Hz, 
1H), 3.87 (dd, J = 9.7 Hz, J = 8.7 Hz, 1H), 3.75 (dd, J = 10.7 Hz, J = 2.0 Hz, 1H), 3.69 (dd, 
J = 10.9 Hz, J = 4.7 Hz, 1H), 3.60-3.56 (m, 1H), 3.46 (dd, = 11.2 Hz, J = 9.5 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ = 159.26, 138.11, 137.41, 136.38, 132.51, 132.44, 129.19, 
128.79, 128.54, 128.48, 128.40, 128.31, 128.14, 128.08, 127.82, 127.78, 127.74, 86.72, 83.72, 
80.24, 74.07, 73.72, 73.51, 68.88, 60.68, 47.94; IR (neat): ν = 1768, 1019, 698;  HRMS (ESI): 
calcd for C34H33NO5SNa (M + Na+) 590.1977, found 590.1953. 
 
Phenyl 6-O-benzyl-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-α-D-
mannopyranoside (15) 
To a solution of mannothioglycoside 14 (1.20 g, 3.11 mmol) in dry 
DMF (120 mL) was added NaH (1.5 equiv., 186 mg, 60% in mineral 
oil, 4.66 mmol) and the mixture was stirred for 1 h under argon.  
Benzyl bromide (1.05 equiv., 389 µL, 3.27 mmol) was added and 
stirring continued for 10 h. The reaction was quenched by addition 
of sat. NH4Cl and the solvent evaporated. The crude residue was 
dissolved in CH2Cl2, washed with H2O, dried over MgSO4, filtered and the solvent 
evaporated. Chromatography on silica gel afforded compound 15 (1.16 g, 2.43 mmol, 
78%) as colourless gum. RF = 0.26 (EtOAc/heptane, 1/3); [α]20D = +235.0 (c = 0.01 g mL-1, 
CH2Cl2); 1H NMR (400 MHz, CDCl3 + drop D2O): δ = 7.43-7.23 (m, 10H), 5.46  
(d, J = 1.0 Hz, 1H), 4.91 (d, J = 11.9 Hz, 1H), 4.66 (d, J = 11.9 Hz, 1H), 4.30-4.20 (m, 2H), 
4.07 (dd,J = 9.7 Hz, J = 2.8 Hz, 1H), 3.98-3.97 (m, 1H), 3.83-3.75 (m, 2H), 3.32 (s, 3H), 3.29 
(m, 3H), 1.36 (s, 3H), 1.32 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 138.27, 133.86, 131.73, 
129.02, 128.22, 127.91, 127.56, 100.08, 99.68, 87.63, 77.62, 73.32, 72.11, 69.55, 64.06, 61.72, 
48.28, 48.14, 18.16, 18.15; IR (neat): ν = 3475, 2832, 1116, 1047, 738;  HRMS (ESI): calcd 
for C25H32O7SNa (M + Na+) 499.1766, found 499.1753. 
 
Phenyl 3,4-O-(2,3-dimethoxybutane-2,3-diyl)-6-O-tosyl-1-thio-α-D-mannopyranoside 
(16)     
To a solution of mannothioglycoside 15 (2.0 g, 5.18 mmol) in dry 
pyridine (30 mL) was added TsCl (1.1 equiv., 607 mg, 5.70 mmol) 
and the mixture stirred at 4 ºC during 3 d. The pyridine was 
evaporated and the crude residue was dissolved in AcOEt (30 mL) 
and washed with H2O. The organic layer was treated with brine, 
dried over MgSO4 and the solvent evaporated. The crude product was purified by 
silica gel chromatography to afford a small quantity of 2,6-O-ditosylated side product 
(256 mg, 0.37 mmol, 7%) and 16 (2.2 g, 4.07 mmol, 79%) as colourless gum. Analytical 
data for 16: RF = 0.28 (EtOAc/heptane, 2/3); [α]20D = +221.0 (c = 0.01 g mL-1, CH2Cl2); 1H 
NMR (400 MHz, CDCl3): δ = 7.70 (d, J= 8.2 Hz, 2H), 7.40-7.36 (m, 2H), 
7.27-7.25 (m, 5H), 5.38 (s, 1H), 4.40 (ddd, J = 10.0 Hz, J = 5.3 Hz, J = 2.2 Hz, 1H), 4.27 
(dd, J = 10.7 Hz, J = 2.2 Hz, 1H), 4.23 (dd, J = 10.7 Hz, J = 5.3 Hz, 1H), 4.14 (d, J = 2.9 Hz, 
1H) 4.05 (t, J = 10.0 Hz, 1H), 3.95 (dd, J = 10.0 Hz, J = 2.9 Hz, 1H), 3.29 (s, 3H), 3.22  
(s, 3H), 2.58 (br s, 1H), 2.41 (s, 3H), 1.32 (s, 3H), 1.29 (s, 3H); 13C NMR (75 MHz, CDCl3): 
δ = 144.75, 133.56, 132.99, 132.01, 129.76, 129.17, 128.20, 127.82, 100.69, 100.24, 88.14, 
71.09, 69.40, 68.79, 67.84, 63.13, 48.31, 48.30, 21.76, 17.82, 17.77; IR (neat): ν = 3501, 2836, 
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1362, 1134, 1110, 1048;  HRMS (ESI): calcd for C25H32O9S2Na (M + Na+) 563.1385, found 
563.1372. 
 
Phenyl 6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-6-iodo-1-thio-α-D-
mannopyranoside (17)   
To a solution of 16 (1.30 g, 2.4 mmol) in acetone (15 mL) was added 
NaI (1.5 equiv., 540 mg, 3.6 mmol) and mixture stirred under reflux.  
After 2 d the reaction was not completed and extra NaI was added 
(1.0 equiv., 360 mg, 2.4 mmol). After 5 d the reaction was filtered and 
the solvent evaporated. The yellowish crude product was purified 
by silica gel chromatography to afford 17 (1.07 g, 2.16 mmol, 90%) as a white solid.  
RF = 0.37 (EtOAc/heptane, 2/3); [α]20D = +271.5 (c = 0.01 g mL-1, CH2Cl2); mp = 56-57 ºC; 
1H NMR (300 MHz, CDCl3): δ = 7.55-7.52 (m, 2H), 7.34-7.27 (m, 3H), 5.57 (s, 1H), 4.22 
(br s, 1H), 4.11-3.96 (m, 3H), 3.50 (dd, J = 10.7 Hz, J = 2.4 Hz, 1H), 3.37-3.33 (m, 7H), 2.55 
(d, J = 2.4 Hz, 1H), 1.36 (s, 3H), 1.34 (s, 3H); 13C NMR (75 MHz, CDCl3): 
δ = 133.13, 131.50, 128.88, 127.38, 100.42, 100.02, 88.24, 71.38, 70.49, 68.27, 67.20, 48.67, 
48.29, 17.98, 17.87, 5.00; IR (neat): ν = 3447, 2829, 1135, 1113, 1048;  HRMS (ESI): calcd 
for C18H25IO6SNa (M + Na+) 519.0315, found 519.0309. 
 
Phenyl 6-azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-α-D-
mannopyranoside (18)    
To a solution of 17 (980 mg, 1.97 mmol) in DMF (15 mL) was added 
NaN3 (2 equiv., 256 mg, 3.94 mmol) and the mixture stirred under N2 
for 12 h. The DMF was evaporated and the residue dissolved in 
AcOEt, washed with H2O, treated with brine, dried over MgSO4 and 
filtered. The AcOEt was evaporated and the crude product was 
purified by silica gel chromatography to afford 18 (804 mg, 1.95 mmol, 99%) as a white 
gum which solidified slowly into a white solid. RF = 0.3 (EtOAc/heptane, 1/2);  
[α]20D = +266.0 (c = 0.01 g mL-1, CH2Cl2); mp = 81-82 ºC; 1H NMR (300 MHz, CDCl3):  
δ = 7.49-7.46 (m, 2H), 7.34-7.25 (m, 3H), 5.57 (s, 1H), 4.40-4.34 (m, 1H), 4.21 (br s, 1H), 
4.08 (t, J = 9.9 Hz, 1H), 3.99 (dd, J = 9.9 Hz, J = 2.9 Hz, 1H), 3.53-3.41 (m, 2H), 3.32  
(s, 3H), 3.25 (s, 3H), 2.66 (br s, 1H), 1.35 (s, 3H), 1.32 (s, 3H); 13C NMR (75 MHz, CDCl3):  
δ = 133.25, 131.40, 128.93, 127.43, 100.40, 99.94, 87.91, 71.08, 70.87, 68.58, 64.25, 50.67, 
48.27, 48.09, 17.92, 17.84; IR (neat): ν = 3442, 2833, 2094, 1135, 1113, 1148;  HRMS (ESI): 
calcd for C18H25N3O6SNa (M + Na+) 434.1362, found 434.1330. 
 
Phenyl 2-O-acetyl-6-azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-α-D-
mannopyranoside (19) 
To a solution of mannothioglycoside 18 (300 mg, 0.729 mmol), Et3N 
(10 equiv., 1.01 mL, 7.29 mmol) and DMAP (0.1 equiv., 8.9 mg, 0.073 
mmol) in CH2Cl2 (10 mL) was added Ac2O (5 equiv., 345 µL, 3.645 
mmol). The reaction mixture was stirred for 10 h and then poured 
onto ice-H2O, extracted with CH2Cl2 followed by brine, dried over 
MgSO4 and concentrated under reduced pressure. Purification was performed by silica 
gel chromatography to afford 19 (240 mg, 0.529 mmol, 73%) as colourless oil which 
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solidified slowly. RF = 0.4 (EtOAc/heptane, 1/3); [α]20D = +196.7 (c = 0.01 g mL-1, 
CH2Cl2); mp = 74-75 ºC; 1H NMR (400 MHz, CDCl3): δ = 7.50-7.48 (m, 2H), 7.34-7.28 (m, 
3H), 5.48 (s, 1H), 5.31-5.30 (m, 1H), 4.40-4.37 (m, 1H), 4.10-4.03 (m, 2H), 3.55 (dd, 
J = 13.3 Hz, J = 2.3 Hz, 1H), 3.43 (dd, J = 13.3 Hz, J = 5.9 Hz, 1H), 3.30 (s, 3H), 3.27 (s, 
3H), 2.15 (s, 3H), 1.30 (s, 3H), 1.29 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 170.09, 133.15, 
131.76, 128.96, 127.69, 100.28, 99.85, 86.69, 71.98, 71.08, 66.59, 64.39, 50.54, 48.23, 48.11, 
21.34, 17.96, 17.81; IR (neat): ν = 2829, 2094, 1748, 1225, 1139, 1109, 1035;  HRMS (ESI): 
calcd for C20H27N3O7SNa (M + Na+) 476.1467, found 476.1490. 
 
Phenyl 6-azido-2-O-benzyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-α-D-
mannopyranoside (21) 
Compound 18 (1.50 g, 3.65 mmol) was dissolved in THF (30 mL) and 
cooled to 0 ºC. NaH (1.3 equiv., 190 mg, 60% in mineral oil, 4.74 
mmol) was added in portions. After 1 h TBAI (0.1 equiv., 135 mg, 
0.365 mmol) and BnBr (1.3 equiv., 564 µL, 4.74 mmol) were added. 
After 1 h the ice bath was removed and stirring continue for 10 h. 
The reaction was quenched by addition of sat. NH4Cl. The solvent was evaporated, the 
crude product redissolved in CH2Cl2 and washed with H2O, then treated with brine. 
The organic phase was dried with MgSO4, filtered and the solvent evaporated. 
Chromatography on silica gel afforded 21 (1.56 g, 3.11 mmol, 85%) as white crystalline 
solid. RF = 0.36 (EtOAc/heptane, 1/7); [α]20D = +181.6 (c = 0.01 g mL-1, CH2Cl2); 
mp = 127-128 ºC; 1H NMR (400 MHz, CDCl3): δ = 7.44-7.41 (m, 4H), 7.35-7.27 (m, 6H), 
5.50 (s, 1H), 4.90 (d, J = 12.2 Hz, 1H), 4.69 (d, J = 12.2 Hz, 1H), 4.37-4.32 (m, 1H), 4.18  
(t, J = 10.0 Hz, 1H), 4.02 (dd, J = 10.0 Hz, J = 2.7 Hz, 1H), 3.97-3.96 (m, 1H), 3.51  
(dd, J = 13.1 Hz, J = 2.7 Hz, 1H), 3.45 (dd, J = 13.1 Hz, J = 6.5 Hz, 1H), 3.31 (s, 3H), 3.27 
(s, 3H), 1.35 (s, 3H), 1.31 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 138.32, 134.00, 131.39, 
129.08, 128.25, 127.86, 127.56, 127.47, 100.03, 99.73, 87.35, 77.43, 72.99, 71.39, 69.19, 64.72, 
50.69, 48.03, 47.95, 17.758 (2xCH3); IR (neat): ν = 2098, 1136, 1113, 1049, 739; HRMS 
(ESI): calcd for C25H31N3O6SNa (M + Na+) 524.1831, found 524.1889. 
 
3-O-[6-Azido-2-O-benzyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-
mannopyranosyl]-1,2:5,6-di-O-isopropylidene-D-glucofuranose (22)     
Mannothioglycoside 21 (70 mg, 0.140 mmol), PSP (1.2 equiv., 
35.2 mg, 0.168 mmol) and TTBP13  (2 equiv., 69.2 mg, 0.280 
mmol) were placed together in a flask and coevaporated with 
dry toluene three times keeping an atmosphere of argon. The 
mixed reagents were dissolved in dry CH2Cl2 (5 mL) and 
activated 4Å powdered MS (40 mg) were added. The reaction 
mixture was cooled to –60 ºC and Tf2O (1.2 equiv., 28.4 µL, 
0.168 mmol) was added slowly. After 15 min a solution of 
diisopropylidene-D-glucose 214 (1.5 equiv., 54.7 mg, 0.210 mmol) in dry CH2Cl2 (2 mL) 
was added slowly. The reaction mixture was stirred for 20 min at –60 ºC and then 
warmed to rt, filtered, washed with sat. NaHCO3, followed by brine, dried over MgSO4 
and concentrated under reduced pressure. Purification was performed by silica gel 
chromatography to afford 22 (57 mg, 0.087 mmol, 62%) as colourless oil. 
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RF = 0.46 (EtOAc/heptane, 1/3); [α]20D = +111.0 (c = 0.002 g mL-1, CH2Cl2); 1H NMR  
(400 MHz, CDCl3): δ = 7.42-7.40 (m, 2H), 7.35-7.25 (m, 3H), 5.83 (d, J = 3.5 Hz, 1H), 5.11 
(d, J = 1.0 Hz, 1H), 4.89 (d, J = 12.1 Hz, 1H), 4.70-4.67 (m, 2H), 4.25 (s, 1H), 4.14-4.04  
(m, 4H), 3.98-3.89 (m, 3H), 3.71-3.70 (m, 1H), 3.57 (dd, J = 13.1 Hz, J = 2.1 Hz, 1H), 3.45 
(dd, J = 13.1 Hz, J = 7.0 Hz, 1H), 3.26 (s, 6H), 1.49 (s, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 1.30 
(s, 9H); 13C NMR (75 MHz, CDCl3): δ = 138.57, 128.38, 127.94, 127.70, 112.18, 109.41, 
105.43, 100.81, 100.10, 99.90, 83.78, 81.47, 81.45, 75.49, 73.27, 72.71, 71.47, 68.75, 67.86, 
64.67, 50.96, 48.31, 48.12, 26.94, 26.91, 26.19, 25.57, 17.97, 17.94; IR (neat): ν = 2829, 2099, 
1130, 1074, 1034;  HRMS (ESI): calcd for C31H45N3O12SNa (M + Na+) 674.2901, found 
674.2881. 
 
3-O-[6-Amino-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
1,2:5,6-di-O-isopropylidene-D-glucofuranose (23) 
Compound 22 (50 mg, 0.077 mmol) was dissolved in EtOH  
(3 mL), a catalytic amount of Pd(OH)2 was added and the 
reaction was stirred under H2 (1 atm) for 10 h. The mixture 
was filtered through celite and the solvent evaporated to 
afford 23 (36 mg, 0.068 mmol, 88%) as colourless amorphous 
solid. 1H NMR (400 MHz, CD3OD): δ = 5.93 (d, J = 3.4 Hz, 
1H), 5.04 (s, 1H), 4.74 (d, J = 3.7 Hz, 1H), 4.27 (d, J = 2.5 Hz, 
1H), 4.23-4.18 (m, 1H), 4.12-4.09 (m, 2H), 3.94-3.86 (m, 4H), 
3.78-3.73 (m, 1H), 3.24 (s, 6H), 3.12 (dd, J = 13.4 Hz, J = 2.6 Hz, 1H), 2.84 (dd, J = 13.4 
Hz, J = 8.1 Hz, 1H), 1.46 (s, 3H), 1.40 (s, 3H), 1.33 (s, 3H), 1.32 (s, 3H), 1.30 (s, 3H), 1.25 
(s, 3H) ; IR (neat): ν = 3373, 2833, 1135, 1074, 1035. 
 
4-O-[6-Azido-2-O-benzyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-
mannopyranosyl]-1,3-di-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-
deoxystreptamine (24)  
Mannothioglycoside 21 (502 mg, 1.0 mmol), PSP  
(1.2 equiv., 251 mg, 1.2 mmol) and TTBP (2 equiv., 297 mg, 
2.0 mmol) were placed together in a flask and 
coevaporated with dry toluene three times keeping an 
atmosphere of argon. The mixed reagents were dissolved 
in dry CH2Cl2 (20 mL) and activated 4Å powdered MS 
(250 mg) were added. The reaction mixture was cooled to 
–60 ºC and Tf2O (1.2 equiv., 202 µL, 1.2 mmol) was added slowly. After 15 min a 
solution of 2-DOS 615 (1.3 equiv., 664 mg, 1.3 mmol) in dry CH2Cl2 (15 mL) was added 
slowly. The reaction mixture was stirred for 20 min at –60 ºC, then warmed to –30 ºC 
and quenched with P(OEt)3(1.2 equiv., 206 µL, 1.2 mmol). The mixture was allowed to 
warm to rt, filtered, washed with sat. NaHCO3, followed by brine, dried over MgSO4 
and concentrated under reduced pressure. Purification was performed by silica gel 
chromatography to afford 24 (650 mg, 0.721 mmol, 72%) as colourless thick oil which 
solidify slowly to give a white powder. RF = 0.3 (EtOAc/heptane, 1/2); [α]20D = +81.0  
(c = 0.01 g mL-1, CH2Cl2); mp = 96-97 ºC; 1H NMR (400 MHz, CDCl3):  
δ = 7.42-7.25 (m, 15H), 5.34 (s, 1H), 5.23 (d, J = 11.9 Hz, 1H), 5.11-5.05 (m, 3H), 4.88-4.79 
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(m, 3H), 4.74 (d, J = 12.5 Hz, 1H), 4.07-3.93 (m, 3H), 3.78-3.70 (m, 4H), 3.53-3.46 (m, 2H), 
3.42-3.34 (m, 2H), 3.31 (s, 3H), 3.24 (s, 3H), 2.52 (m, 1H), 1.68-1.46 (m, 9H), 1.32 (br s, 
5H), 1.22 (s, 3H); 13C NMR(75 MHz, CDCl3): δ = 155.77, 155.64, 138.69, 136.55, 136.32, 
128.66, 128.57, 128.45, 128.31, 128.29, 128.19, 127.81, 127.52, 113.08, 99.98, 99.90, 98.32, 
80.82, 78.65, 77.51, 75.82, 73.11, 71.20, 68.63, 67.43, 67.29, 64.91, 51.43, 51,38, 49.89, 48.32, 
48.28, 36.91, 36.65, 36.45, 25.50, 24.44, 24.20, 18.43, 18.37; IR (neat): ν = 3309, 2854, 1691, 
1136, 1110, 1039, 732;  HRMS (ESI): calcd for C47H59N5O13Na (M + Na+) 924.4007, found 
924.4079. 
 
4-O-[6-Amino-6-N-benzyloxycarbonyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α-D-mannopyranosyl]-1,3-di-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-
deoxystreptamine (26) 
Compound 24 (200 mg, 0.222 mmol) was dissolved in THF 
(3 mL) and tert-butyl alcohol (0.5 mL). The solution was 
cooled to –30 ºC and liquid NH3 (approx. 5 mL) was 
added. Small pieces of Li were added until the solution 
remained blue. The reaction mixture was stirred for 1 h, 
warmed to rt and quenched by addition of H2O. Then 
AcOH was added until pH ≈ 7 and the solvents evaporated under reduced pressure. 
The crude mixture was dissolved in H2O (5 mL) and a solution of DMAP (0.3 equiv., 
8.1 mg, 0.067 mmol) and Boc2O (6 equiv., 291 mg, 1.332 mmol) in 1,4-dioxane (5 mL) 
was added. After 1 d TLC showed little formation of product, and more Boc2O 
(6 equiv., 291 mg, 1.332 mmol) was added dissolved in 1,4-dioxane (3 mL). After 2 d 
the reaction was diluted with H2O and extracted with AcOEt, followed by brine, dried 
over MgSO4 and concentrated under reduced pressure. Purification was performed by 
silica gel chromatography with a gradient 1/2→1/1 of AcOEt/heptane to afford 26  
(65 mg, 0.079 mmol, 36%) as white solid. RF = 0.47 (EtOAc/heptane, 1/1); [α]20D = +70.3  
(c = 0.01 g mL-1, CH2Cl2); mp = 131-133 ºC; 1H NMR (400 MHz, CDCl3): δ = 5.20 (s, 1H), 
5.00 (br s, 1H), 4.72 (br s, 1H), 4.55 (br s, 1H), 3.93 (s, 1H), 3.86 (br s, 3H), 3.65 (br s, 3H), 
3.47-3.43 (m, 2H), 3.37-3.29 (m, 2H), 3.19 (s, 3H), 3.17 (s, 3H), 2.54-2.47 (m, 2H), 1.61-1.52 
(m, 8H), 1.43-1.41 (m, 30H), 1.26 (s, 3H), 1.19 (s, 3H); 13C NMR (75 MHz, CDCl3): 
δ = 156.11, 155.32, 155.12, 112.80, 100.30, 99.96, 99.19, 80.77, 80.27, 79.98, 79.41, 78.42, 
77.36, 69.77, 68.06, 64.05, 50.58, 49.25, 47.95, 47.87, 40.72, 37.07, 36.52, 36.26, 28.59, 28.48, 
25.10, 23.89, 23.83, 17.90, 17.73; IR (neat): ν = 3343, 2859, 1697, 1152, 1040, 728;  HRMS 
(ESI): calcd for C39H67N3O15Na (M + Na+) 840.4470, found 840.4424. 
 
Phenyl 6-azido-2-O-tert-butydimethylsilyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-1-thio-α-D-mannopyranoside (27) 
To a solution of mannothioglycoside 18 (50 mg, 0.122 mmol) and 
2,6-lutidine (3 equiv., 39 µL, 0.336 mmol) in dry CH2Cl2 (5 mL) was 
added tert-butyldimethylsilyl triflate (TBSOTf) (1.5 equiv., 42 µL, 
0.183 mmol). After 2 h TLC showed remaining starting material 
and extra 2,6-lutidine (3 equiv.) and TBSOTf (1.5 equiv.) were 
added. After 10 h the reaction was quenched with MeOH and the 
solvents evaporated under reduced pressure. Purification by silica gel chromatography 
afforded 27 (60 mg, 0.114 mmol, 93%) as thick oil which solidified slowly to give an 
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amorphous solid. RF = 0.5 (EtOAc/heptane, 1/9); [α]20D = +177.7 (c = 0.01 g mL-1, 
CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.49-7.46 (m, 2H), 7.34-7.24 (m, 3H), 5.33  
(d, J = 0.98 Hz, 1H), 4.34-4.29 (m, 1H), 4.15-4.10 (m, 2H), 3.87 (dd, J = 9.9 Hz, J = 2.6 Hz, 
1H), 3.53 (dd, J = 13.2 Hz, J = 2.3 Hz, 1H), 3.37 (dd, J = 13.2 Hz, J = 5.9 Hz, 1H), 3.29  
(s, 3H), 3.21 (s, 3H), 1.28 (s, 3H), 1.27 (s, 3H), 0.91 (s, 9H), 0.13 (s, 3H), 0.07 (s, 3H);  
13C NMR (75 MHz, CDCl3): δ = 133.98, 131.24, 128.87, 127.19, 99.77, 99.45, 89.73, 71.92, 
71.37, 68.56, 63.91, 50.65, 48.00, 47.70, 25.82, 18.38, 17.92, 17.77, -4.49, -4.65; IR (neat):  
ν = 2828, 2094, 1143, 1052;  HRMS (ESI): calcd for C24H39N3O6SSiNa (M + Na+) 548.2227, 
found 548.2276. 
 
Phenyl 6-azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-2-O-trimethylsilyl-1-
thio-α-D-mannopyranoside (28) 
To a solution of mannothioglycoside 18 (1.8 g, 4.374 mmol) in 
acetonitrile (90 mL) were added 4Å MS (1 g), HMDS (5 equiv., 4.53 
mL, 21.87 mmol) and a catalytic amount of TMSCl (0.1 equiv., 55.5 
µL, 0.437 mmol). After 24 h the reaction mixture was filtered 
through hyflo and the solvent was evaporated under reduced 
pressure to afford analytically pure 28 (2.10 g, 4.350 mmol, 99%) as 
white powder. RF = 0.36 (EtOAc/heptane, 1/12); [α]20D = +191.6 (c = 0.005 g mL-1, 
CH2Cl2); mp = 103-104 ºC; 1H NMR (400 MHz, CDCl3): δ = 7.51-7.49 (m, 2H), 7.34-7.24 
(m, 3H), 5.39 (s, 1H), 4.36-4.31 (m, 1H), 4.17-4.15 (m, 1H), 4.00 (t, J = 10.0 Hz, 1H), 3.86 
(dd, J = 10.0 Hz, J = 2.7 Hz, 1H), 3.52-3.43 (m, 2H), 3.29 (s, 3H), 3.22 (s, 3H), 1.30 (s, 3H), 
1.28 (s, 3H), 0.16 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 134.39, 131.42, 129.22, 127.51, 
100.23, 99.85, 90.25, 72.45, 71.72, 69.01, 64.62, 51.10, 48.39, 48.14, 18.31, 18.18, 1.06;  
IR (neat): ν = 2828, 2098, 1138, 1124, 864, 845; HRMS (ESI): calcd for C21H33N3O6SSiNa 
(M + Na+) 506.1757, found 506.1780. Elemental analysis calcd for C21H33N3O6SSi:  
C, 52.15; H, 6.88; N, 8.69. Found: C, 52.17; H, 6.87; N, 8.49.   
 
3-O-[6-Azido-2-O-tert-butydimethylsilyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α-D-mannopyranosyl]-1,2:5,6-di-O-isopropylidene-D-glucofuranose (29a)  
Mannothioglycoside 27 (50 mg, 0.095 mmol) and PSP  
(1.2 equiv., 23.9 mg, 0.114 mmol) were placed together in a 
flask and coevaporated with dry toluene three times. The 
mixed reagents were redissolved in dry CH2Cl2 (2.5 mL) 
under an atmosphere of argon. TTBP (2 equiv., 69 mg, 0.280 
mmol) which was previously dried in a desiccator and 
activated 4Å powdered MS (30 mg) were added. The reaction 
mixture was cooled to –60 ºC and Tf2O (1.2 equiv., 19.2 µL, 
0.104 mmol) was added slowly. After 15 min a solution of diisopropylidene-D-glucose 
214 (1.3 equiv., 32 mg, 0.123 mmol) in dry CH2Cl2 (1.5 mL) was added slowly. The 
reaction mixture was stirred for 20 min at –60 ºC, then slowly warmed to –20 ºC and 
quenched with P(OEt)3 (1.1 equiv., 17.9 µL, 0.104 mmol). The mixture was allowed to 
warm to rt, filtered, washed with sat. NaHCO3, followed by brine, dried over MgSO4 
and concentrated under reduced pressure. Purification was performed by silica gel 
chromatography to afford 29a (60 mg, 0.089 mmol, 93%) as colourless thick oil.  
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RF = 0.35 (EtOAc/heptane, 1/4); [α]20D = +103.0 (c = 0.01 g mL-1, CH2Cl2); 1H NMR  
(400 MHz, CDCl3): δ = 5.82 (d, J = 3.7 Hz, 1H), 4.90 (d, J = 1.6 Hz, 1H), 4.63 (d, J = 3.5 
Hz, 1H), 4.26 (d, J = 2.7 Hz, 1H), 4.17-4.00 (m, 5H), 3.91-3.87 (m, 2H), 3.79 (dd, J = 10.0 
Hz, J = 2.7 Hz, 1H), 3.60 (dd, J = 13.1 Hz, J = 2.1 Hz, 1H), 3.52 (dd, J = 13.1 Hz, J = 6.1 
Hz, 1H), 3.25 (s, 3H), 3.20 (s, 3H), 1.49 (s, 3H), 1.40 (s, 3H), 1.30 (s, 6H), 1.27 (s, 3H), 1.26 
(s, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.06 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 112.21, 
109.57, 105.51, 102.95, 100.08, 99.82, 84.20, 81.73, 81.16, 72.91, 71.82, 70.40, 68.17, 67.99, 
64.05, 51.05, 48.51, 48.08, 27.43, 27.31, 26.60, 26.19, 25.87, 18.74, 18.31, 18.18, -4.20, -4.39;  
IR (neat): ν = 2832, 2098, 1129, 1039, 840;  HRMS (FAB): calcd for C30H54N3O12Si  
(M + H+) 676.3477, found 676.3445. 
 
3-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
1,2:5,6-di-O-isopropylidene-D-glucofuranose (30a)  
Compound 29a (50 mg, 0.074 mmol) was dissolved in THF  
(3 mL) and TBAF (1.1 equiv., 81.4 µL from 1M solution in 
THF) was added. The reaction mixture was stirred for 10 h 
and the solvent was evaporated. The residue was dissolved 
in AcOEt and washed with H2O. The H2O was extracted with 
additional AcOEt and the combined organic layers were 
treated with brine, dried over MgSO4 and evaporated under 
reduced pressure. Purification by silica gel chromatography 
gave 30a (36 mg, 0.064 mmol, 86%) as colourless oil. RF = 0.42 (EtOAc/heptane, 1/1); 
[α]20D = +94.6 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 5.85  
(d, J = 3.3 Hz, 1H), 5.11 (s, 1H), 4.70 (d, J = 3.3 Hz, 1H), 4.28 (br s, 1H), 4.16-4.06 (m, 3H), 
4.02-3.89 (m, 5H), 3.56 (d, J = 13.0 Hz, 1H), 3.43 (dd, J = 13.0 Hz, J = 7.0 Hz, 1H), 3.26  
(s, 3H), 3.23 (s, 3H), 2.54 (br s, 1H), 1.48 (s, 3H), 1.39 (3H), 1.31 (br s, 9H), 1.28 (s, 3H);  
13C NMR (75 MHz, CDCl3): δ = 111.89, 109.14, 105.15, 101.24, 100.30, 99.94, 83.51, 81.63, 
81.15, 72.47, 70.82, 69.38, 67.92, 67.73, 63.95, 50.80, 48.33, 48.08, 26.96, 26.92, 26.21, 25.47, 
17.93, 17.87; IR (neat): ν = 3481, 2840, 2103, 1139, 1079, 1031; HRMS (FAB): calcd for 
C24H40N3O12 (M + H+) 562.2612, found 562.2620. 
 
6-O-[6-Azido-2-O-tert-butydimethylsilyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α-D-mannopyranosyl]-1,2:3,4-di-O-isopropylidene-D-galactofuranose (29b) 
Mannothioglycoside 27 (193 mg, 0.367 mmol) and PSP  
(1.2 equiv., 92 mg, 0.440 mmol) were placed together in a 
flask and coevaporated with dry toluene three times. The 
mixed reagents were redissolved in dry CH2Cl2 (6 mL) 
under an atmosphere of argon. TTBP (2.5 equiv., 228 mg, 
0.917 mmol) which was previously dried in a desiccator 
and activated 4Å powdered MS (100 mg) were added. The 
reaction mixture was cooled to –60 ºC and Tf2O (1.2 equiv., 
74 µL, 0.440 mmol) was added slowly. After 15 min a solution of diisopropylidene-D-
galactose16 (1.2 equiv., 115 mg, 0.440 mmol) in dry CH2Cl2 (5 mL) was added slowly. 
The reaction mixture was stirred for 20 min at –60 ºC, then slowly warmed to –20 ºC 
and quenched with P(OEt)3 (1.2 equiv., 76 µL, 0.440 mmol). The mixture was allowed 
to warm to rt, filtered, washed with sat. NaHCO3, followed by brine, dried over MgSO4 
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and concentrated under reduced pressure. Purification was performed by silica gel 
chromatography to afford the α-couple product 29b (170 mg, 0.252 mmol, 69%) as 
colourless gum, and a non-separable fraction of α/β mixture in an 8/1 ratio (40 mg, 
0.059 mmol, 16%). Analytical data are given only for the α-coupled product 29b.  
RF = 0.33 (EtOAc/heptane, 1/5); [α]20D = +82.2 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 
MHz, CDCl3): δ = 5.52 (d, J = 4.9 Hz, 1H), 4.77 (d, J = 1.2 Hz, 1H), 4.61 (dd, J = 7.8 Hz,  
J = 2.3 Hz, 1H), 4.31 (dd, J = 5.0 Hz, J = 2.4 Hz, 1H), 4.20 (dd, J = 7.9 Hz, J = 1.8 Hz, 1H), 
4.06-3.99 (m, 2H), 3.91-3.84 (m, 3H), 3.81-3.71 (m, 2H), 3.48 (dd, J = 13.1 Hz, J = 2.1 Hz, 
1H), 3.32 (dd, J = 13.1 Hz, J = 5.9 Hz, 1H), 3.22 (s, 3H), 3.19 (s, 3H), 1.51 (s, 3H), 1.44  
(s, 3H), 1.32 (s, 3H), 1.31 (s, 3H), 1.25 (s, 3H), 1.24 (s, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.05 
(s, 3H); 13C NMR (75 MHz, CDCl3): δ = 109.43, 108.61, 100.18, 99.77, 99.51, 96.44, 71.34, 
71.19, 70.92, 70.73, 70.48, 67.98, 65.16, 64.92, 63.82, 50.71, 48.14, 47.79, 26.42, 26.29, 26.02, 
25.25, 24.86, 18.56, 18.08, 17.98, -4.35, -4.64; IR (neat): ν = 2832, 2097, 1126, 1070; HRMS 
(FAB): calcd for C30H54N3O12Si (M + H+) 676.3477, found 676.3434. 
 
6-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
1,2:3,4-di-O-isopropylidene-D-galactofuranose (30b)  
Compound 29b (118 mg, 0.175 mmol) was dissolved in THF 
(8 mL) and TBAF (1.1 equiv., 193 µL from 1M solution in 
THF) was added. After 3½ h TLC showed only half 
conversion. Extra TBAF was added (0.5 equiv., 87 µL from 
1M solution in THF). The reaction mixture was stirred for 
10 h and the solvent was evaporated. The crude product 
was purified by silica gel chromatography to afford 30b  
(94 mg, 0.167 mmol, 95%) as colourless gum. RF = 0.26 
(EtOAc/heptane, 2/3); [α]20D = +93.2 (c = 0.005 g mL-1, CH2Cl2); 1H NMR (400 MHz, 
CDCl3): δ = 5.51 (d, J = 5.1 Hz, 1H), 4.90 (s, 1H), 4.60 (dd, J = 7.9 Hz, J = 2.4 Hz, 1H), 4.30 
(dd, J = 5.0 Hz, J = 2.4 Hz, 1H), 4.21 (dd, J = 7.9 Hz, J = 1.9 Hz, 1H), 4.02-3.89 (m, 5H), 
3.81 (dd, J = 10.7 Hz, J = 6.9 Hz, 1H), 3.73 (dd, J = 10.7 Hz, J = 6.6 Hz, 1H), 3.48  
(dd, J = 13.1 Hz, J = 2.5 Hz, 1H), 3.42 (dd, J = 13.1 Hz, J = 5.7 Hz, 1H), 3.25 (s, 3H), 3.22 
(s, 3H), 2.52 (br s, 1H), 1.53 (s, 3H), 1.43 (s, 3H), 1.32 (br s, 6H), 1.30 (s, 3H), 1.26 (s, 3H);  
13C NMR (75 MHz, CDCl3): δ = 109.43, 108.64, 100.35, 99.97, 99.56, 96.36, 71.09, 70.81, 
70.77, 70.50, 69.71, 68.15, 66.01, 65.46, 64.05, 50.76, 48.37, 48.16, 26.40, 26.27, 25.24, 24.87, 
18.07, 18.02; IR (neat): ν = 3487, 2830, 2098, 1132, 1114, 1069, 1042; HRMS (FAB): calcd 
for C24H39N3O12Na (M + Na+) 584.2431, found 584.2444. 
 
3-O-[6-Azido-2-O-tert-butydimethylsilyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α-D-mannopyranosyl]-N-benzyloxycarbonyl-L-serine benzyl ester (29c) 
Mannothioglycoside 27 (114 mg, 0.217 mmol) and PSP  
(1.2 equiv., 54.4 mg, 0.260 mmol) were placed together in a 
flask and coevaporated with dry toluene three times. The 
mixed reagents were redissolved in dry CH2Cl2 (5.5 mL) 
under an atmosphere of argon. TTBP (2.5 equiv., 135 mg, 
0.543 mmol) which was previously dried in a desiccator and 
activated 4Å powdered MS (75 mg) were added. The reaction mixture was cooled to  
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–60 ºC and Tf2O (1.2 equiv., 44 µL, 0.260 mmol) was added slowly. After 15 min a 
solution of N-Cbz-L-serine benzyl ester (1.2 equiv., 86 mg, 0.260 mmol) in dry CH2Cl2 
(4.5 mL) was added slowly. The reaction mixture was stirred for 20 min at –60 ºC, then 
slowly warmed to –20 ºC and quenched with P(OEt)3 (1.2 equiv., 44.6 µL, 0.260 mmol). 
The mixture was allowed to warm to rt, filtered, washed with sat. NaHCO3, followed 
by brine, dried over MgSO4 and concentrated under reduced pressure. Purification was 
performed by silica gel chromatography to afford 29c (135 mg, 0.181 mmol, 83%) as 
colourless oil. RF = 0.31 (EtOAc/heptane, 1/4); [α]20D = +108.3 (c = 0.01 g mL-1, CH2Cl2); 
1H NMR (400 MHz, CDCl3): δ = 7.38 (m, 10H), 5.68 (d, J = 8.6 Hz, 1H), 5.19 (s, 2H), 5.14 
(s, 2H), 4.60-4.58 (m, 2H), 4.05-3.93 (m, 3H), 3.80-3.72 (m, 3H), 3.46 (dd, J = 13.1 Hz,  
J = 2.0 Hz, 1H), 3.27 (dd, J = 13.1 Hz, J = 6.0 Hz, 1H), 3.21 (s, 3H), 3.19 (m, 3H), 1.26 (s, 
3H), 1.25 (s, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDCl3):  
δ = 169.66, 155.75, 136.06, 135.04, 128.58, 128.46, 128.14, 128.06, 102.27, 99.80, 99.54, 
71.50, 70.31, 68.79, 67.91, 67.57, 67.35, 63.49, 54.67, 50.57, 48.18, 47.82, 25.97, 18.51, 18.07, 
17.97, -4.32, -4.64; IR (neat): ν = 3333, 2830, 2099, 1725, 1130, 1038; HRMS (FAB): calcd 
for C36H52N4O11SiNa (M + Na+) 767.3300, found 767.3312. 
 
3-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-2-O-trimethylsilyl-α-D-
mannopyranosyl]-N-benzyloxycarbonyl-L-serine benzyl ester (29d) and β-isomer  
Mannothioglycoside 28 (180 mg, 
0.372 mmol) and PSP (1.2 equiv., 93 
mg, 0.446 mmol) were placed 
together in a flask and coevaporated 
with dry toluene three times. The 
mixed reagents were redissolved in 
dry CH2Cl2 (6 mL) under an atmosphere of argon. TTBP (2.5 equiv., 231 mg, 0.930 
mmol) which was previously dried in a desiccator and activated 4Å powdered MS  
(90 mg) were added. The reaction mixture was cooled to –60 ºC and Tf2O (1.2 equiv.,  
75 µL, 0.446 mmol) was added slowly. After 15 min a solution of N-Cbz-L-serine 
benzyl ester (1.2 equiv., 147 mg, 0.446 mmol) in dry CH2Cl2 (5 mL) was added slowly. 
The reaction mixture was stirred for 20 min at –60 ºC, then slowly warmed to –20 ºC 
and quenched with P(OEt)3 (1.2 equiv., 76 µL, 0.446 mmol). The mixture was allowed 
to warm to rt, filtered, washed with sat. NaHCO3, followed by brine, dried over MgSO4 
and concentrated under reduced pressure. Purification was performed by silica gel 
chromatography to afford 29d (195 mg, 0.277 mmol, 75%) and its β-isomer (7 mg,  
0.010 mmol, 7%), both as colourless oil. (α/β ratio 28/1). Analytical data are given for 
both isomers. 29d: RF = 0.28 (EtOAc/heptane, 1/4); [α]20D = +101.1 (c = 0.01 g mL-1, 
CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.38-7.32 (m, 10H), 5.69 (d, J =8.6 Hz, 1H), 5.24 
(d, J =12.3 Hz, 1H), 5.18-5.14 (m, 3H), 4.61-4.58 (m, 2H), 3.98-3.88 (m, 3H), 3.81-3.71  
(m, 3H), 3.44 (dd, J = 13.0 Hz, J = 2.2 Hz, 1H), 3.37 (dd, J = 13.0 Hz, J = 6.5 Hz, 1H), 3.21 
(s, 3H), 3.19 (s, 3H), 1.28 (s, 3H), 1.25 (s, 3H), 0.14 (s, 9H); 13C NMR (75 MHz, CDCl3):  
δ = 169.64, 155.75, 136.06, 135.11, 128.55, 128.44, 128.10, 128.04, 102.45, 99.86, 99.55, 
71.31, 70.45, 68.84, 68.00, 67.51, 67.34, 63.83, 54.62, 50.68, 48.18, 47.84, 18.07, 17.98, 0.83; 
IR (neat): ν = 3327, 2831, 2099, 1725, 1129, 1038; HRMS (FAB): calcd for C33H47N4O11Si 
(M + H+) 703.3011, found 703.3007. 
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β-Isomer: RF = 0.14 (EtOAc/heptane, 1/4); [α]20D = +66.4 (c = 0.005 g mL-1, CH2Cl2);  
1H NMR (400 MHz, CDCl3): δ = 7.37-7.31 (m, 10H), 5.62 (d, J = 8.0 Hz, 1H), 5.30-5.12  
(m, 4H), 4.59-4.57 (m, 1H), 4.43 (s, 1H), 4.36 (dd, J = 10.1 Hz, J = 3.6 Hz, 1H), 3.95-3.83 
(m, 3H), 3.56-3.49 (m, 2H), 3.38-3.36 (m, 2H), 3.24 (s, 3H), 3.18 (m, 3H), 1.27 (m, 3H), 
1.24 (s, 3H), 0.12 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 169.45, 155.73, 136.18, 135.27, 
128.49, 128.46, 128.15, 128.11, 128.07, 100.78, 99.86, 99.61, 77.36, 74.92, 70.23, 69.12, 67.49, 
67.24, 64.18, 54.56, 50.70, 48.19, 47.95, 18.05, 17.89, 0.76; IR (neat): ν = 3438, 3335, 2832, 
2097, 1725, 1128, 1050; HRMS (ESI): calcd for C33H46N4O11SiNa (M + Na+) 725.2830, 
found 725.2841. 
 
3-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
N-benzyloxycarbonyl-L-serine benzyl ester (30d)  
To a stirred solution of 29d (140 mg, 0.199 mmol) in THF  
(25 mL) was added TBAF (1.1 equiv., 219 µL from 1M 
solution in THF). TLC after 1½ h showed about half 
conversion. Extra TBAF (0.5 equiv., 100 µL from 1M solution 
in THF) was added, but this time its basicity was previously 
neutralised with AcOH. After 4 h the reaction finished and the solvent was evaporated 
under reduce pressure. Purification was performed by silica gel chromatography to 
afford 30d (120 mg, 0.191 mmol, 96%) as a colourless gum. RF = 0.40 (EtOAc/heptane, 
1/1); [α]20D = +102.9 (c = 0.0115 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.38-
7.32 (m, 10H), 5.67 (d, J = 8.4 Hz, 1H), 5.27 (d, J = 12.1 Hz, 1H), 5.14-5.11 (m, 3H), 4.66  
(s, 1H), 4.61-4.59 (m, 1H), 3.99-3.94 (m, 3H), 3.83-3.77 (m, 2H), 3.67-3.66 (m, 1H), 3.44 
(dd, J = 13.1 Hz, J = 2.3 Hz, 1H), 3.36 (dd, J = 13.1 Hz, J = 6.0 Hz, 1H), 3.23 (s, 3H), 3.22 
(s, 3H), 2.41 (br s, 1H), 1.30 (s, 3H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 169.50, 
155.72, 136.01, 135.08, 128.59, 128.50, 128.45, 128.27, 128.14, 128.13, 100.90, 100.35, 99.99, 
70.69, 69.37, 69.13, 67.98, 67.56, 67.37, 63.73, 54.60, 50.58, 48.43, 48.18, 18.03, 18.00;  
IR (neat): ν = 3434, 3339, 2833, 2098, 1720, 1133, 1114, 1036; HRMS (FAB): calcd for 
C30H39N4O11 (M + H+) 631.2615, found 631.2623. 
 
4-O-[6-Azido-2-O-tert-butydimethylsilyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-
diyl)-α-D-mannopyranosyl]-1,3-bis-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-
deoxystreptamine (29e) 
Mannothioglycoside 27 (302 mg, 0.575 mmol) and PSP  
(1.2 equiv., 144.4 mg, 0.690 mmol) were placed together in 
a flask and coevaporated with dry toluene three times. 
The mixed reagents were redissolved in dry CH2Cl2  
(15 mL) under an atmosphere of argon. TTBP (2 equiv., 
286 mg, 1.150 mmol) which was previously dried in a 
desiccator and activated 4Å powdered MS (150 mg) were added. The reaction mixture 
was cooled to –60 ºC and Tf2O (1.2 equiv., 116.6 µL, 0.690 mmol) was added slowly. 
After 15 min a solution of 2-DOS 615 (1.3 equiv., 382 mg, 0.748 mmol) in dry CH2Cl2  
(9 mL) was added slowly. The reaction mixture was stirred for 20 min at –60 ºC, then 
slowly warmed to –20 ºC and quenched with P(OEt)3 (1.2 equiv., 118.3 µL, 0.690 mmol). 
The mixture was allowed to warm to rt, filtered, washed with sat. NaHCO3, followed 
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by brine, dried over MgSO4 and concentrated under reduced pressure. Purification was 
performed by silica gel chromatography using a mixture of EtOAc/heptane with 1% 
Et3N to afford 29e (426 mg, 0.460 mmol, 80%) as white powder. RF = 0.26 
(EtOAc/heptane, 2/5); [α]20D = +84.0 (c = 0.01 g mL-1, CH2Cl2); mp = 140-142 ºC;  
1H NMR (400 MHz, CDCl3): δ = 7.38-7.29 (m, 10H), 5.21 (d, J = 11.9 Hz, 1H), 5.13-5.05 
(m, 4H), 4.85 (br s, 1H), 4.79 (d, J = 8.0 Hz, 1H), 3.98-3.90 (m, 3H), 3.83-3.74 (m, 4H), 
3.54-3.51 (m, 2H), 3.39-3.27 (m, 5H), 3.18 (s, 3H), 2.55-2.52 (m, 1H), 1.69-1.43 (m, 9),  
1.33-1.30 (m, 2H), 1.24 (s, 3H), 1.18 (s, 3H), 0.90 (s, 9H), 0.11 (3H), 0.07 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ = 155.44, 155.30, 136.17, 135.99, 128.31, 128.22, 128.18, 127.95, 127.85, 
112.75, 100.31, 99.46, 99.34, 80.54, 78.35, 77.20, 70.94, 70.37, 67.56, 67.09, 66.93, 63.76, 
51.11, 50.98, 49.62, 47.89, 47.61, 36.64, 36.32, 35.99, 25.83, 25.04, 23.83, 23.66, 18.40, 17.96, 
17.87, -4.57, -4.87; IR (neat): ν = 3300, 2096, 1691, 1126, 1038; HRMS (ESI): calcd for 
C46H67N5O13SiNa (M + Na+) 948.4402, found 948.4429.  
 
4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-2-O-trimethylsilyl-α-D-
mannopyranosyl]-1,3-bis-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-
deoxystreptamine (29f)  
Mannothioglycoside 28 (600 mg, 1.241 mmol) and PSP  
(1.2 equiv., 311.7 mg, 1.489 mmol) were placed together in 
a flask and coevaporated with dry toluene three times. 
The mixed reagents were redissolved in dry CH2Cl2  
(25 mL) under an atmosphere of argon. TTBP (2.5 equiv., 
771 mg, 3.102 mmol) which was previously dried in a 
desiccator and activated 4Å powdered MS (350 mg) were added. The reaction mixture 
was cooled to –60 ºC and Tf2O (1.2 equiv., 250.5 µL, 1.489 mmol) was added slowly. 
After 15 min a solution of 2-DOS 615 (1.3 equiv., 823.7 mg, 1.613 mmol) in dry CH2Cl2 
(20 mL) was added slowly. The reaction mixture was stirred for 20 min at –60 ºC, then 
slowly warmed to –20 ºC and quenched with P(OEt)3 (1.2 equiv., 255.3 µL, 1.489 mmol). 
The mixture was allowed to warm to rt, filtered, washed with sat. NaHCO3, followed 
by brine, dried over MgSO4 and concentrated under reduced pressure. Purification was 
performed by silica gel chromatography using a mixture of EtOAc/heptane with 1% 
Et3N to afford 29f (826 mg, 0.934 mmol, 75%) as white powder. RF = 0.24 
(EtOAc/heptane, 1/3); [α]20D = +79.3 (c = 0.01 g mL-1, CH2Cl2); mp = 89-90 ºC; 1H NMR 
(400 MHz, CDCl3): δ = 7.36-7.29 (m, 10H), 5.21 (d, J = 11.9 Hz, 1H), 5.14-5.04 (m, 4H), 
4.94 (br s, 1H), 4.88 (d, J = 8.4 Hz, 1H), 3.97-3.70 (m, 7H), 3.55-3.47 (m, 2H), 3.41-3.36  
(m, 2H), 3.30 (s, 3H), 3.18 (s, 3H), 2.54-2.52 (m, 1H), 1.68-1.50 (m, 8H), 1.48-1.44 (m, 1H), 
1.38-1.27 (m, 2H), 1.26 (s, 3H), 1.19 (s, 3H), 0.15 (s, 9H); 13C NMR (75 MHz, CDCl3):  
δ = 155.63, 155.46, 136.35, 136.14, 128.44, 128.35, 128.23, 128.09, 127.94, 112.85, 100.65, 
99.66, 99.52, 80.68, 78.47, 77.40, 71.03, 70.45, 67.64, 67.20, 67.07, 64.17, 51.21, 51.16, 49.71, 
48.01, 47.83, 36.76, 36.46, 36.18, 25.18, 24.10, 23.89, 18.12, 18.03, 0.63; IR (neat): ν = 3309, 
2099, 1694, 1127, 1039; HRMS (FAB): calcd for C43H62N5O13Si (M + H+) 884.4113, found 
884.4122. 
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4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
1,3-bis-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine (30f) 
To a stirred solution of 29f (268 mg, 0.303 mmol) in THF 
(10 mL) was added TBAF (1.1 equiv., 333 µL from 1M 
solution in THF). TLC after 10 min showed almost full 
conversion. The reaction was stirred for 1 h and the 
solvent was evaporated under reduced pressure. 
Purification was performed by silica gel chromatography 
using a mixture of EtOAc/heptane with 1% Et3N to afford 30f (225 mg, 0.277 mmol, 
91%) as white powder. RF = 0.24 (EtOAc/heptane, 2/3); [α]20D = +90.5 (c = 0.01 g mL-1, 
CH2Cl2); mp = 110-111 ºC; 1H NMR (400 MHz, CDCl3): δ = 7.36-7.30 (m, 10H), 5.30  
(s, 1H), 5.21 (d, J = 9.9 Hz, 1H), 5.12-5.05 (m, 3H), 4.96 (br s, 1H), 4.86 (d, J = 8.6 Hz, 1H), 
4.00-3.90 (m, 4H), 3.79-3.75 (m, 3H), 3.54-3.48 (m, 2H), 3.40-3.35 (m, 2H), 3.31 (s, 3H), 
3.21 (s, 3H), 2.55-2.52 (m, 1H), 2.45 (br s, 1H), 1.63-1.56 (m, 8H), 1.37-1.33 (m, 3H), 1.30 
(s, 3H), 1.21 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 155.53, 155.48, 136.29, 136.14, 
128.46, 128.39, 128.24, 128.11, 128.02, 112.95, 100.25, 99.97, 98.78, 80.56, 78.38, 77.27, 
70.47, 69.77, 67.90, 67.22, 67.08, 64.14, 51.24, 51.11, 49.63, 48.23, 48.09, 36.59, 36.40, 25.25, 
24.07, 23.98, 18.11, 18.09; IR (neat): ν = 3413, 3313, 2098, 1697, 1134, 1115; HRMS (FAB): 
calcd for C40H54N5O13 (M + H+) 812.3718, found 812.3712. 
 
4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-2-O-trimethylsilyl-α-D-
mannopyranosyl]-1,3-diazido-1,3-dideamino-5,6-O-cyclohexylidene-2-
deoxystreptamine (29g) 
 Mannothioglycoside 28 (82 mg, 0.170 mmol) and PSP  
(1.2 equiv., 42.7 mg, 0.204 mmol) were placed together in a 
flask and coevaporated with dry toluene three times. The 
mixed reagents were redissolved in dry CH2Cl2 (3 mL) 
under an atmosphere of argon. TTBP (2.5 equiv., 106 mg, 
0.425 mmol) which was previously dried in a desiccator and 
activated 4Å powdered MS (70 mg) were added. The 
reaction mixture was cooled to –60 ºC and Tf2O (1.2 equiv., 34.3 µL, 0.204 mmol) was 
added slowly. After 15 min a solution of 1,3-diazido-1,3-dideamino-5,6-O-
cyclohexylidene-2-deoxystreptamine4 (1.2 equiv., 60 mg, 0.204 mmol) in dry CH2Cl2  
(2 mL) was added slowly. The reaction mixture was stirred for 20 min at  
–60 ºC, then slowly warmed to –20 ºC and quenched with P(OEt)3 (1.2 equiv., 35 µL, 
0.204 mmol). The mixture was allowed to warm to rt, filtered, washed with  
sat. NaHCO3, followed by brine, dried over MgSO4 and concentrated under reduced 
pressure. Purification was performed by silica gel chromatography, using a mixture of 
EtOAc/heptane with 1% Et3N, to afford the α-couple product 29g (80 mg,  
0.120 mmol, 71%) as white solid, and a non separable fraction of α/β mixture in an 4/5 
ratio (2 mg, 0.003 mmol, 2%). Analytical data are given only for the α-couple product 
29g. RF = 0.24 (EtOAc/heptane, 1/12); [α]20D = +119.2 (c = 0.01 g mL-1, CH2Cl2);  
mp = 144-146 ºC; 1H NMR (400 MHz, CDCl3): δ = 5.19 (s, 1H), 4.10-4.05 (m, 1H),  
3.97-3.91 (m, 2H), 3.88-3.79 (m, 2H), 3.64-3.58 (m, 1H), 3.50-3.36 (m, 5H), 3.21 (s, 3H), 
3.20 (s, 3H), 2.32 (dt, J = 13.7 Hz, J = 5.0 Hz, 1H), 1.68-1.46 (m, 11H), 1.26 (s, 3H), 1.25  
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(s, 3H), 0.15 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 113.65, 100.81, 99.82, 99.65, 79.85, 
79.36, 76.84, 71.52, 70.49, 67.62, 63.92, 60.75, 57.55, 50.78, 47.93, 47.77, 36.40, 36.19, 33.92, 
24.98, 23.92, 23.71, 17.90, 17.80, 0.40; IR (neat): ν = 2100, 1127, 1036; HRMS (ESI): calcd 
for C27H45N9O9SiNa (M + Na+) 690.3007, found 690.3002. 
 
4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-
1,3-diazido-1,3-dideamino-5,6-O-cyclohexylidene-2-deoxystreptamine (30g)  
To a stirred solution of 29g (163 mg, 0.244 mmol) in THF  
(20 mL) was added TBAF (1.1 equiv., 268 µL from 1M 
solution in THF). The reaction was stirred for 2 h and the 
solvent was evaporated under reduced pressure. 
Purification was performed by silica gel chromatography 
using a mixture of EtOAc/heptane with 1% Et3N to afford 
30g (144 mg, 0.242 mmol, 99%) as colourless gum. RF = 0.24 (EtOAc/heptane, 1/3); 
[α]20D = +111.7 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 5.38 (s, 1H), 
4.10-4.06 (m, 1H), 40.3-3.99 (m, 2H), 3.96 (br s, 1H), 3.86-3.81 (m, 1H), 3.66-3.57 (m, 1H), 
3.53-3.37 (m, 5H), 3.23 (s, 3H), 3.22 (s, 3H), 2.54 (br s, 1H), 2.30 (dt, J = 13.5 Hz,  
J = 5.0 Hz, 1H), 1.65-1.58 (m, 8H), 1.48 (q, J = 13.5 Hz, 1H), 1.38-1.37 (m, 2H), 1.30  
(s, 3H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 113.73, 100.35, 100.08, 98.74, 79.66, 
79.42, 76.49, 70.95, 69.73, 67.82, 63.85, 60.89, 57.38, 50.71, 48.12, 48.04, 36.34, 36.20, 33.91, 
25.00, 23.89, 23.75, 17.84, 17.80; IR (neat): ν = 3464, 2098, 1135, 1035; HRMS (ESI): calcd 
for C24H37N9O9Na (M + Na+) 618.2612, found 618.2593. 
 
Phenyl 6-O-benzyl-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-2-O-trimethylsilyl-1-thio-α-
D-mannopyranoside (31) 
To a solution of mannothioglycoside 15 (966 mg, 2.027 mmol) in 
acetonitrile (50 mL) were added 4Å MS (400 mg), HMDS (5equiv., 
2.1 mL, 10.135 mmol) and a catalytic amount of TMSCl (0.1 equiv., 
26 µL, 0.203 mmol). After 10 h the reaction mixture was filtered 
through celite and the solvent was evaporated under reduced 
pressure. Chromatography on silica gel gave 31 (1.10 g, 2.006 
mmol, 99%) as colourless oil. RF = 0.58 (EtOAc/heptane, 1/3); [α]20D = +199.3  
(c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.46-7.40 (m, 4H), 7.33-7.21 
(m, 6H), 5.50 (d, J = 1.4 Hz, 1H), 4.86 (d, J = 12.3 Hz, 1H), 4.67 (d, J = 12.3 Hz, 1H),  
4.24-4.18 (m, 2H), 4.05-4.01 (m, 1H), 3.94-3.93 (m, 1H), 3.84-3.83 (m, 2H), 3.30 (s, 3H), 
3.28 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H), 0.08 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 138.53, 
134.58, 131.57, 128.80, 128.07, 127.66, 127.30, 127.22, 100.02, 99.60, 87.27, 77.80, 72.97, 
72.74, 69.64, 63.89, 61.49, 48.21, 48.17, 18.21, 18.17, 0.08; IR (neat): ν = 2832, 1130, 1114; 
HRMS (ESI): calcd for C28H40O7SSiK (M + K+) 587.1901, found 587.1905. 
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4-O-[6-O-Benzyl-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranosyl]-1,3-bis-
N-benzyloxycarbonyl-2-deoxystreptamine (33) 
Mannothioglycoside 31 (380 mg, 0.629 mmol) and PSP  
(1.2 equiv., 174 mg, 0.830 mmol) were placed together in a 
flask and coevaporated with dry toluene three times. The 
mixed reagents were redissolved in dry CH2Cl2 (12 mL) 
under an atmosphere of argon. TTBP (2.5 equiv., 430 mg, 
1.730 mmol) which was previously dried in a desiccator 
and activated 4Å powdered MS (250 mg) were added. The 
reaction mixture was cooled to –60 ºC and Tf2O (1.2 equiv., 140 µL, 0.830 mmol) was 
added slowly. After 15 min a solution of 2-DOS 615 (1.2 equiv., 424 mg, 0.830 mmol) in 
dry CH2Cl2 (10 mL) was added slowly. The reaction mixture was stirred for 20 min at  
–60 ºC, then slowly warmed to rt, quenched with sat. NaHCO3, followed by brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification was 
performed by silica gel chromatography, using EtOAc/heptane with 1% Et3N, to 
afford a non-separable mixture of desilylated α-couple product 32 and 2-DOS 6  
(256 mg), both with the same RF value. The presence of 32 was confirmed by HRMS. 
The mixture was dissolved in AcOH/THF/H2O (v/v/v, 3/2/1, 12 mL) and stirred at 
55 ºC for 6 h. The solvent was evaporated and the crude product was purified by silica 
gel chromatography to obtain 33 (192 mg, 0.241 mmol, 35%) as white powder. RF = 0.39 
(EtOAc/heptane, 4/1); [α]20D = +99.3 (c = 0.01 g mL-1, CH2Cl2); mp = 117-118 ºC;  
1H NMR (400 MHz, CDCl3): δ = 7.39-7.18 (m, 15H), 5.47 (br s, 1H), 5.38 (s, 1H), 5.34  
(br s, 1H), 5.13-4.97 (m, 4H), 4.84 (d, J = 11.8 Hz, 1H), 4.60 (d, J = 11.8 Hz, 1H), 3.98-3.91 
(m, 4H), 3.77-3.75 (m, 2H), 3.54-3.43 (m, 5H), 3.25-3.18 (m, 7H), 2.16-2.10 (m, 1H), 1.98 
(br s, 2H), 1.29 (s, 3H), 1.25-1.20 (m, 4H); 13C NMR (75 MHz, CDCl3): δ = 157.02, 156.10, 
138.58, 136.73, 136.37, 128.62, 128.55, 128.32, 128.22, 127.67, 99.78, 99.65, 98.55, 78.91, 
77.02, 76.30, 75.30, 73.31, 72.09, 68.57, 67.03, 66.98, 64.09, 61.64, 51.29, 49.41, 47.98, 47.87, 
34.03, 17.97, 17.90; IR (neat): ν = 3325, 2831, 1697, 1132, 1116, 1035; HRMS (ESI): calcd 
for C41H52N2O14Na (M + Na+) 819.3316, found 819.3303. 
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Chapter 5 
 
Conversion of α-mannosides to α-glucosides via 
inversion of configuration at C2 
 
 
 
Abstract: 
 
A general method for stereoselective 1,2-cis glycosylation applicable to a wide range of 
substrates is still unrealised. In order to obtain free 2’-OH neamine analogues with an  
α-glucoside configuration, an indirect approach was investigated. Having at hand a set of 
DMB-protected 6-azido-6-deoxy-α-mannosides, as described in Chapter 4, an oxidation–
reduction sequence leading to inversion of configuration at C2’ was achieved. The oxidation step 
was performed with Dess–Martin periodinane, while a range of reducing agents was screened in 
search for stereoselectivity. 
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5.1 Introduction 
 
 Despite the impressive progress in the synthesis of oligosaccharides, there is 
still no broadly applicable solution for the stereoselective installation of a 1,2-cis 
glycosidic bond1. Most recently, some elegant approaches have been documented that 
may prove to be of high value for 1,2-cis glycosides2, but application to 2-aminosugars 
has not yet been achieved3. As described in the previous chapter, it was in our interest 
to obtain neamine analogues with an α-glucoside configuration. We succeeded in the 
synthesis of several free 2'-OH α-mannosides as 2'-modified neamine analogues. 
However, it was also envisaged that 2'-OH mannosides could be applied as 
intermediates towards free 2'-OH α-glucosides by inversion of configuration at C2'. The 
latter glucosides may serve as building blocks for further functionalisation at 2'-OH. 
 First attempts focused on the transformation of the 2'-OH into a good leaving 
group by treatment with tosyl chloride or triflic anhydride, followed by SN2 
displacement with azide, but no reaction occurred. Mitsunobu conditions in the 
presence of diphenyl phosphoryl azide also failed. Nucleophilic attack from an 
equatorial position therefore turned out to be difficult and the few examples in 
literature also show poor yields4. In addition, it seems that the dimethoxybutanediyl 
(DMB) protection further prevents such substitution by conformational restriction of 
the sugar in a chair, thereby thwarting Walden inversion.  
 An alternative method for the formation of comparable 1,2-cis manno-
configured carbohydrates involve net inversion of configuration at C2 to provide  
β-mannosides via oxidation of a 2-hydroxy-β-glucoside to a 2-ketoglycoside 
intermediate followed by stereoselective reduction5. Such 2-keto-β-D-arabino-
hexopyranosides have been also synthesised by direct nucleophilic attack of an alcohol 
on 2-ulosylbromides6, followed by stereoselective reduction towards β-mannosides5e,7. 
Some α-glucosides have been oxidised at the 2-position for other purposes than 
subsequent reduction8, while stereoselective reduction of α-2-ulosides to 1,2-cis-α-
glycosides has been reported for several deoxysugars9.  We were interested in an 
oxidation–reduction sequence to transform α-mannosides to α-glucosides since the 
requisite to uniquely expose the 2'-OH group was already accomplished. In the 
following chapter, application of such an oxidation–reduction sequence on the 
compounds described in Chapter 4 is discussed.  
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5.2 Model investigations on inversion of configuration at C2 
 
 A readily accessible model compound (3) was synthesised in order to study the 
possibilities of transforming α-mannosides into α-glucosides by inversion of 
configuration at C2 via an oxidation–reduction sequence. Thus, DMB-protected methyl  
α-D-mannopyranoside 110 was transformed into the 6-azido derivative 3 by consecutive 
treatment with p-tosyl chloride in pyridine and sodium azide in DMF (Scheme 5.1) 
 
 
 
 
 
 
Scheme 5.1 
 
 The remaining free 2-OH of compound 3 was exposed to Dess–Martin 
periodinane (1.5 equiv.), leading to rapid and complete C2 oxidation (Scheme 5.2). The 
resulting 2-ulose 4, isolated in acceptable purity (>90%) as indicated by NMR analysis, 
was subjected to reduction without intermediate purification due to the inherent 
instability of 4 and the tendency to form a hydrate. Several reaction conditions were 
applied in the search for stereoselective carbonyl reduction of 4 to alcohol 5 as 
summarised in Table 3.1. The stereoselectivity of formation of the new stereogenic C2 
centre was determined by 1H NMR of the crude mixture. 
 
 
 
 
Scheme 5.2 
 
Initially, sodium borohydride was tested in dichloromethane at 0 and 40 ºC but the 
gluco vs. manno ratio was nearly 1:1 at both temperatures (entries 1 and 2). Gratifyingly, 
a simple change of solvent to methanol led to significantly enhanced stereoselectivity, 
leading to a 7:2 gluco:manno ratio (entry 3). Reduction via Luche's protocol11 in the 
presence of cerium(III)chloride is known to enhance stereoselective reductions on 
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chiral substrates, but in our case led to complete loss of stereoselectivity (entry 4).  
More reactive reducing agents such as lithium borohydride or lithium tri-sec-
butylborohydride (L-selectride) at 0 ºC promoted the formation of undesired 
α-mannoside (entries 5 and 6) in modest excess. In contrast, the more bulky lithium  
tri-tert-butoxyaluminiumhydride at room temperature gave a better result than the 
other lithium hydride salts, leading to the formation of a 2:1 ratio of gluco:manno 
epimers (entry 7). A similar stereoselectivity was induced by borane-tetrahydrofuran 
and borane-dimethyl sulfide complexes (entries 8 and 9), while the more hindered 
9-borabicyclo[3.3.1]nonane (9-BBN) gave no reaction (entry 10). Finally, the α-D-
glucoside 5 was isolated in 58% yield for the two-step process of oxidation and 
reduction induced by sodium borohydride in methanol (entry 3). The undesired 
stereoisomer 3 was also isolated in a yield of 18%. 
 
 
 
Table 5.1. a Based on crude 1H NMR analysis. Isolated yield in entry 3: 58% glc and 18% man. 
 
 
5.3 Application of the oxidation–reduction methodology 
 
 Encouraged by the positive result of the oxidation–reduction sequence on 
model substrate 3, the same protocol was applied to three other manno-configured 
entry reducing agent solvent T (ºC) glc:mana 
1  NaBH4 CH2Cl2 0 1:1 
2  NaBH4 CH2Cl2 40 2:3 
3  NaBH4 MeOH rt 7:2 
4  NaBH4/CeCl3 MeOH rt 1:1 
5  LiBH4 MeOH 0 3:4 
6  L-selectride THF 0 1:3 
7  LiAl(OtBu)3H THF rt 2:1 
8  BH3·THF THF rt 3:2 
9  BH3·Me2S THF rt 2:1 
10  9-BBN THF rt N.R. 
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glycosides 6a-c (Table 5.2). In all cases, Dess–Martin periodinane oxidation worked 
excellently, and the crude 2-ulose intermediates 7a-c were subjected to reduction 
without purification with 1-2 equivalents of reducing agent. Initially, 7a was exposed 
to the previously established condition of sodium borohydride in methanol, to obtain 
alcohols 8a and 6a in a 5:2 gluco:manno ratio (entry 1). Although the observed 
stereoselectivity was acceptable, it was slightly reduced with respect to the test 
substrate 3. Therefore, it was decided to test other conditions in search for 
improvement. Rather surprisingly, Luche's protocol now led to a better result than 
before (4:1 ratio, entry 2), while sodium borohydride in dichloromethane was slightly 
worse (entry 3). To our delight, reduction under the action of the bulky L-selectride 
proceeded with complete stereoselectivity. No trace of formation of the mannoside 
could be detected, and α-D-glucoside 8a was isolated in 84% yield.  
 
 
 
 
 
entry R (7a-c) reducing agent solvent glc:mana glc (8a-c) (%)b man (%)b 
1 
2 
3 
4 
O
O
O
O
O
O
 
a 
NaBH4 
NaBH4/CeCl3 
NaBH4 
L-selectride 
MeOH 
MeOH 
CH2Cl2 
THF 
5:2 
4:1 
3:2 
1:0 
 
 
 
84 
 
 
 
0 
5 
6 
O
O
O
O
O
O
 
b 
L-selectride 
LiAl(OtBu)3H 
THF 
THF 
4:3 
10:3 
 
49 
 
17 
7 
8 
9 
10 
CbzHN CO2Bn
O
 
c 
NaBH4 
L-selectride 
LiAl(OtBu)3H 
BH3·Me2S 
THF 
MeOH 
THF 
THF 
- 
- 
- 
0:1 
 
 
 
0 
 
 
 
70 
 
Table 5.2     All reactions were performed at rt. a Crude 1H NMR analysis.  b Isolated yields. 
 
At this point it became clear that the stereoselectivity of the reduction was not only 
dependent on the reducing agent, but also on other interactions (sterics,  
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hydrogen-bond formation) with the anomeric substituent. For example, subjection of 
the oxidation–reduction protocol to substrate 7b with L-selectride produced the 
desired stereoisomeric product 8b with a modest 4:3 gluco:manno ratio (entry 5), in 
sharp contrast to the exquisite stereoselectivity observed under identical conditions for 
compound 7a. For compound 7b, application of the bulky reducing agent lithium  
tri-tert-butoxyaluminiumhydride improved the stereoselectivity to a 10:3 ratio (entry 6) 
and in this case, 8b was obtained in 49% yield along with 17% of 6b. Finally, reduction 
of the crude L-serine α-D-arabino-hexosidulose 7c again led to a different profile.  
A range of different hydride sources was applied, but led predominantly to 
degradation of the substrate (entries 7-9), possibly due to elimination. In this case, 
treatment with the milder borane-dimethyl sulfide complex induced a completely 
stereoselective reduction, but instead of desired gluco-configured alcohol 8c, the  
manno-configured 6c was isolated as the sole product in 70% yield (entry 10).  
 From Tables 5.1 and 5.2 we can conclude that the reduction step for each 
substrate requires optimisation using different hydrides, however, a satisfactory to 
excellent outcome can be achieved. For the stereoselective reduction of disaccharides, 
bulky lithiated hydrides appeared to be most suitable, as shown for compounds 7a-b. 
 Based on these experiments, an attempt was made to convert the protected 
neamine analogue 9 into the gluco-configured analogue 10. Again, Dess–Martin 
periodinane, followed by L-selectride reduction, proceeded with excellent 
stereoselectivity (Scheme 5.3) as analysis of the crude product by 1H NMR revealed a 
49:1 gluco:manno ratio. Purification by silica gel column chromatography afforded the 
desired α-D-glucoside 10 in 81% yield, along with recovery of 1.6% of  
α-D-mannoside 9. 
 
Scheme 5.3 
 
 When the same L-selectride conditions were applied to 11, bearing azides 
instead of benzyloxy carbamates on the 2-deoxystreptamine moiety (Scheme 5.4), a 
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rather disappointing result was obtained since reduction yielded only a 8:5 gluco:manno 
ratio. In search for improvement, lithium tri-tert-butoxyaluminiumhydride and 
sodium borohydride were also tested as depicted in Table 5.3. Interestingly, in this case 
sodium borohydride gave the best result (entry 3) and α-D-glucoside 12 was isolated in 
61% yield. 
 
 
 
 
 
Scheme 5.4 
 
 
entry reducing agent solvent glc:mana glc (12) (%)b man (%)b 
1 L-selectride THF  8:5 47 33 
2 LiAl(OtBu)3H THF 10:6 48 24 
3 NaBH4 MeOH 13:5 61 20 
 
Table 5.3    All reactions were performed at rt. a Crude 1H NMR analysis.  b Isolated yields. 
 
 The inversion of configuration at C2' was confirmed by the changes in the  
1H NMR spectra, more specifically in the anomeric proton coupling constant (Table 
5.4). Interestingly, of the starting materials, only methyl α-mannoside 3 has a typical 
small diequatorial coupling constant J1,2 = 1.2 Hz, while the rest of the mannosides 
show a singlet, i.e. a coupling constant of less than 0.5. Based on the vicinal Karplus 
correlation12 this implies a near 90º dihedral angle for the 1,2-trans protons, probably 
due to the conformational restriction induced by the 3,4-dimethoxybutanediyl 
protection. The α-glucosides formed after oxidation and reduction showed a typical 
anomeric coupling constant of 3.7-3.9 Hz13, although a number could not be deduced 
for 10 due to overlay of the anomeric proton signal by others. α-Glucosides were 
generally also distinct from the mannosides by a longer retention time (lower RF value) 
on silica gel. 
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mannoside signal ppm glucoside signal ppm 
3 d , J = 1.2 Hz 4.74 5 d, J = 3.9 Hz  4.81 
6a s 5.11 8a d, J = 3.7 Hz 5.07 
6b s 4.90 8b d, J = 3.9 Hz 4.93 
6c s 5.14 8c - - 
9 s 5.30 10 m, overlap ≈5.20 
11 s 5.30 12 d, J = 3.9 Hz 5.36 
 
Table 5.4     Signals of anomeric protons, 1H NMR (400 MHz, CDCl3) 
 
 
5.4 Conclusions 
 
 An oxidation–reduction sequence was developed in order to obtain 
α-glucosides from α-mannosides. Conditions were optimised for a methylglycoside test 
substrate, but unfortunately were not generally applicable for the synthesis of 
α-glycosides, thus requiring optimisation of reaction conditions for each individual 
substrate. Nevertheless, all α-mannosides shown in this chapter except 7c could be 
efficiently converted into the corresponding α-glucosides in a range of 49-84% yield. 
The presented oxidation–reduction methodology may find suitable application in 
target-oriented synthesis of α-glycosides, as is the case of the neamine derivatives 10 
and 12, since the desired α-glucoside configuration may in some cases be difficult to 
achieve by standard glycosidation methodology. For example, compound 10 was 
obtained, after coupling and 2-O-deprotection (described in Chapter 4) followed by 
inversion at C2, in 55% overall yield for the three steps, which may be difficult to 
achieve by standard glycosidation. Moreover, compounds 10 and 12 have the 2-OH 
selectively unprotected and further derivatisation at O2 may therefore be conveniently 
applied, for example alkylation or the formation of conformationally constrained 
neamine analogues. 
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5.6 Experimental Section 
 
General methods and materials (see: Section 2.5). 
 
Methyl 3,4-O-(2,3-dimethoxybutane-2,3-diyl)-6-O-tosyl-α-D-mannopyranoside (2) 
p-TsCl (1.2 equiv., 6.08 g, 31.87 mmol) was added to an ice bath 
cooled solution of compound 1 (8.19 g, 26.56 mmol) in pyridine  
(75 mL). The reaction was stirred under argon at 4 ºC during 20 h. 
The solvent was evaporated and the residue was coevaporated three 
times with toluene. The crude product was purified by silica gel 
chromatography to afford 2 (4.73 g, 10.23 mmol, 39%) as white solid. 
RF = 0.32 (AcOEt/heptane, 1/1); [α]20D = +156.5 (c = 0.01 g mL-1, CH2Cl2); mp = 126-127 
ºC; 1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 4.62 
(s, 1H), 4.29 (d, J = 10.5 Hz, J = 1.8 Hz, 1H), 4.22 (dd, J = 10.5 Hz, J = 5.5 Hz, 1H),  
3.95-3.86 (m, 4H), 3.28 (s, 3H), 3.24 (s, 3H), 3.19 (s, 3H), 2.44 (s, 3H), 2.35 (br s, 1H), 1.29 
(s, 3H), 1.25 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 144.58, 132.99, 129.65, 127.96, 
100.97, 100.44, 100.06, 69.64, 68.56, 68.35, 68.21, 63.03, 55.16, 48.35, 48.31, 21.97, 18.04, 
18.02; IR (neat): ν = 3489, 3058, 2946, 2834, 1362, 1113, 1045; HRMS (ESI): calcd for 
C20H30O10SNa (M + Na+) 485.1457, found 485.1457. 
 
Methyl 6-azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-mannopyranoside 
(3) 
NaN3 (2.0 equiv., 1.33 g, 20.46 mmol) was added to a solution of 2 
(4.73 g, 10.23 mmol) in DMF (45 mL). The reaction was stirred at  
55 ºC under N2 for 10 h. The solvent was evaporated and the crude 
product was purified by silica gel chromatography to afford 3  
(3.14 g. 9.42 mmol, 92%) as white powder. RF = 0.44 
(AcOEt/heptane, 1/1); [α]20D = +212.6 (c =0.01 g mL-1, CH2Cl2);  
mp = 116-117 ºC; 1H NMR (400 MHz, CDCl3): δ = 4.74 (d, J = 1.2 Hz, 1H), 3.99-3.85 (m, 
4H), 3.50 (dd, J = 13.0 Hz, J = 2.5 Hz 1H), 3.43 (dd, J = 13.0 Hz, J = 6.4 Hz, 1H), 3.40 (s, 
3H), 3.26 (s, 3H), 3.22 (s, 3H), 2.43 (br s, 1H), 1.31 (s, 3H), 1.27 (s, 3H);  13C NMR  
(75 MHz, CDCl3): δ = 101.05, 100.39, 100.00, 70.15, 69.73, 68.17, 64.24, 55.25, 50.88, 48.36, 
48.16, 18.06, 18.01; IR (neat): ν = 3473, 2946, 2833, 2098, 1129, 1116, 1044;  HRMS (FAB): 
calcd for C13H24N3O7 (M + H+) 334.1614, found 334.1603. 
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Methyl 6-azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-arabino-
hexopyranosid-2-uloside (4) and methyl 6-azido-6-deoxy-3,4-O-(2,3-
dimethoxybutane-2,3-diyl)-α-D-glucopyranoside (5)  
Dess–Martin periodinane (1.5 equiv., 382 mg, 
0.900 mmol) was added to a stirred solution of 
compound 3 (200 mg, 0.600 mmol) in CH2Cl2  
(20 mL). After 10 h the reaction was diluted with 
CH2Cl2 (20 mL) and quenched with 1M NaOH  
(30 mL). The mixture was stirred for 30 min after 
which the organic layer was separated. The water layer was twice extracted with 
CH2Cl2 and the combined organic layers were dried with MgSO4. Filtration and 
evaporation of the solvent afforded the crude ulose 4 (180 mg) as a white solid.  
1H NMR (400 MHz, CDCl3): δ = 4.82 (d, J = 10.6 Hz, 1H), 4.71 (s, 1H), 4.26 (m, 1H), 3.92 
(t, J = 10.2 Hz, 1H), 3.60 (dd, J = 13.3 Hz, J = 2.5 Hz, 1H), 3.48 (s, 3H), 3.44 (dd,  
J = 13.3 Hz, J = 5.7 Hz, 1H), 3.26 (s, 3H), 3.22 (s, 3H), 1.37 (s, 3H), 1.28 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ = 194.32, 101.10, 100.60, 99.88, 72.50, 70.01, 69.63, 55.99, 50.34, 48.75, 
48.37, 17.85, 17.82; IR (neat): ν = 2835, 2100, 1757, 1036. 
The crude ulose 4 (180 mg) was dissolved in MeOH (20 mL) and NaBH4 (1 equiv., 0.600 
mmol, 22.70 mg) was added. After 30 min the solvent was evaporated and the residue 
was dissolved in CH2Cl2, washed with sat. NH4Cl and the solvent evaporated again. 
The crude product was purified by silica gel chromatography to afford the desired  
α-glucopyranoside 5 (116 mg, 0.348 mmol, 58%) as white powder, and  
α-mannopyranoside 3 (36 mg, 0.108 mmol, 18%). Analytical data for compound 5:  
RF = 0.29 (AcOEt/heptane, 1/1); [α]20D = +228.3 (c = 0.01 g mL-1, CH2Cl2);  
mp = 104-105 ºC; 1H NMR (400 MHz, CDCl3): δ = 4.81 (d, J = 3.9 Hz, 1H), 3.91-3.86 (m, 
2H), 3.77-3.72(m, 1H), 3.60 (t, J = 9.9 Hz, 1H), 3.53 (dd, J = 13.1 Hz, J = 2.3 Hz, 1H), 3.45 
(s, 3H), 3.36 (dd, J = 13.1 Hz, J = 5.8 Hz, 1H), 3.29 (s, 3H), 3.25 (s, 3H), 2.11 (d, J = 8.6 Hz, 
1H), 1.33 (s, 3H), 1.28 (s, 1H); 13C NMR (75 MHz, CDCl3): δ = 99.78, 99.55, 70.20, 69.95, 
69.27, 66.86, 55.69, 50.65, 48.29, 48.26, 18.09, 17.97; IR (neat): ν = 3491, 2945, 2834, 2100, 
1135, 1026;  HRMS (FAB): calcd for C13H24N3O7 (M + H+) 334.1614, found 334.1588. 
 
3-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-glucopyranosyl]-
1,2:5,6-di-O-isopropylidene-D-glucofuranose (8a) 
Dess–Martin periodinane (1.5 equiv., 147 mg, 0.346 mmol) 
was added to a stirred solution of compound 6a (130 mg, 
0.231 mmol) in CH2Cl2 (6 mL). After 10 h the reaction was 
diluted with CH2Cl2 (6 mL) and quenched with 1M NaOH 
(10 mL). The mixture was stirred for 30 min after which the 
organic layer was separated. The water layer was twice 
extracted with CH2Cl2 and the combined organic layers were 
dried with MgSO4, filtrated and the solvent evaporated. The 
crude intermediate 7a was dissolved in THF (6 mL) and L-selectride (1.5 equiv., 346 µL 
from 1M solution in THF) was added. After 2 h the reaction was quenched with 
MeOH, the solvent was evaporated and the residue was dissolved in CH2Cl2, washed 
with sat. NH4Cl, dried over MgSO4, filtered and the solvent evaporated again. The 
crude product was purified by silica gel chromatography to give solely compound 8a 
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(109 mg, 0.194 mmol, 84%) as colourless oil. RF = 0.24 (AcOEt/heptane, 1/2);  
[α]20D = +112.3 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 5.92 (d,  
J = 3.5 Hz, 1H), 5.07 (d, J = 3.7 Hz, 1H), 4.83 (d, J = 3.5 Hz, 1H), 4.29-4.22 (m, 2H),  
4.19-4.14 (m, 2H), 4.02-3.95 (m, 2H), 3.80 (t, J = 10.0 Hz, 1H), 3.69 (td, J = 10.0 Hz,  
J = 3.7 Hz, 1H), 3.57-3.53 (m, 2H), 3.38-3.32 (m, 2H), 3.29 (s, 3H), 3.24 (s, 3H), 1.49 (s, 
3H), 1.41 (s, 3H), 1.33 (s, 3H), 1.32 (s, 6H), 1.29 (s, 3H); 13C NMR (75 MHz, CDCl3):  
δ = 112.50, 109.82, 105.98, 101.64, 100.00, 99.99, 85.40, 83.25, 81.86, 73.63, 70.75, 70.51, 
70.31, 68.54, 67.22, 51.13, 48.48, 48.21, 27.42, 27.15, 26.63, 25.45, 18.27, 18.15; IR (neat):  
ν = 3450, 2833, 2099, 1138, 1027;  HRMS (FAB): calcd for C24H40N3O12 (M + H+) 562.2612, 
found 562.2600. 
 
6-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-glucopyranosyl]-
1,2:3,4-di-O-isopropylidene-D-galactofuranose (8b) 
Dess–Martin periodinane (2.0 equiv., 80 mg, 0.188 mmol) 
was added to a stirred solution of compound 6b (53 mg, 
0.094 mmol) in CH2Cl2 (4 mL). After 10 h the reaction was 
diluted with CH2Cl2 (4 mL) and quenched with 1M NaOH 
(5 mL). The mixture was stirred for 30 min after which the 
organic layer was separated. The water layer was twice 
extracted with CH2Cl2 and the combined organic layers 
were dried over MgSO4, filtered and the solvent evaporated. The crude intermediate 7b 
was dissolved in THF (4 mL) and LiAl(OtBu)3H (1.5 equiv., 128 µL from 1.1 M solution 
in THF) was added. After 2 h the reaction was quenched with MeOH, the solvent was 
evaporated and the residue was dissolved in CH2Cl2, washed with sat. NH4Cl, dried 
over MgSO4, filtered and the solvent evaporated again. The crude product was purified 
by silica gel chromatography to afford some quantity of manno-configured product 6b 
(9 mg, 0.016 mmol, 17%) and 8b (26 mg, 0.046 mmol, 49%) as colourless gum. RF = 0.27 
(AcOEt/heptane, 1/1); [α]20D = +129.8 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, 
CDCl3): δ = 5.51 (d, J = 5.1 Hz, 1H), 4.93 (d, J = 3.9 Hz, 1H), 4.62 (dd, J = 7.9 Hz, J = 2.4, 
1H), 4.33 (dd, J = 5.0 Hz, J = 2.4 Hz, 1H), 4.25 (dd, J = 7.8 Hz, J = 2.0 Hz, 1H), 4.02-3.92 
(m, 3H), 3.85 (t, J = 9.9 Hz, 1H), 3.74-3.70 (m, 2H), 3.62 (t, J = 9.9 Hz, 1H), 3.53 (dd,  
J = 13.3 Hz, J = 2.3 Hz, 1H), 3.36 (dd, J = 13.1 Hz, J = 5.3 Hz, 1H), 3.29 (s, 3H), 3.25 (s, 
3H), 2.58 (br s, 1H), 1.54 (s, 3H), 1.44 (s, 3H), 1.33 (s, 9H), 1.28 (s, 3H);  13C NMR  
(75 MHz, CDCl3): δ = 109.59, 108.81, 99.75, 99.74, 99.37, 96.26, 71.22, 70.81, 70.65, 70.40, 
69.92, 69.68, 67.78, 66.68, 65.87, 50.53, 48.29, 48.18, 26.38, 26.25, 25.23, 24.81, 18.12, 17.98; 
IR (neat): ν = 3469, 2829, 2100, 1135, 1070, 1032;  HRMS (ESI): calcd for C24H39N3O12Na 
(M + Na+) 584.2432, found 584.2437. 
 
4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-glucopyranosyl]-1,3-
bis-N-benzyloxycarbonyl-5,6-O-cyclohexylidene-2-deoxystreptamine (10) 
Dess–Martin periodinane (2.0 equiv., 627 mg, 1.478 mmol) 
was added to a stirred solution of compound 9 (600 mg, 
0.739 mmol) in CH2Cl2 (20 mL). After 10 h the reaction 
was diluted with CH2Cl2 (20 mL) and quenched with 1 M 
NaOH (30 mL). The mixture was vigorously stirred for  
10 min after which the organic layer was separated. The 
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water layer was twice extracted with CH2Cl2 and the combined organic layers were 
treated with brine and dried over anhydrous Na2SO4, filtered and the solvent 
evaporated. The crude intermediate was dissolved in THF (25 mL) and L-selectride  
(2.0 equiv., 1.478 mL from 1 M solution in THF) was added. After 10 h H2O was added 
(20 mL) and the reaction neutralised with AcOH (3 equiv., 127 µL, 2.217 mmol). The 
THF was evaporated and the H2O extracted with CH2Cl2. The combined organic 
extracts were treated with brine and dried over MgSO4, filtered and the solvent 
evaporated. The crude product was purified by silica gel chromatography to afford 
some quantity of manno-configured product 9 (10 mg, 0.012 mmol, 1.6%) and 10 (488 
mg, 0.601 mmol, 81%) as white powder. RF = 0.39 (AcOEt/heptane, 3/2);  
[α]20D = +108.2 (c = 0.01 g mL-1, CH2Cl2); mp = 109-110 ºC; 1H NMR (400 MHz, CDCl3):  
δ = 7.33-7.28 (m, 10H), 5.21 (br s, 1H), 5.18-5.06 (m, 6H), 3.96-3.92 (m, 1H), 3.87-3.89 (m, 
5H), 3.59-3.40 (m, 4H), 3.31 (s, 3H), 3.28-3.25 (m, 1H), 3.23 (s, 3H), 2.51 (br s, 2H),  
1.68-1.53 (m, 9H), 1.48-1.36 (m, 2H), 1.32 (s, 3H), 1.24 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ = 155.51, 155.47, 136.07, 128.41, 128.21, 128.09, 128.07, 113.26, 99.70, 99.62, 
99.16, 80.12, 79.53, 78.20, 70.00, 69.94, 69.76, 67.20, 67.05, 66.60, 51.83, 50.54, 49.59, 48.18, 
48.09, 36.58, 36.27, 25.12, 24.00, 23.90, 18.11, 17.96; IR (neat): ν = 3314, 2832, 2100, 1696, 
1137, 1027;  HRMS (FAB): calcd for C40H53N5O13Na (M + Na+) 834.3538, found 834.3591. 
 
4-O-[6-Azido-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-glucopyranosyl]-1,3-
diazido-1,3-dideamino-5,6-O-cyclohexylidene-2-deoxystreptamine (12) 
Dess–Martin periodinane (2.0 equiv., 37 mg, 0.088 mmol) 
was added to a stirred solution of compound 11 (26 mg, 
0.044 mmol) in CH2Cl2 (3 mL). After 10 h the reaction was 
diluted with CH2Cl2 (3 mL) and quenched with 1M NaOH 
(4 mL). The mixture was stirred for 20 min after which the 
organic layer was separated. The water layer was twice 
extracted with CH2Cl2 and the combined organic layers were dried over MgSO4, 
filtered and the solvent evaporated. The crude intermediate was dissolved in MeOH  
(2 mL) and NaBH4 (2 equiv., 3.3 mg, 0.088 mmol)) was added. After 1 h the solvent was 
evaporated and the residue was dissolved in CH2Cl2, washed with sat. NH4Cl, dried 
over MgSO4, filtered and the solvent evaporated again. The crude product was purified 
by silica gel chromatography to afford some quantity of manno-configured product 11 
(5.3 mg, 0.009 mmol, 20%) and 12 (16 mg, 0.027 mmol, 61%) as colourless gum.  
RF = 0.26 (AcOEt/heptane, 1/2); [α]20D = +168.2 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 
MHz, CDCl3): δ = 5.36 (d, J = 3.9 Hz, 1H), 4.13-4.08 (m, 1H), 3.92 (t, 9.9 Hz, 1H),  
3.81-3.76 (m, 2H), 3.67-3.56 (m, 3H), 3.51-3.38 (m, 4H), 3.27 (s, 3H), 3.26 (s, 3H), 2.35 (dt, 
J = 13.0 Hz, J = 5.0 Hz, 1H), 1.68-1.59 (m, 8H), 1.50 (q, J = 13.0 Hz, 1H), 1.39-1.36 (m, 
2H), 1.33 (s, 3H), 1.29 (s, 3H);  13C NMR (75 MHz, CDCl3): δ = 114.10, 99.89, 99.83, 98.88, 
79.41, 79.24, 78.75, 70.11, 70.05, 69.86, 66.52, 61.18, 57.38, 50.45, 48.21, 48.11, 36.29, 36.27, 
34.08, 24.95, 23.86, 23.79, 17.92, 17.78; IR (neat): ν = 3464, 2832, 2100, 1136, 1030;  HRMS 
(ESI): calcd for C24H37N9O9Na (M + Na+) 618.2612, found 618.2560. 
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Chapter 6 
 
Conformational restriction of neamine 
 
 
 
Abstract: 
 
Based on NMR binding experiments and crystallographic data, a conformationally restricted 
neamine analogue resembling the bioactive conformation of the neamine core of 4,5-linked 
aminoglycosides was designed and synthesised. Several strategies were followed in order to 
obtain derivatives of neamine covalently linked between positions 2’ and 5. 
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6.1 Introduction 
 
 Aminoglycoside antibiotics target specific areas in the bacterial ribosome 
affecting the molecular machinery involved in protein synthesis. During the last 
decade much research has been executed to understand the binding mode of these 
antibiotics. Neamine-containing aminoglycosides have been found to interact 
specifically with the A-site, located in the 16S ribosomal subunit. By displacing two 
universally conserved adenine residues (A1492 and A1493) involved in mRNA codon 
and cognate tRNA anticodon recognition, paromomycin and related aminoglycosides 
facilitate the binding of near-cognate tRNAs. Consequently, aminoglycoside binding, 
by increasing the error rate of the ribosome, leads to production of aberrant 
polypeptides1. Puglisi et al. performed NMR analysis of paromomycin docked into a 27 
nucleotide sequence encompassing the highly conserved A-site, establishing the 
intimate interactions of an aminoglycoside with rRNA2. Further research by Puglisi 
established the importance of the neamine moiety for antibacterial activity as well as 
the presence of an internal hydrogen bond between N2' and O4'' (Figure 6.1), 
suggesting that such an interaction may help to orient ring I for specific binding with 
RNA3. Furthermore, it seemed that rings III and IV play a weak role in specific 
interactions but are mainly contributing in terms of non-specific electrostatic 
interactions with the RNA backbone.  
Based on these observations, we envisioned that a covalent linkage in the neamine core 
between N2' and O5 might effectively lock the aminoglycoside in the bioactive 
conformation (Figure 6.1). In this fashion, enhancement of affinity for the A-site could 
be accompanied with increased specificity over other RNA elements. Furthermore, it 
was not excluded that such a constrained analogue may no longer be a substrate for 
resistance enzymes that require a specific conformation in their binding pocket4. 
Subsequent papers confirmed Puglisi's findings and shed more light on the 
understanding of the interactions of aminoglycosides with the A-site.  
Ramakrishnan et al. reported a crystal structure of the 30S ribosomal subunit in 
complex with paromomycin5 and, shortly after, Vincens and Westhof solved a complex 
between an oligonucleotide incorporating the A-site and paromomycin by high 
resolution X-ray crystallography6. The latter study led to a further insight on the 
specific aminoglycoside-RNA interactions and corroborated not only the N2' and O4'' 
intramolecular hydrogen bond, but in addition one linking N2' and O5''. 
Conformational restriction of neamine 
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Figure 6.1 
 
 In the following sections, several approaches towards conformationally 
restricted neamine analogues by linking the N2' and O5 positions are described. Based 
on intramolecular interactions a cycle consisting of 8 to 13 atoms would be of interest.  
Initial attempts focused on the introduction of a covalent linkage between a free 2'-OH 
of an α-D-glucoside linked to 2-deoxystreptamine described in Chapter 5. A less 
flexible but more straightforward strategy was also investigated involving the free  
2'-NH2 of a neamine derivative reported by Wong et al.7 By the latter approach, a 
N2',O5-linked neamine derivative was effectively obtained. 
 While our research was in process, Vincens and Westhof proposed a similar 
idea8, which was simultaneously put into practice by Asensio et al.9 and Tor et al.10 
They performed an identical straightforward approach to conformationally lock 
neomycin in its bioactive conformation (Figure 6.2). Biological assays showed MIC 
values in the low micromolar range. The conformational restricted neomycin was also 
tested against an adenylylating resistance enzyme9 (ANT4).  
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The oligosaccharide conformation recognised by the rRNA and the enzyme are 
remarkably different and the locked neomycin proved to be very stable against ANT4. 
 These findings validated the principle and we aimed for a conformationally 
restricted neamine analogue lacking rings III and IV, which are responsible for  
non-specific interactions. 
 
 
6.2 Cyclisation attempts of a 2'-modified neamine analogue  
 
 In Chapter 5 a method to obtain neamine derivatives such as compound 1, 
possessing a free 2'-OH at the position of the amino function normally present in 
neamine, is reported. It was envisioned that the hydroxyl group could be 
functionalised and the cyclohexylidene selectively removed to expose both 5-OH and 
6-OH, followed by the selective introduction of a covalent linkage between 2'-OH and 
5-OH. With this strategy in mind, selective O2' allylation was attempted. 
Unfortunately, due to a similar basicity of the carbamate protons a mixture of allylated 
compounds was obtained (Scheme 6.1), and separation of the desired product 2 was 
difficult to achieve. 
 
 
 
 
Scheme 6.1 
 
 An alternative route was therefore investigated involving treatment of 1 with 
bromoacetyl bromide followed by selective hydrolysis of the cyclohexylidene acetal to 
obtain compound 3 in 39% for the two steps. The proximity of 5-OH to the highly 
electrophilic α-carbon of the bromoacetyl group was expected to be beneficial in an 
intramolecular SN2 reaction. Thus, 3 was treated with an equimolar amount of 
potassium hexamethyldisilazanide in DMF to, disappointingly, observe only 
degradation of the substrate (Scheme 6.2) and it was concluded that 3 was not stable in 
the presence of a strong base. Therefore, the compound was converted into the  
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5,6-dibutyltin acetal as an alternative strategy to enhance the nucleophilicity of a 
hydroxyl from a diol without the need of a base.11,12 Thus, compound 3 was exposed to 
dibutyltin oxide in toluene with a Dean-Stark set-up for azeotropic removal of water, 
but after several trials no intramolecular reaction was observed and only starting 
material was recovered. 
Scheme 6.2 
 
The failure to achieve the introduction of a covalent linkage between 2' and 5-OH of 
compound 1 by the routes delineated above, in combination with the scarcity of 
starting material, urged us to explore alternative routes to conformationally restricted 
neamine analogues. 
 
 
6.3 Conformationally restricted neamine derivatives 
 
 While the work on conformation restriction of compound 1 was in progress, a 
report appeared on the chemoselective azide reduction of tetraazido-tri-O-benzyl 
neamine 6 by Wong et al.13 Thus, after protection and selective hydrolysis of the 
furanosyl glycosidic bond of neomycin (5), it was serendipitously found that selective 
reduction of 2'-N3 occurred while attempting the reduction of the more exposed 6'-N3 
under Staudinger conditions7, leading to neamine derivative 7 with a free 2'-NH2 and 
5-OH (Scheme 6.3). It was reasoned that reduction was driven by electronic rather than 
steric factors, and the 2'-azide would be the most electron-deficient since is adjacent to 
the anomeric center. We were attracted to the methodology because chemoselective 
reduction at N2' could serve as a useful stepping stone towards N2',O5-linked 
derivatives.  
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Scheme 6.3 
 
Alcohol 6 was prepared in straightforward fashion starting from neomycin. In order to 
have a suitable handle for the projected ring-closure onto O5 by olefin metathesis, the 
alcohol was allylated under the action of sodium hydride in the presence of allyl 
bromide, to give compound 8 in excellent yield (Scheme 6.4)13. Next, Staudinger 
reduction of the 2'-azide was attempted under a range of conditions, but it was found 
that no selective reduction occurred and only intractable mixtures of products were 
formed. Apparently, the free 5-OH plays an important role in the chemoselective 
Staudinger reduction at 2'-N3, contrary to solely the 2'-electron deficiency proposed by 
Wong13. In fact, recent findings by Chang et al. have corroborated that steric factors also 
influence the regioselectivity of the Staudinger reduction of azides on neamine and in 
particular protection at O514. As an alternative, we also tested the 2'-N3 reduction of 
1,2',3,6'-tetraazido neamine, but also in this case no selectivity in reduction was 
observed. 
 
 
 
 
 
Scheme 6.4 
 
A logical alternative to ring-closure via olefin metathesis is to employ the free 
heteroatoms at O5 and N2' of neamine derivative 7, offering the possibility to achieve 
cyclisation in one single step. Disappointingly, however, treatment of 7 with 
carbonyldiimidazole to produce 10 with a linking carbamate or with dimethylmalonyl 
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chloride towards 11 did not afford any of the desired compounds (Scheme 6.5). 
Instead, analysis of the crude products by mass spectrometry showed the formation of 
dimeric structures 12 and 13. Apparently, dimerisation of the more nucleophilic amino 
groups is more beneficial than ring-closure to the 8- or 11-membered cycles 10 and 11, 
respectively. 
Scheme 6.5 
 
 A step-wise approach was also attempted involving exposure of 7 to phthalic 
anhydride15 in ethyl acetate to produce the N-phthalamic acid functionalised neamine 
derivative 14 in high yield. Disappointingly, attempts to perform a macrolactonisation 
under Yamaguchi conditions16 or acidic lactonisation failed (Scheme 6.6). 
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 Finally, attention was focused on a methodology recently described by  
Cramer et al. on the nucleophilic addition of amines onto vinyl carbamates and vinyl 
carbonates17. Subsequent treatment with ethylenediamine should lead to a cyclic 
product, upon liberation of vinyl alcohol as leaving group in the form of its tautomer, 
acetaldehyde. Thus, treatment of 7 with excess vinyl chloroformate in dichloromethane 
afforded 16 with the O5 and N2' functionalised as vinyl carbonate and vinyl carbamate, 
respectively. To our satisfaction, subjection of compound 16 to ethylene diamine led to 
the formation of conformationally restricted neamine derivative 17 in 73% yield 
(Scheme 6.7). Removal of the protecting groups for bioassays and NMR binding 
experiments is reported in the following chapter. 
Scheme 6.7 
 
 
6.4 Conclusions 
 
 Several strategies were followed in order to prepare conformationally restricted 
neamine derivatives. Initial experiments focused on the 2'-hydroxy analogue of 
neamine, prepared via a glycosylation route of 2-deoxystreptamine (Chapter 5), but 
were not successful. Chemoselective reduction of a readily available tetraazido 
derivative of neamine gave the 2'-amino compound 7, but only if O5 was not protected. 
Several unsuccessful attempts were first undertaken to obtain a N2',O5-linked neamine 
analogue, but finally derivative 7 proved to be an excellent substrate for such task. 
After two easy steps involving functionalisation of the amino and hydroxyl groups 
with a vinyloxycarbonyl moiety and subsequent reaction with ethylenediamine, the 
conformationally restricted 13-membered-ring neamine analogue 17 was obtained in 
good yield.  
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6.6 Experimental Section 
 
General methods and materials (see: Section 2.5). 
 
4-O-[6-Azido-2-O-bromoacetyl-6-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α-D-
glucopyranosyl]-1,3-bis-N-benzyloxycarbonyl-2-deoxystreptamine (3) 
A stirred solution of 1 (207 mg, 0.255 mmol), DMAP  
(0.1 equiv., 3 mg, 0.025 mmol) and Et3N (3.0 equiv.,  
106 µL, 0.656 mmol) in dry CH2Cl2 (6 mL) was cooled to  
0 ºC and bromoacetyl bromide (2.0 equiv., 44 µL,  
0.510 mmol) was added. After 4½ h the reaction was 
quenched with sat. NaHCO3, the organic layer was 
separated and the H2O was extracted twice with CH2Cl2. 
The combined organic layers were washed with brine and dried over Na2SO4, filtered 
and the solvent evaporated. The crude intermediate was dissolved in a mixture of 
AcOH/THF/H2O (v/v/v, 3/2/1) and stirred at 60 ºC. After 6 h the solvents were 
evaporated and the crude product was purified by  silica gel chromatography to afford 
3 (85 mg, 0.100 mmol, 39%) as colourless gum. RF = 0.43 (EtOAc/heptane, 3/2);  
[α]20D = +132.0 (c = 0.01 g mL-1, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.32-7.28 (m, 
10H), 5.37 (d, J = 3.9 Hz, 1H), 5.31 (br s, 1H), 2.21 (br s), 5.10-5.02 (m, 4H), 4.84 (dd,  
J = 10.5 Hz, J = 3.9 Hz, 1H), 4.11 (t, J = 10.5 Hz, 1H), 4.01-3.97 (m, 1H), 3.92 (s, 2H),  
3.71-3.66 (m, 1H), 359-3.36 (m, 6H), 3.34-3.27 (m, 4H), 3.25-3.22 (m, 4H), 3.14-3.11 (m, 
1H), 2.40-2.36 (m, 1H), 2.08 (br s, 1H), 1.29-1.26 (m, 7H); 13C NMR (75 MHz, CDCl3):  
δ = 167.10, 157.14, 155.78, 136.26, 136.23, 128.71, 128.45, 128.39, 128.35, 128.21, 99.94, 
99.84, 97.77, 82.63, 76.81, 76.03, 71.99, 69.10, 67.30, 67.22, 66.43, 66.22, 51.20, 50.44, 50.16, 
48.17, 48.16, 34.32, 26.35, 17.80, 17.70; IR (neat): ν = 3379, 2833, 2103, 1701, 1136, 1031; 
HRMS (ESI): calcd for C36H46BrN5O14Na (M + Na+) 874.2122, found 874.2098. 
 
N-(1,3,6'-Triazido-3',4',6-tri-O-benzyl-1,2',3,6'-tetradeaminoneamin-2'-yl)-phthalamic 
acid (14) 
A solution of phthalic anhydride (1.0 equiv., 11 mg, 0.075 
mmol) in EtOAc (0.5 mL) was poured onto a solution of 7  
(50 mg, 0.075 mmol) in EtOAc (0.5 mL). The reaction was 
stirred at rt and after 10 h the solvent was evaporated. The 
crude product was purified by silica gel chromatography 
using a gradient of EtOAc/heptane (3/1)→EtOAc to afford 14 
(59 mg, 0.072 mmol, 96%). [α]20D = +108.0 (c = 0.007 g mL-1, 
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CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 7.86-7.83 (m, 1H), 7.40-7.18 (m, 17H), 7.06-7.04 
(m, 1H), 6.44 (br s, 1H), 5.66, (d, J = 3.6 Hz, 1H), 4.85-4.50 (m, 7H), 4.20-4.11 (m, 1H), 
3.81 (t, J = 10.0 Hz, 1H), 3.62-3.18 (m, 9H), 2.22 (dt, J = 12.5 Hz, J = 4.2 Hz, 1H), 1.49 (q,  
J = 12.5 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 172.60, 170.81, 138.28, 137.91, 137.62, 
137.56, 132.10, 130.70, 130.00, 128.85, 128.77, 128.73, 128.65, 128.60, 128.44, 128.10, 
128.06, 127.95, 127.92, 127.85, 97.87, 84.32, 80.12, 79.56, 79.22, 77.56, 76.34, 76.31, 75.36, 
71.70, 60.33, 59.98, 53.90, 51.71, 32.77; IR (neat): ν = 3418, 3275, 2100, 1051; HRMS (FAB): 
calcd for C41H43N10O9 (M + H+) 819.3214, found 819.3221. 
 
1,3,6'-Triazido-3',4',6-tri-O-benzyl-1,3,6'-trideamino-2'-N,5-O-
bis(vinyloxycarbonyl)neamine (16) 
Compound 7 (100 mg, 0.149 mmol), DMAP (0.3 equiv., 5.5 mg, 
0.045 mmol) and Et3N (10 equiv., 207 µL, 1.49 mmol) were 
dissolved in dry CH2Cl2 (16 mL) and vinyl chloroformate (6.0 
equiv., 76 µL, 0.894 mmol) was slowly added. The reaction 
mixture was stirred at rt for 2 h and then quenched by 
addition of H2O. The water phase was extracted with CH2Cl2 
and the combined organic phases were treated with brine and 
dried over Na2SO4, filtered and the solvent evaporated. The crude residue was purified 
by silica gel chromatography to afford 16 (98 mg, 0.121 mmol, 81%) as a sticky powder. 
RF = 0.55 (EtOAc/heptane, 1/2); [α]20D = +101.9 (c = 0.0073 g mL-1, CH2Cl2); 1H NMR 
(300 MHz, CDCl3): δ = 7.31-7.20 (m, 15H), 7.11 (dd, J = 13.8 Hz, J = 6.3 Hz, 1H), 6.89 
(dd, J = 13.8 Hz, J = 6.1 Hz, 1H), 5.05 (d, J = 3.9 Hz, 1H), 4.87-4.75 (m, 6H), 4.63-4.56 (m, 
3H), 4.52 (dd, J = 6.3 Hz, J = 2.4 Hz, 1H), 4.44-4.39 (m, 1H), 4.25-4.20 (m, 1H), 3.97 (td,  
J = 10.2 Hz, J = 3.6 Hz, 1H), 3.65-3.45 (m, 5H), 3.39-3.29 (m, 4H), 2.31 (dt, J = 13.0 Hz,  
J = 4.5 Hz, 1H), 1.51 (q, J = 13.0 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 153.14, 152.35, 
142.78, 142.18, 137.82, 137.80, 136.76, 128.68, 128.60, 128.55, 128.36, 128.20, 128.17, 
128.13, 128.03, 99.23, 98.83, 95.67, 82.04, 80.54, 80.29, 79.04, 77.78, 76.28, 75.97, 75.52, 
72.20, 60.11, 59.07, 54.77, 51.39, 32.53; IR (neat): ν = 3357, 2100, 1765, 1649, 1251, 1048; 
HRMS (ESI): calcd for C39H43N10O10 (M + H+) 811.3164, found 811.3158. 
 
1,3,6'-Triazido-3',4',6-tri-O-benzyl-1,3,6'-trideamino-2'-N,5-O-
(ethylenediiminodicarbonyl)neamine (17) 
Compound 16 (70 mg, 0.086 mmol) was dissolved in dry THF 
(5 mL) and ethylenediamine (1.5 equiv., 8.6 µL, 0.129 mmol) 
was added. The reaction was stirred under reflux for 10 h and 
then the solvent was evaporated. The crude residue was 
purified by silica gel chromatography to afford 17 (49 mg, 
0.063 mmol, 73%) as a gum.  RF = 0.29 (EtOAc/heptane, 1/1); 
[α]20D = +73.3 (c = 0.0067 g mL-1, CH2Cl2); 1H NMR (300 MHz, 
CDCl3): δ = 7.37-7.28 (m, 15H), 5.05-4.59 (m, 10H), 4.31-4.26 (m, 2H), 4.11-3.99 (m, 2H), 
3.69-3.40 (m, 7H), 3.36-3.26 (m, 2H), 3.01-2.91 (m, 2H), 2.35 (dt, J = 13.0 Hz, J = 4.5 Hz, 
1H), 1.57 (q, J = 13.0 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ = 159.09, 157.62, 138.16, 
137.71, 137.09, 128.58, 128.48, 128.41, 128.35, 128.04, 127.96, 127.84, 127.71, 82.21, 79.12, 
78.62, 77.36, 75.85, 75.37, 74.68, 71.15, 60.61, 59.92, 58.70, 54.18, 51.42, 41.76, 32.20;  
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IR (neat): ν = 3292, 2102, 1705, 1558, 1265; HRMS (FAB): calcd for C37H43N12O8 (M + H+) 
783.3327, found 783.3344. 
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Chapter 7 
 
Deprotection of neamine analogues, bioassays and 
NMR binding experiments 
 
 
 
Abstract: 
 
A deprotection and purification protocol was developed on two protected model neamines and 
applied on five different neamine analogues. A variety of bioassays was performed including 
antibiotic disk assay, test of bacterial translation inhibition and MICs. Final compounds were 
subjected to NMR binding experiments on the A-site of the E. coli 16S rRNA, the AAC(6’)-Ib 
resistance enzyme and the primer of HIV-1 reverse transcription tRNALys3. 
 
 
 
 
 
 
 
 
NMR binding experiments and bioassays: 
Frédérique Maurice, Frédéric Dardel and Carine Tisné 
Laboratoire de Cristallographie et RMN Biologiques, UMR 8015 CNRS, Université 
Paris Descartes, 4 avenue de l'Observatoire, 75006 Paris (France). 
 
Determination of MICs: 
Judith Toonen, Hannie Willemsen and Tanja Schülin-Casonato, Dept. of Medical 
Microbiology, UMC St Radboud, MMB 574, P.O. Box 9101, 6500 HB Nijmegen (The 
Netherlands). 
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7.1 Introduction 
 
 From the research described in previous chapters a number of neamine 
analogues were obtained still carrying protecting groups derived from their synthetic 
process (Figure 7.1). For RNA affinity determination and biological evaluation it is 
obvious that deprotection is a requisite. However, although often considered a trivial 
part of the process in a final synthesis, a large number of total syntheses have failed 
precisely due to protective group resisting removal. Here we describe a practical 
protocol for deprotection and purification of the aminoglycosides prepared in previous 
chapters. First, several reaction conditions and purification techniques were tested on 
two protected neamine model compounds. The resulting optimal deprotection protocol 
was applied to neamine derivatives 1-5 (Figure 7.1) to obtain five final molecules.  
 
Figure 7.1 
 
 Next, bioactivity of the resulting neamine analogues was evaluated on 
antibiotic disk with E. coli. Three compounds showed some activity and NMR was 
used for the analysis of their molecular interactions with the A-site of the E. coli 16S 
rRNA. Previous NMR experiments of the A-site interacting with aminoglycosides1 and 
2-deoxystreptamine2 provided a good structural base for the study of new neamine-
derived compounds.   
 Two additional NMR experiments for analysis of molecular interaction were 
conducted with the newly synthesised compounds. One with AAC(6')-Ib protein, a 
clinically prevalent resistance enzyme that deactivates aminoglycosides by acetylation 
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at 6'-NH2 position3. Another to evaluate the binding with tRNALys3, the primer of 
HIV-1 reverse transcription. Molecules that specifically bind to tRNALys3 and that 
could interfere with the initiation process of HIV-1 reverse transcription would be of 
great pharmaceutical interest. The available crystallographic data4 and the in vivo 
production of recombinant tRNALys35 provided structural NMR data6 suitable for 
application in NMR screening of tRNALys3 ligands7. Finally, to complement the data 
on antibiotic activity, minimal inhibitory concentrations (MICs) were obtained for 5 
compounds on different bacteria. 
 
 
7.2 Deprotection of model aminoglycosides 
 
 The final molecules 1-5 carry a plethora of structurally distinct protecting 
groups such as acetals, benzyls, carbamates and azides. Additionally, compounds 1 
and 2 have a nitro group or a silyl ether at the 2'-position, respectively. Removal of the 
dimethoxybutanediyl group (DMB), cyclohexylidene acetal and trimethylsilyl (TMS) 
group under acidic conditions occurred without difficulties. The remaining structures 
were initially treated with palladium on carbon and hydrogen in order to reduce azido 
functions and remove benzyl group in one simultaneous process. In search for optimal 
conditions, several reactions were performed varying the type of palladium and 
solvents.  
 
 
 
 
Scheme 7.1 
 
Disappointingly, in the case of neamine derivatives containing azides, a simultaneous 
process gave many side-products. Therefore, a variety of deprotection protocols was 
first evaluated on two model substrates. Thus, for tetraazidoneamine 6 the optimal 
reduction of the azides was performed via Staudinger reaction with 
trimethylphosphine8 under basic conditions. Due to poor solubility of the substrate and 
reactants, a 4:1 ratio of THF to H2O was determinant for a proper outcome (Scheme 
7.1).  
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 Deprotection and azide reduction of the tribenzylated compound 8 proceeded 
well in two steps, performing first a Staudinger reduction on the azides under similar 
conditions as before, followed by treatment of the crude material with palladium 
hydroxide (Degussa type) and hydrogen. The choice of solvents was a key element for 
a successful hydrogenolysis of the benzyl groups. After attempts with MeOH and 
EtOH, a mixture of iPrOH, H2O and AcOH proved to be a good solvent system. 
Scheme 7.2 
 
 Although the deprotection conditions for compound 8 proceeded cleanly and 
selectively, along with neamine 7 a small quantity of side-products were inevitably 
formed. Several attempts to separate the impurities from 7 by chromatography on 
sulfonic acid or carboxylic acid-functionalised silica (Dowex) failed. Retention on 
Amberlite CG-50, a polyacrylate resin, and elution with a gradient of ammonium 
hydroxide also failed. Finally, it was established that the optimal purification 
conditions required a two-step process of first passing 7 through a column of normal 
silica gel by elution with a mixture of ammonium hydroxide (25% in H2O), 
dichloromethane, n-butanol and ethanol (v/v/v/v, 6/2/4/5), thus separating 
impurities from 7. Secondly, since silica is partially soluble in the mixture of eluents 
and butanol was difficult to remove completely, deprotected product 7 was purified on 
a column of Amberlite CG-50 in its ammonium form9 by consecutive elution with 
water and 1 M NH4OH. Evaporation of the eluent would afford pure compound 7 as 
the free base. However, due to the fact that aminoglycosides with free amines are very 
hygroscopic and difficult to handle, the final molecules were preferentially isolated as 
acetate salts by dissolving the final compound in a minimal amount of water, addition 
of a few drops of acetic acid and finally lyophilisation. 
 An additional argument to transform an aminoglycoside from its free base form 
to the acetate salt lies in the cumbersome analysis by NMR. In the typical solvent D2O 
exchange of solvent with the free amines takes place, forming an equilibrium with the 
aminoglycoside ammonium hydroxide form. As a consequence, NMR analysis 
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indicates the presence of several compounds instead of a homogeneous product, in 
contrast with the NMR spectrum of the acetate salt (Figure 7.2). 
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Figure 7.2    1H NMR spectra of neamine (7) in D2O. (a) Free tetraamine. (b) Tetraacetate salt. 
 
 
7.3 Deprotection of neamine analogues 
 
The synthesis of 1 via Michael addition was described in Section 3.3. Removal of 
the protecting groups afforded a new neamine analogue with galacto-configured  
2-deoxy-2-aminosugar as ring I. Reduction of the nitro group and hydrogenolysis of 
benzyl and benzyloxycarbonyl substituents were performed simultaneously with 
hydrogen and palladium hydroxide. Conveniently, the presence of acetic acid as a  
co-solvent led to the simultaneous hydrolysis of the cyclohexylidene group. First silica 
and then ion-exchange chromatography gave pure compound 10 in 58% yield (Scheme 
7.3). 
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Scheme 7.3 
 
 In Section 4.4 the synthesis of several protected disaccharides and 
pseudodisaccharides was described. We were particularly interested in the biological 
activity of the 2-DOS-containing compounds 2 and 3 as new neamine analogues to 
explore the effect of the manno-configuration and the 2-hydroxy substituent instead of 
an amino function. 
 Therefore, compound 2 was subjected to a 9/1 mixture of TFA/H2O for  
4 minutes, leading to hydrolysis of both DMB, cyclohexylidene acetal and TMS group 
in a single step to yield 1110. Reaction time was found to be critical since longer 
exposure led to hydrolysis of the glycosidic bond. Rapid evaporation of solvent 
afforded compound 11 in good yield. Azide reduction of 11 was successfully 
performed by Staudinger reaction with trimethylphosphine. Chromatography on silica 
gel followed by ion-exchange chromatographic purification gave new neamine 
analogue 12 possessing as sugar the 6-deoxy-6-aminomannose ring. The product was 
isolated as its triammonium acetate salt after treatment with acetic acid (Scheme 7.4).  
 
Scheme 7.4 
 
 In a similar way, compound 3 was subjected to TFA/H2O for 4 min to 
hydrolyse the DMB acetal. The crude intermediate was treated with palladium 
hydroxide on carbon (Degussa type) and hydrogen (1 atm) to hydrogenolyse the 
benzyloxycarbonyl groups. Again, chromatography on silica gel followed by ion-
exchange chromatographic purification afforded the new neamine analogue 13, with 
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mannose as the sugar attached to 2-DOS. Compound 13 was isolated as diammonium 
acetate salt (Scheme 7.5). 
Scheme 7.5 
 
 In order to be able to interpret the influence of the manno-configuration on the 
RNA-binding affinity of the analogues 12 and 13, a 6-amino-6-deoxy-gluco-configured 
analogue was required. This purpose was nicely served by compound 4, obtained by 
application of the oxidation-reduction methodology described in Section 5.3 to convert 
α-mannosides into α-glucosides. Removal of the protecting groups was performed in 
three steps. Hydrolysis of the acetals under acidic conditions as aforementioned was 
followed by reduction of the 6'-azide of the intermediate under Staudinger conditions. 
The remaining benzyloxycarbonyl groups were hydrogenolysed to obtain 2'-deamino-
2'-hydroxyneamine 14 (Scheme 7.6). The same neamine analogue was earlier reported 
by Wong et al.11, although synthesised in a different manner.  
Scheme 7.6 
 
 Conformationally restricted neamine derivative 5 was synthesised as described 
in Section 6.3. Azide reduction and benzyl group removal were performed applying 
the previously developed conditions and purification protocol to obtain 15 as a 
triacetate salt (Scheme 7.7). 
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Scheme 7.7 
 
 
7.4 Interaction with rRNA A-site 
 
 In the clinic, aminoglycosides are predominantly applied as antibiotics. 
Therefore, antibacterial activity of the final compounds 10 and 12-15 was first 
determined on antibiotic Kirby-Bauer disk assays. In such an assay, a rapid and 
qualitative determination of antibacterial activity can be obtained by visual inspection 
of the bacteria-free zones around a piece of cotton containing the molecules of interest. 
Neamine and compound 14, which are both known to have antibacterial activity, were 
used as reference. As can be observed in Figure 7.3 only 10 and 15 have a very weak 
capacity to inhibit bacterial growth, with an apparent slightly stronger activity for 
compound 10 over compound 15. 
 
 
Figure 7.3       Antibiotic disk assay on the JM101Tr E. coli strain (a standard E. coli K12).  
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 Neamine and compound 14 were shown to act as antibiotics by binding to the 
A-site of ribosomal RNA of bacteria11. Therefore, to pursue the activity analysis of the 
newly synthesised molecules, the binding of the active compounds 10 and 15 on the 
16S E. coli A-site RNA was studied by NMR. In this case, the detection strategy was 
based on monitoring spectral changes induced by ligand binding on the target. Figure 
7.4 shows the superposition of 1D proton spectra when the compounds are added. The 
broadening or the variation of the target RNA imino proton signals indicates that 
binding occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4    Binding assays to the 16S A-site rRNA monitored by 1H NMR chemical shift 
perturbation of the RNA imino protons at 5 °C at equimolar concentration (0.3 mM).  
The asterisks indicate line broadening or shift of the target imino proton NMR signals. 
 
 Globally, both compounds 10 and 15 bind to the 16S E. coli A-site rRNA. For a 
better insight of the antibacterial activity, assays of inhibition of bacterial translation 
were analysed on gel electrophoresis (Figure 7.5). Lane A is a blank test without any 
plasmid or neamine-derived compounds. When bacteria were treated with the plasmid 
that encodes for the elongation factor EF-Ts a band appeared that corresponds to 
overproduction of EF-Ts (36 kDa) as depicted in lane B. The following lanes show the 
results in the presence of plasmid and increasing concentration of 15 and 10. Only 10 
16S + 10 
16S + 15 
16S + 14 
16S + neamine 
16S 
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inhibits the bacterial translation at relatively high concentration (500 µM) since the 
band corresponding to the protein EF-Ts disappeared.  
 
 
 
 
 
 
 
 
 
 
 
       Figure 7.5      Test of bacterial translation inhibition of 10 and 15. 
 
From the newly synthesised compounds, only 10 and 15 showed antibacterial activity. 
Compound 10 has stronger activity than 15, and it has been shown that its activity is 
related to the inhibition of the translation process by binding to the ribosomal bacterial 
A–site, as usual for aminoglycosides.  
 
 
7.5 Binding studies on the AAC(6')-Ib bacterial resistance enzyme 
 
The binding of compounds to the AAC(6')-Ib protein, a bacterial resistance 
enzyme that deactivates aminoglycosides by acetylation at 6'-position, was analysed to 
characterise the chemical groups that are important in recognition of neamine by the 
enzyme (Figure 7.6). In this kind of NMR experiment the intensity of the peaks is 
relative to the dissociation constant magnitude, i.e. the weaker the dissociation 
constant, the higher the intensity of NMR signals12. In order of increasing activity, the 
compounds can be classified as follows: 13 < 12 < 10 < 15 < 14 < neamine.  
Interestingly, binding seems to be sensitive to the configuration at the 2'-position  since 
the manno-configured analogues 12 and 13 show significantly worse binding to 
AAC(6') than the gluco-configured compound 14. Not unexpectedly, the presence of a  
6-hydroxy function in 13 and 10 instead of the amino function that is normally 
15 10 
A B 
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acetylated by the enzyme does not favour the binding to the enzyme. Unfortunately, 
introduction of conformational restriction in 15 does not seem to prevent the binding, 
which might be an indication that the conformation of 15 when bound to the A-site is 
similar to the conformation in the acetylating enzyme13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6  Binding of compounds (1mM) to AAC(6')-Ib, an aminoglycoside resistance  
enzyme (50 µM) monitored by reverse NOE pump in NMR experiment at 25 °C. 
 
 
7.6 Binding experiments on HIV primer tRNALys3 
 
In parallel, the compounds were tested for binding on 
HIV reverse-transcription primer tRNALys3 (Figure 7.7), a 
tRNA recruited by the HIV-1 virus to prime its DNA 
synthesis. In virions, tRNALys3 is strongly bound to the 
genomic RNA through base-pairing of 18 of its 3'-terminal 
nucleotides with the complementary viral PBS (Primer 
Binding Site). It is of special interest to find molecules that 
specifically bind to tRNALys3 to serve as lead structures for 
 
 
 
 
 
 
Figure 7.7   tRNALys3 
neamine 
14 
13 
12 
15 
10 
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the development of inhibitors of the formation of the HIV-1 reverse transcription 
initiation complex.  
 Compounds 13 and 15 do not bind to tRNALys3, at least at the tested 
concentration ratio (Figure 7.8). The three other compounds and neamine bind to 
tRNALys3, with at least two binding sites (the D and T arms of the tRNA from the 
assignments of imino group resonances6a) and perhaps more for the neamine. The 
spectrum is much broadened for neamine and almost all resonances are shifted 
indicating that the binding is probably not specific with several binding sites. Further 
optimisation is therefore required to develop molecules with higher tRNALys3-
specificity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8  Binding of compounds to tRNALys3, the primer of HIV-1 reverse transcription 
monitored by 1H NMR chemical shift perturbation of the RNA imino protons at 15 °C at the 
ratio indicated for each mixture. Only equimolar conditions were tested for 15 due to the low 
amount of available product. 
 
tRNA 
tRNA + nemaine (1:4) 
tRNA + 14 (1:4) 
tRNA + 13 (1:4) 
tRNA + 12 (1:4) 
tRNA + 10 (1:4) 
tRNA + 15 (1:1) 
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7.7 Minimum inhibitory concentrations 
 
 Minimum inhibitory concentrations (MICs) were determined for the 
synthesised neamine analogues on five different bacteria (Table 7.1). Neomycin sulfate 
and neamine as ammonium chloride were used as a reference. In addition, the 
ammonium acetate salt of neamine was also incorporated to evaluate the influence of 
the counterion on antibacterial activity. Overall, the neamine analogues have little 
antibiotic effect which can be classified as follows: 14 > 10 ≈ 15 > 13 > 12. The 
introduction of mannose configuration at ring I has a dramatic effect on activity. 
Conformationally restricted neamine 15 shows much lower activity than neamine 
itself, although some better inhibition can be observed for Pesudomonas aeruginosa. The 
same applies to compound 10 where ring I has a galacto configuration. Wong et al.11 
reported a similar MIC for 14 on E. coli.  
 
Table 7.1  MICs (mg L-1) of synthetic analogues 10, 12-15 compared to neomycin and neamine. 
 
 
7.8 Conclusions 
 
 Deprotection of the final compounds prepared in earlier chapters was 
successfully achieved. An adequate protocol was developed for purification of the 
compounds to obtain four new neamine analogues along with earlier reported 14. 
Bioassays were performed involving an antibiotic disk assay with E. coli, determination 
of bacterial translation inhibition analysed by gel electrophoresis and determination of 
aminoglycoside 
Pseud. 
aeruginosa 
E. coli 
Staph. 
aureus 
Enterobacter 
cloacae 
Klebsiella  
pneumoniae 
neomycin sulfate 64 <1 <1 <1 <1 
neamine·4HCl 512 16 16 32 16 
neamine·4AcOH 512 16 8 32 16 
10 >256 256 >256 >256 256 
12 >1024 >1024 512 >1024 >1024 
13 >1024 >1024 >512 >512 >512 
14 >1024 256 128 256 128 
15 >256 >256 >256 >256 >256 
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MICs on five different bacteria. The disk assay showed that from the new neamine 
analogues only compounds 10 and 15 have some observable antibiotic activity but 
lower than neamine. The stereochemical integrity on ring I is important (manno-
configured 12 and 13 have lost antibacterial activity). Similar loss of activity is 
observed upon replacement of the NH2 group by a hydroxyl group in 10. NMR 
binding experiments were performed on a 27 nucleotide fragment of rRNA containing 
the decoding A-site, on the AAC(6')-Ib protein and on the HIV reverse-transcription 
primer tRNALys3. In the first case, it could be observed that globally compounds 10 
and 15 maintain the capacity to bind to the bacterial A-site rRNA. Modification of 
stereochemistry at the 2'-position strongly affects the binding to AAC(6')-Ib as could be 
observed for 12 and 13.  For the primer of HIV-1 tRNALys3, the compounds bind on 
tRNA with several binding sites, indicating a poor specificity like all molecules of the 
aminoglycoside family. However, coupled with other RNA-binding pharmacophores, 
they could provide more specific molecules.  
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7.10 Experimental Section 
 
General methods and materials (see: Section 2.5). 
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4-O-(2-Amino-2-deoxy-α-D-galactopyranosyl)-2-deoxystreptamine (10)  
Compound 1 (23 mg, 0.024 mmol) was dissolved in glacial 
AcOH/THF/H2O (3/1/0.3 mL) and about the same weight of 
Pd(OH)2 (Degussa type) was added. The reaction was stirred 
under 1 atm of H2 for 15 h. The reaction mixture was filtered 
through celite and the solvents evaporated. The residue was 
purified by flash silica gel chromatography (RF = 0.22, 25% 
NH4OH/CH2Cl2/n-BuOH/EtOH, 6/2/4/5). Remaining silica and organic solvents 
were removed by ion exchange column chromatography (0.5 × 5 cm) with Amberlite 
CG-50 in its NH4+ form (1M NH4OH as eluent). The eluent was evaporated under 
reduced pressure. The product was dissolved in H2O (5 mL) and 2 drops of glacial 
acetic acid were added. After lyophilisation, compound 10 was obtained as sticky 
white foam (7 mg, 0.014 mmol, 58%). [α]20D = +63.1 (c = 0.0035 g mL-1, H2O); 1H NMR 
(400 MHz, D2O): δ = 5.79 (d, J = 4.1 Hz, 1H), 4.15 (dd, J = 8.1 Hz, J = 3.8 Hz, 1H), 4.10 
(dd, J = 11.0 Hz, J = 3.0 Hz, 1H), 4.04 (m, 1H), 3.84-3.75 (m, 3H), 3.66-3.54 (m, 3H),  
3.47-3.40 (m, 1H), 3.33-3.26 (m, 1H), 2.44 (dt, J = 12.7 Hz, J = 4.3 Hz, 1H, H-2eq), 1.93 (s, 
9H), 1.78 (q, J = 12.7 Hz, 1H, H-2ax); 13C NMR (75 MHz, D2O): δ = 180.59, 97.27, 81.83, 
74.22, 72.17, 72.12, 67.42, 65.74, 60.65, 50.57, 49.25, 48.49, 28.67, 22.55; IR (neat): ν = 3127, 
1536, 1403, 1047; HRMS (ESI): calcd for C12H25N3O7Na (M + Na+) 346.1590, found 
346.1581. 
 
4-O-(6-Azido-6-deoxy-α-D-mannopyranosyl)-1,3-diazido-1,3-dideamino-2-
deoxystreptamine (11)  
Compound 2 (100 mg, 0.150 mmol) was dissolved in TFA/H2O 
(v/v, 9/1, 3 mL) and after stirring for 4 min the solvent was 
rapidly evaporated under reduced pressure. Purification was 
performed by silica gel chromatography using 3% of MeOH in 
EtOAc as eluent. After evaporation of the solvent the product 
was coevaporated three times with MeOH10 to afford 11 (53 mg, 
0.132 mmol, 88%) as a colourless gum. RF = 0.27 (3% MeOH in EtOAc); [α]20D = +71.1  
(c = 0.0035 g mL-1, MeOH); 1H NMR (400 MHz, CD3OD): δ = 5.39 (d, J = 1.6 Hz, 1H), 
4.12-4.07 (m, 1H), 3.96 (dd, J = 3.1 Hz, J = 1.8 Hz, 1H), 3.72 (dd, J = 9.57 Hz, J = 3.1 Hz, 
1H), 3.64 (t, J = 9.57 Hz, 1H), 3.51-3.34 (m, 6H), 3.27-3.23 (m, 1H), 2.22 (dt, J = 12.5 Hz,  
J = 4.1 Hz, 1H), 1.39 (q, J = 12.5 Hz, 1H); 13C NMR (75 MHz, CD3OD): δ = 102.47, 80.96, 
77.90, 77.79, 74.17, 72.23, 72.01, 69.21, 61.89, 61.00, 52.95, 33.30; IR (neat): ν = 3361, 2102, 
1039; HRMS (ESI): calcd for C12H19N9O7Na (M + Na+) 424.1305, found 424.1299. 
 
4-O-(6-Amino-6-deoxy-α-D-mannopyranosyl)-2-deoxystreptamine (12)  
Compound 11 (18 mg, 0.045 mmol) was dissolved in 
THF/H2O/1M NaOH (v/v/v, 10/1/0.1, 2.5 mL) and PMe3  
(4.5 equiv., 0.202 mmol, 202 µl from a 1M solution in THF) was 
added. The reaction was stirred for 12 h and the solvent was 
evaporated. The residue was purified by silica gel column 
chromatography (RF = 0.16, 25% NH4OH/CH2Cl2/n-BuOH/EtOH, 6/2/4/5). 
Remaining silica and organic solvents were removed by ion exchange column 
chromatography (0.5 × 5 cm) with Amberlite CG-50 in its NH4+ form (1M NH4OH as 
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eluent). The eluent was evaporated under reduced pressure. The product was 
dissolved in water (5 mL) and 2 drops of glacial acetic acid were added. After 
lyophilisation, compound 12 (16 mg, 0.032 mmol, 71%) was obtained as sticky powder. 
[α]20D = +52.6 (c = 0.0035 g mL-1, H2O); 1H NMR (400 MHz, D2O): δ = 5.43 (d, J = 1.8 Hz, 
1H), 4.14 (dd, J = 3.1 Hz, J = 2.1 Hz, 1H), 3.97-3.92 (m, 1H), 3.89 (dd, J = 9.6 Hz,  
J = 3.1 Hz, 1H), 3.80 (dd, J = 10.2 Hz, J = 9.0 Hz, 1H), 3.66 (t, J = 9.6 Hz, 1H), 3.59 (t,  
J = 9.0 Hz, 1H), 3.52 (t, J = 10.2 Hz, 1H), 3.49-3.41 (m, 2H), 3.33-3.27 (m, 1H), 3.23 (dd,  
J = 13.5 Hz, J = 7.8 Hz, 1H), 2.47 (dt, J = 12.5 Hz, J = 4.2 Hz, 1H), 1.95 (s, 9H), 1.85 (q,  
J = 12.5 Hz, 1H); 13C NMR (75 MHz, D2O): δ = 179.77, 100.41, 78.45, 74.60, 72.14, 69.50, 
69.17, 68.99, 67.15, 49.23, 47.99, 39.88, 27.76, 22.08; IR (neat): ν = 3170, 2912, 1538, 1402, 
1044, 1009, 652; HRMS (ESI): calcd for C12H25N3O7Na (M + Na+) 346.1590, found 
346.1580. 
 
4-O-(α-D- Mannopyranosyl)-2-deoxystreptamine (13) 
Compound 3 (30 mg, 0.038 mmol) was dissolved in TFA/H2O 
(v/v, 9/1, 2 mL) and after stirring for 4 min the solvent was 
rapidly evaporated under reduced pressure. The residue was 
dissolved in 2-propanol/H2O/AcOH (v/v/v, 3/2/1, 5 mL) and 
Pd(OH)2 on carbon (Degussa type, 60 mg) was added. The 
reaction was stirred under 1 atm of H2 for 24 h. The mixture was filtered through celite 
washing with H2O and the solvents were evaporated. The residue was purified by 
silica gel chromatography (RF = 0.17, 25% NH4OH/CH2Cl2/n-BuOH/EtOH, 6/2/4/5). 
Remaining silica and organic solvents were removed by ion exchange column 
chromatography (0.5 × 5 cm) with Amberlite CG-50 in its NH4+ form (1M NH4OH as 
eluent). The eluent was evaporated under reduced pressure. The product was 
dissolved in water (5 mL) and 2 drops of glacial acetic acid were added. After 
lyophilisation, compound 13 (15 mg, 0.034 mmol, 89%) was obtained as sticky powder.  
[α]20D = +47.0 (c = 0.001 g mL-1, H2O); 1H NMR (400 MHz, D2O): δ = 5.23 (d, J =  1.9 Hz, 
1H), 4.11-4.10 (m, 1H), 3.93 (dd, J = 11.7 Hz, J = 1.8 Hz, 1H), 3.85 (dd, J = 9.4 Hz,  
J = 3.3 Hz, 1H), 3.82-3.69 (m, 3H), 3.65 (t, J = 9.4 Hz, 1H), 3.60-3.52 (m, 2H), 3.51-3.44 (m, 
1H), 3.36-3.26 (m, 1H), 2.47 (dt, J = 12.5 Hz, J = 4.1 Hz, 1H), 1.93 (s, 6H), 1.83 (q,  
J = 12.5 Hz, 1H); 13C NMR (75 MHz, D2O): δ = 180.40, 101.42, 80.77, 74.07, 73.80, 71.79, 
69.57, 69.50, 66.26, 60.46, 49.24, 48.50, 27.83, 22.46; IR (neat): ν = 3161, 2926, 1545, 1405, 
1047, 1014, 654; HRMS (ESI): calcd for C12H24N2O8Na (M + Na+) 347.1430, found 
347.1443. 
 
4-O-(6-Amino-6-deoxy-α-D-glucopyranosyl)-2-deoxystreptamine (14) 
Compound 4 (60 mg, 0.074 mmol) was dissolved in TFA/H2O 
(v/v, 9/1, 2.5 mL) and after stirring for 4 min the solvent was 
rapidly evaporated under reduced pressure. The residue was 
dissolved in THF/H2O/1M NaOH (v/v/v, 10/1/0.1, 4 mL) and 
PMe3 (3 equiv., 0.222 mmol, 222 µl from a 1M solution in THF) 
was added. The reaction was stirred for 12 h and the solvent was evaporated. The 
crude intermediate was dissolved in MeOH/AcOH (v/v, 10/1, 5.5 mL) and Pd on 
carbon (60 mg) was added. The reaction was stirred under 1 atm of H2 for 20 h. The 
mixture was filtered through celite washing with H2O and the solvents were 
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evaporated. The residue was purified by silica gel chromatography (eluents: 25% 
NH4OH/CH2Cl2/n-BuOH/EtOH, 6/2/4/5). Remaining silica and organic solvents 
were removed by ion exchange column chromatography (0.5 × 5 cm) with Amberlite 
CG-50 in its NH4+ form (1M NH4OH as eluent). The eluent was evaporated under 
reduced pressure. The product was dissolved in water (5 mL) and 2 drops of glacial 
acetic acid were added. After lyophilisation, compound 14 (23 mg, 0.046 mmol, 62%) 
was obtained as sticky powder. Analytical data were identical to those reported by 
Wong et al.11  
 
2'-N,5-O-(Ethylenediiminodicarbonyl)-3',4',6-tri-O-benzyl neamine (15) 
Compound 5 (15 mg, 0.019 mmol) was dissolved in 
THF/H2O/1M NaOH (v/v/v, 10/1/0.1, 3.0 mL) and PMe3 
(4.5 equiv., 0.086 mmol, 86 µl from a 1M solution in THF) was 
added. The reaction was stirred for 20 h and the solvent was 
evaporated. The crude residue was dissolved in  
2-propanol/H2O/AcOH (v/v/v, 3/2/2, 4 mL) and Pd(OH)2 
on carbon (Degussa type, 40 mg) was added. The reaction was 
stirred under 1 atm of H2 for 15 h. The mixture was filtered through celite washing 
with H2O and the solvents were evaporated. The residue was purified by silica gel 
chromatography (RF = 0.34, 25% NH4OH/CH2Cl2/n-BuOH/EtOH, 6/2/4/5). 
Remaining silica and organic solvents were removed by ion exchange column 
chromatography (0.5 × 5 cm) with Amberlite CG-50 in its NH4+ form (1M NH4OH as 
eluent). The eluent was evaporated under reduced pressure. The product was 
dissolved in water (5 mL) and 2 drops of glacial acetic acid were added. After 
lyophilisation, compound 15 (4 mg, 0.007 mmol, 37%) was obtained as sticky powder. 
[α]20D = +25.6 (c = 0.0009 g mL-1, H2O); 1H NMR (400 MHz, D2O): δ = 5.13 (s, 1H), 4.95 (t, 
J = 9.7 Hz, 1H), 4.04-3.95 (m, 2H), 3.84-3.77 (m, 2H), 3.73-3.64 (m, 2H), 3.58-3.48 (m, 3H), 
3.44-3.34 (m, 3H), 3.10-3.02 (m, 2H), 2.52 (dt, J = 12.5 Hz, J = 4.1 Hz, 1H), 1.98 (s, 9H), 
1.86 (q, J = 12.5 Hz, 1H) ; 13C NMR (75 MHz, D2O): δ = 179.33, 160.68, 157.89, 100.12, 
75.16, 70.87, 70.78, 68.49, 67.80, 53.26, 49.12, 48.15, 40.44, 40.00, 39.38, 28.47, 21.77;  
IR (neat): ν = 3267, 1550, 1016; HRMS (ESI): calcd for C16H30N6O8Na (M + Na+) 
457.2023, found 457.2034. 
 
General methods and materials for NMR binding experiments and bio-assays 
Samples: The 27-mer RNA fragment corresponding to the ribosomal A-site was 
purchased from PERBIO Dharmacon, deprotected as indicated by the supplier, 
extensively dialysed against water and freeze-dried. NMR samples were prepared by 
dissolving the RNA in 20 mM sodium phosphate buffer (pH 6.5) in 90% H2O/10% 
2H2O at a final concentration of 0.3 mM. Broad spectrum AAC6'-1b was purified from a 
recombinant E. coli strain and kept in 20 mM potassium phosphate pH 7.5. Neamine 
was prepared by methanolysis of neomycine (Sigma). tRNALys3 was expressed and 
purified as previously described14. 
 
NMR interaction studies:  Spectra were recorded on a 600 MHz Bruker Avance 
spectrometer equipped with a 3 mm triple resonance flow-injection probe connected to 
a LC215 Gilson pipetting robot (Bruker BEST system). The solvent resonance was 
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suppressed by presaturation, excitation sculpting15 or a jump-return sequence for 
imino proton detection16. Ligand binding was monitored by reverse NOE-pumping 
methods17 and/or 1D chemical shift perturbation on the imino proton spectral window 
(9 to 15 ppm) using the flow-injection NMR system. 
 
Disk assay:  50 µl of a fresh overnight culture was diluted in 5 mL of warm liquid  
H-top agar and poured on top of a Luria-Bertani agar plate. After solidification of the 
top layer, a solution of the tested compound (10 µl of a 50 mM solution) was pipetted 
onto a paper filter disk that was subsequently placed onto the plate. After overnight 
incubation at 37 °C, the growth inhibition diameter was monitored.  
 
Protein translation inhibition:  The assay was performed using the easyXpress® kit from 
Qiagen, under conditions recommended by the supplier. The plasmid DNA template 
was the control plasmid included in the kit, which encodes a His-tagged elongation 
factor EF-Ts. Incubations were conducted in the presence of increasing concentrations 
of the tested compound. Aliquots were analysed by denaturing SDS polyacrylamide 
gel electophoresis (12%). Protein bands were revealed with Coomassie R250 staining. 
Contamination of the reagents by RNAses was ruled out by controlling that under the 
tested incubation conditions no detectable degradation of a purified reporter RNA 
could be observed. 
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Summary 
 
Exploration of Synthetic Methodologies in the 
Preparation of Neamine-type RNA Ligands 
 
 
 Aminoglycosides such as neomycin (Figure 1) form an important class of 
antibiotics based on a strong interaction with the rRNA A-site (acceptor site) or 
decoding centre, which is located on the bacterial 16S subunit. Rings I (2,6-diamino-2,6-
dideoxyglucose) and II  (2-deoxystreptamine or 2-DOS) together are named neamine 
(2) and they appear to be responsible for the specificity of the interaction with rRNA. 
The disadvantages of neomycin lie in the associated oto- and nephrotoxicity and the 
fact that neomycin is prone to bacterial resistance mechanisms. In recent years, several 
modifications and reconstructions on neamine have been reported in an attempt to 
circumvent undesired side-effects and the problem of bacterial resistance to 
aminoglycoside antibiotics. An overview on such modifications of neamine and 
synthesis of neamine analogues is described in Chapter 1. 
 
 
 
 
 
 
 
Figure 1 
 
Selective protection and modification of aminoglycosides is complicated due to the 
plethora of hydroxyl and amino functions, which thwarts the differentiation between 
distinct positions. Our contribution to the synthesis of neamine analogues was based 
on the exploration of several convergent approaches towards the neamine moiety from 
its individual building blocks. Such a strategy would allow a selective modification 
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and/or functionalisation of certain positions on the neamine moiety. Specifically, the 
2'-position was an interesting target due to its implication in internal hydrogen bonds 
which stabilises the neamine skeleton in its bioactive conformation. 
The 2-DOS aminocyclohexitol is a highly conserved structure in 
aminoglycosides antibiotics. Chapter 2 describes how to obtain asymmetrically 
protected 2-DOS by degradation of neomycin (Scheme 1). The resulting 2-DOS 
derivatives 6 and 7 were used as main building blocks in our research. 
Scheme 1 
 
 Chapter 3 describes the first approaches towards neamine analogues, which 
involved glycals as precursors of the sugar moiety. Initially, oxidative coupling of  
2-DOS to glucal (8) via iodonium ion generation was investigated. Although the 
coupling step worked well, attempts to convert the intermediate 2'-iodo compound 
into an azido-substituted glucoside failed (Scheme 2).  
Scheme 2 
 
Alternatively, functionalisation of glycals with a nitro group in the  
2-position was investigated, since it was known that 2-nitroglycals are excellent 
substrates for Michael additions. After test reactions with diisopropylidene-protected 
D-glucofuranose, both 2-nitroglucal and 2-nitrogalactal generated the desired Michael 
adducts with 2-DOS, with the 2'-NO2 functionality offering the possibility for 
subsequent selective manipulation. The adduct 14 obtained from addition to  
2-nitrogalactal is depicted in Scheme 3, and afforded a unique neamine epimer after 
full deprotection. 
OPO
PO
OP
I ROH
9
O
OR
PO
PO
IPO
10 11
O
OR
PO
PO
PO
N3
N3OPO
PO
OP
I
8
P = protecting group
HO
[N] [N]
O
O
O
[N] [N]
OHO
HO
OH
[N]
[N]
OH
1
MeO OMe
TsOH, DMFsteps
1.
2. NaIO4, THF/H2O/dioxane
3. Et3N, EtOH
4. NaBH4, EtOH/H2O
4 [N] = NHCbz
5 [N] = N3
6 [N] = NHCbz
7 [N] = N3
Summary 
 
127 
Scheme 3 
 
 In order to improve yields and enhance the desired α-selectivity, an alternative 
approach was studied involving thioglycoside coupling, as described in  
Chapter 4. Conditions were first investigated employing oxazolidinone-protected  
2-amino-2-deoxy-D-thioglucosides, but the expected dimers were obtained with 
marginal success. Consequently, attention was turned to 3,4-O-dimethoxybutanediyl-
protected (DMB) mannothioglycosides as carbohydrate donors. The coupling was 
performed with a range of model acceptors and proved effective, by subsequent and 
selective 2'-O-desilylation, in the preparation of α-mannoglycosides with a free 2'-OH 
group (Scheme 4). Application of 2-DOS as acceptor afforded two new neamine 
analogues with mannose configuration on the sugar ring and the possibility of selective 
manipulation at 2'-OH. 
Scheme 4 
 
 There is no general method for stereoselective 1,2-cis glycosylation applicable to 
a wide range of substrates. Therefore, in order to obtain free 2'-OH neamine analogues 
with an α-glucoside configuration, an indirect approach was investigated as shown in 
Chapter 5. As a result of synthetic efforts described in the previous chapter, a set of 
DMB-protected 6-azido-6-deoxy-α-mannosides with a free 2'-OH had become 
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available. The 2'-unprotected dimers were subjected to an oxidation–reduction 
sequence, leading to successful inversion of configuration at C2'. The oxidation step 
was performed with Dess–Martin periodinane, while a range of reducing agents was 
screened in search for high stereoselectivity (Scheme 5). The developed methodology 
was applied to obtain the desired neamine analogues with different protective groups. 
 
 
 
 
 
Scheme 5 
 
 Chapter 6 shows several attempts to synthesise conformationally restricted 
neamine analogues with a covalent link between positions 2' and 5. Based on NMR 
binding experiments and crystallographic data, such a restriction would resemble the 
bioactive conformation of the neamine core of 4,5-linked aminoglycosides (Figure 2).  
 
 
 
 
 
 
 
 
Figure 2 
 
It was envisioned that the neamine moiety might enhance its selectivity and binding 
activity for the A-site by reducing the number of degrees of freedom. At the same time, 
it was hypothesised that the conformational restriction would prevent binding in the 
active site of aminoglycoside resistance enzymes, and thus possibly overcome bacterial 
resistance and undesired side-effects. Initially, an unsuccessful approach was 
attempted from one of the previously obtained free 2'-OH neamine analogues. 
Subsequently, following reported chemistry by Wong et al., the neamine derivative 24 
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with the 2' and 5-positions free was synthesised. It served as an intermediate to obtain 
the 2',5-linked neamine derivative 25 (Scheme 6). 
Scheme 6 
 
A number of neamine analogues were obtained still carrying protecting groups 
derived from their synthetic process. As shown in Chapter 7, a deprotection and 
purification protocol was investigated to afford five final compounds (Figure 3), which 
were subjected to a variety of bioassays. 
Figure 3 
 
Bioactivity of the resulting neamine analogues was first evaluated on antibiotic disk 
with E. coli. Three compounds showed some activity and NMR was used for the 
analysis of their molecular interactions with the A-site of the E. coli 16S rRNA. For a 
better insight of the antibacterial activity, assays of inhibition of bacterial translation 
were analysed on gel electrophoresis. The final compounds were also subjected to 
NMR binding experiments on the AAC(6')-Ib resistance enzyme and  the primer of  
HIV-1 reverse transcription tRNALys3. Finally, minimum inhibitory concentrations 
(MICs) were determined for the synthesised neamine analogues on five different 
bacteria. 
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Samenvatting 
 
Verkenning van Synthetische Methodologieën in de 
Bereiding van RNA liganden van het Neamine-type 
 
 
 Aminoglycosiden zoals neomycine (Figuur 1) vormen een belangrijke klasse 
van antibiotica gebaseerd op een sterke wisselwerking met de rRNA A-plaats 
(acceptor-plaats) of translatie-centrum, dat zich op de bacteriële 16S subeenheid 
bevindt. Ringen I (2,6-diamino-2,6-dideoxyglucose) en II (2-deoxystreptamine of  
2-DOS) worden samen neamine genoemd (2) en zij lijken verantwoordelijk voor de 
specificiteit van de wisselwerking met rRNA. De nadelen van neomycine berusten op 
de geassocieerde oto- en nefrotoxiciteit en het feit dat neomycine vatbaar is voor de 
mechanismen van bacteriële resistentie. In een poging om deze ongewenste 
bijwerkingen en het probleem van bacteriële resistentie tegen aminoglycoside 
antibiotica te omzeilen, zijn in recente jaren meerdere synthetische varianten van 
neamine beschreven. Een overzicht van deze varianten van neamine en synthese van 
neamine-analoga wordt in Hoofdstuk 1 beschreven. 
 
 
 
 
 
 
 
Figuur 1 
 
Als gevolg van de overvloed aan hydroxyl- en aminofuncties is de selectieve 
bescherming en modificatie van één specifieke positie van een aminoglycoside een 
ingewikkelde zaak. Onze bijdrage in de synthese van neamine-analoga is gebaseerd op 
de verkenning van enkele convergente synthetische benaderingen naar het neamine 
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bestanddeel door middel van het opbouwen uit de individuele bouwstenen. Een 
dergelijke strategie is flexibel in de zin dat het een selectieve modificatie en/of 
functionalisatie van één specifieke positie van het neamine bestanddeel mogelijk 
maakt. In dit verband vormt met name de 2'-positie een interessant doel als gevolg van 
deelname van deze amino-functie in diverse interne waterstofbruggen die de neamine 
structuur in zijn bioactieve conformatie stabiliseren. 
 De 2-DOS aminocyclohexitol is een zeer geconserveerde structuur in 
aminoglycoside antibiotica. Hoofdstuk 2 beschrijft op welke wijze een asymmetrisch 
beschermde 2-DOS variant kan worden verkregen door milde decompositie van 
neomycine (Schema 1). De verkregen 2-DOS derivaten 6 en 7 werden gebruikt als 
essentiële bouwstenen in ons onderzoek.  
Schema 1 
 
 Hoofdstuk 3 beschrijft de eerste benaderingen naar neamine-analoga, waarbij 
glycalen werden gebruikt als uitgangsstof voor het suiker bestanddeel van neamine. 
Hiervoor werd aanvankelijk de oxidatieve koppeling van 2-DOS aan glucal (8) via een 
iodonium ion onderzocht. Hoewel de koppeling goed werkte, zijn de pogingen om de 
tussenliggende 2'-iodo verbinding in een azido-gesubstitueerd glucoside om te zetten 
mislukt (Schema 2). 
 
Schema 2 
 
Als alternatief werd de synthese van glycalen met een nitro groep in de 2-positie 
onderzocht. Het is bekend dat 2-nitroglycalen uitstekende substraten zijn voor Michael 
addities. Testreacties met als nucleofiel het diisopropylideen-beschermde  
D-glucofuranose genereerden de gewenste Michael adducten met zowel 2-nitroglucal 
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als 2-nitrogalactal. Ook reactie met 2-DOS derivaat 13 gaf het gewenste product, 
waarbij de 2'-NO2 functionaliteit de mogelijkheid bood voor verdere selectieve 
manipulatie op deze positie. Het verkregen adduct 14 uit de additie van 13 aan 2-
nitrogalactal wordt in Schema 3 afgebeeld en gaf een unieke neamine epimeer na een 
complete ontscherming. 
Schema 3 
 
Hoofdstuk 4 beschrijft een alternatieve invalshoek om de opbrengst en de 
gewenste α-selectiviteit met thioglycoside koppeling te verbeteren. Allereerst werden 
de condities onderzocht voor het gebruik van het oxazolidinon-beschermde 2-amino-2-
deoxy-D-thioglucoside, maar de verwachte dimeren werden met beperkt succes 
verkregen. Om die reden werd vervolgens de aandacht gericht op 3,4-O-
dimethoxybutanediyl–beschermde (DMB) mannothioglycosides als donoren voor 
koolhydraatsynthese. De laatstgenoemde procedure werd toegepast op een reeks 
model acceptors en bleek geschikt, na selectieve 2'-O-desilylering, voor de bereiding 
van mannoglycosides met een vrije 2'-OH groep (Schema 4). Toepassing van 2-DOS als 
acceptor gaf twee nieuwe neamine-analoga met de mannose configuratie op de 
suikerring en de mogelijkheid van selectieve manipulatie op 2'-OH. 
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Er bestaat geen methode voor een volledig stereoselectieve 1,2-cis glycosylering 
die toepasbaar is op een grote diversiteit aan substraten. Om die reden zijn methoden 
onderzocht om neamine-analoga met een vrije 2'-OH te verkrijgen via een indirecte 
benadering, zoals wordt beschreven in Hoofdstuk 5. Als gevolg van de synthetische 
inspanningen zoals beschreven in het vorige hoofdstuk, was een set van DMB-
beschermde 6-azido-6-deoxy-α-mannosides met een vrije 2'-OH verkregen. De 2'-
onbeschermde dimeren werden achtereenvolgens onderworpen aan oxidatie en 
reductie, wat leidde tot een succesvolle inversie van configuratie op C2'. De 
oxidatiestap werd uitgevoerd met Dess-Martin periodinaan, terwijl een variatie aan 
reductie middelen is gebruikt in de zoektocht naar hoge stereoselectiviteit (Schema 5). 
De ontwikkelde methode werd toegepast om de gewenste neamine-analoga met 
verschillende beschermgroepen te verkrijgen. 
 
 
 
 
 
Schema 5 
 
Hoofdstuk 6 beschrijft de verschillende pogingen voor het synthetiseren van 
neamine-analoga met een structuur, die conformationeel is vastgelegd door middel 
van een covalente verbinding tussen posities 2' en 5. Gebaseerd op NMR 
bindingsexperimenten en kristallografische gegevens, zou een dergelijke verstarde 
structuur lijken op de bioactieve conformatie van het neamine gedeelte van  
4,5-verknoopte aminoglycosiden (Figuur 2). 
 
 
 
 
 
 
 
 
Figuur 2 
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Een interessante hypothese omvat het idee dat het verminderen van vrijheidsgraden 
van het neamine bestanddeel, zijn selectiviteit en bindingsaffiniteit voor de A-plaats 
versterkt. Tegelijkertijd werd verondersteld dat dezelfde conformationele beperking de 
binding van het neamine in het actieve centrum van de resistentie-enzymen zou 
kunnen verhinderen. Op deze manier zou mogelijk de bacteriële weerstand tegen 
aminoglycosiden overwonnen kunnen worden. Allereerst werd een benadering 
gekozen met een van de eerder verkregen vrije 2'-OH neamine-analoga, maar deze was 
niet succesvol. Vervolgens werd het neamine derivaat 24 gesynthetiseerd met vrije 2' 
en 5 posities, volgens de chemie van Wong et al. Na enkele onsuccesvolle pogingen 
bleek verbinding 24 geschikt als intermediair om het 2',5-verbonden neamine derivaat 
25 te verkrijgen (Schema 6). 
Schema 6 
 
De verkregen neamine-analoga dragen nog steeds beschermgroepen afgeleid 
van hun synthetisch proces. Een ontschermings- en zuiveringsprotocol werd 
onderzocht om de laatste vijf stoffen te verkrijgen (Figuur 3), die werden onderworpen 
aan een variatie van bioassays zoals beschreven in Hoofdstuk 7.  
Figuur 3 
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De biologische activiteit van de verkregen neamine-analoga werd eerst op een 
antibiotische schijf met E. coli geëvalueerd. Drie stoffen toonden activiteit waarna NMR 
werd gebruikt voor de analyse van hun moleculaire wisselwerking met de A-plaats 
van de E. coli 16S rRNA. De assay van inhibitie van bacteriële translatie werd door 
middel van gel-elektroforese geanalyseerd om een beter inzicht te krijgen van de 
antibacteriële activiteit. De uiteindelijke moleculen werden ook onderworpen aan 
NMR bindingsexperimenten op het AAC(6')-Ib resistentie-enzym en de primer van  
HIV-1 reverse transcriptie tRNALys3. Tenslotte werden minimale inhibitie 
concentraties (MICs) bepaald voor de gesynthetiseerde neamine-analoga op vijf 
verschillende bacteriën. 
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Sumario 
 
Exploración de Metodologías de Síntesis en la 
Preparación de Ligandos de ARN de Tipo Neamina 
 
 
Los aminoglicósidos, como la neomicina (Figura 1), forman una importante 
clase de antibióticos cuya actividad se basa en una fuerte interacción con el sitio A 
(sitio aceptor) o centro descodificador del ARNr, el cual está localizado en la 
subunidad bacteriana 16S. Los ciclos I (2,6-diamino-2,6-didesoxiglucosa) y II  
(2-desoxiestreptamina o 2-DOS) unidos se designan como neamina (2) y son 
responsables de la interacción específica con el ARNr. Las desventajas de la neomicina 
recaen en su oto- y nefrotoxicidad asociada y en el hecho de que es propensa a 
mecanismos de resistencia bacteriana. En años recientes se han realizado varias 
modificaciones y reconstrucciones de la neamina, con la intención de sortear los efectos 
secundarios indeseados y el problema de la resistencia bacteriana. Un compendio sobre 
modificaciones de la neamina y síntesis de análogos de neamina está descrito en el 
Capítulo 1. 
 
 
 
 
 
 
 
Figura 1 
 
La modificación y protección selectiva de los aminoglicósidos es complicada debido a 
la plétora de grupos hidroxilo y amino presentes, lo que dificulta la diferenciación 
entre distintas posiciones. Nuestra contribución a la síntesis de análogos de neamina se 
basó en la exploración de varias rutas convergentes desde sus unidades individuales. 
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Una estrategia de este tipo nos permitiría una funcionalización y/o modificación 
selectiva de ciertas posiciones de la neamina. Específicamente, la posición 2' fue un 
objetivo interesante debido a su implicación en enlaces de hidrógeno intramoleculares 
que estabilizan la conformación bioactiva de la neamina. 
 El aminociclohexitol 2-DOS es una estructura altamente conservada en los 
antibióticos aminoglicósidos. El Capítulo 2 describe cómo obtener 2-DOS 
asimétricamente protegida por degradación de neomicina (Esquema 1). Los derivados 
de 2-DOS resultantes 6 y 7 fueron unidades principales de construcción sintética en 
nuestra investigación. 
Esquema 1 
 
 El Capítulo 3 describe nuestros primeros intentos por producir análogos de 
neamina mediante el uso de glicales como precursores del ciclo I. Inicialmente se 
investigó el acoplamiento oxidante de 2-DOS al glucal (8) vía ión yodonio. Aunque se 
produjo el acoplamiento deseado, intentos por sustituir el yodo en posición 2' por 
azida resultaron infructuosos (Esquema 2). 
Esquema 2 
 
De forma alternativa, se investigó la funcionalización de glicales mediante un grupo 
nitro en la posición 2. Es sabido que los 2-nitroglicales son excelentes sustratos para 
realizar adiciones de Michael. Tras realizar reacciones de prueba con diisopropiliden-
D-glucofuranosa, tanto el 2-nitroglucal como el 2-nitrogalactal generaron los aductos de 
Michael deseados con 2-DOS, donde la función 2'-NO2 remanente ofrece la posibilidad 
de manipulación selectiva. El aducto 14 obtenido de la adición al 2-nitrogalactal se 
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muestra en el Esquema 3, y proporcionó un nuevo epímero de neamina tras 
desprotección completa. 
Esquema 3 
 
 Con el propósito de mejorar el rendimiento y la selectividad α se investigó el 
acoplamiento mediante el uso de tioglicósidos, como se describe en el Capítulo 4. Las 
condiciones de reacción fueron inicialmente estudiadas con la utilización de 2-amino-2-
desoxi-D-tioglucósidos protegidos mediante oxazolidinona, pero los dímeros esperados 
fueron obtenidos de forma limitada. Por consiguiente, nuestra atención giró al uso de 
manotioglicósidos protegidos con el grupo 3,4-O-dimetoxibutanodiilo (DMB) como 
carbohidratos donadores. El acoplamiento se realizó con una gama de aceptores 
modelo, y tras la 2'-O-desililación selectiva se comprobó su efectividad en la 
preparación de α-manoglicósidos con un grupo 2'-OH libre (Esquema 4). La utilización 
de 2-DOS como aceptor produjo dos nuevos análogos de neamina con configuración de 
manosa en el ciclo I y la posibilidad de manipulación selectiva sobre el grupo 2'-OH. 
Esquema 4 
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obtener análogos α-glucósidos de neamina con el grupo 2'-OH libre se investigó una 
síntesis indirecta como se muestra en el Capítulo 5. Como resultado de la síntesis 
descrita en el capítulo anterior, una serie de 6-azido-6-desoxi-α-manósidos protegidos 
con DMB y con el grupo 2'-OH libre se encontraban a nuestra disposición. Para obtener 
α-glucósidos de forma indirecta, los dímeros desprotegidos en la posición 2' fueron 
sometidos a una secuencia de oxidación–reducción, generando con éxito una inversión 
de configuración en la posición C2'. El paso oxidante se realizó con peryodinano de 
Dess–Martin, mientras que una variada gama de agentes reductores se utilizaron en 
búsqueda de estereoselectividad (Esquema 5). 
Esquema 5 
 
 En el Capítulo 6 se muestran varios intentos de sintetizar análogos de neamina 
conformacionalmente restringidos mediante un enlace covalente entre las posiciones 2' 
y 5. En base a experimentos de RMN y datos cristalográficos, una restricción de este 
tipo se asemejaría a la conformación bioactiva de la neamina para el caso de los 
aminoglicósidos con enlaces a 2-DOS en posiciones 4 y 5 (Figura 2). 
Figura 2 
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se pensó que la restricción en la conformación podría prevenir la interacción con el sitio 
activo de los enzimas resistentes a los aminoglicósidos, y así lidiar con la resistencia 
bacteriana y con efectos secundarios indeseados. Inicialmente se intentó una síntesis 
desde uno de los análogos de neamina previamente obtenidos con el grupo 2'-OH 
libre, aunque sin éxito. Posteriormente, en base al trabajo publicado por Wong et ál., se 
sintetizó el derivado de neamina 24 con las posiciones 2' y 5 libres. Este compuesto 
sirvió como intermedio para obtener el derivado de neamina 25 con un enlace 
covalente entre dichas posiciones (Esquema 6). 
Esquema 6 
 
 Los análogos de neamina obtenidos contenían grupos protectores como 
consecuencia del proceso de síntesis. En el Capítulo 7 se muestra el protocolo de 
desprotección y purificación investigado para obtener cinco compuestos finales  
(Figura 3), los cuales fueron sometidos a varios ensayos biológicos. 
Figura 3 
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RMN se utilizaron para el análisis de sus interacciones moleculares  con el sitio A del 
RNAr 16S de E. coli. Ensayos de inhibición de traslación se analizaron mediante 
electroforesis para comprender mejor la actividad antibacteriana. Los compuestos 
finales también fueron sometidos a experimentos de RMN para estudiar su capacidad 
de enlace con el enzima resistente AAC(6')-Ib, y el cebador del VIH-1 transcriptasa 
inversa ARNtLys3. Finalmente, las concentraciones de inhibición mínimas (MICs, por 
sus siglas en inglés) fueron determinadas para los análogos de neamina utilizando 
cinco bacterias diferentes. 
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